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Abstract 
The protozoan parasites Trypanosoma cruzi and Trypanosoma brucei are the causative 
agents of Chagas disease and Human African sleeping sickness respectively. Existing 
therapies are toxic and ineffective against the later stages of the two diseases, 
consequently safer, improved therapies are urgently required. Here, two areas of 
trypanosome biology are explored. In the first section, the process of cell division is 
approached from a fundamental biology perspective. Centromeres are the region of 
DNA where kinetochore structures form, allowing the attachment of microtubules to 
facilitate chromosome segregation. In T. brucei we have characterized the nature and 
location of centromeres by exploiting the localized activity of topoisomerase-II, a 
cancer chemotherapy target, at the centromere. Etoposide mediated DNA cleavage 
mapping revealed the presence of signature AT-rich repeat regions coupled with 
adjacent retrotransposons at the centromere. Further experiments demonstrate that of the 
two nuclear T. brucei topoisomerase-II isoforms, only topoisomerase-IIα is essential 
and active at the centromere. The second section centres on pro-drug development 
against a trypanosome type I nitroreductase. This enzyme has previously been 
implicated in activation of nifurtimox and benznidazole, the two therapies in clinical use 
against Chagas disease. Initially we have developed a luciferase based drug assay 
system in the clinically relevant intracellular T. cruzi stage and rapidly screened a range 
of nitroaromatic based compounds for trypanocidal activity. A series of derived 
nitrofuryl compounds previously developed against Chagas disease were also screened 
against T. brucei, where most demonstrate trypanocidal activities of less than 1 µM. 
Further we show that these compounds are active substrates of nitroreductase, and act as 
pro-drugs within the parasite by specific activation of nitroreductase to generate 
cytotoxic moieties.          
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1 General Introduction to Trypanosomatids 
1.1 The Trypanosomatid Diseases 
Trypanosomatidae are a family of parasitic protozoa in the Order Kinetoplastida. As a 
grouping, this family of pathogens can infect an array of hosts ranging from plants 
through to higher mammals. In humans they are responsible for several major infections 
including Chagas disease, African sleeping sickness (also known as human African 
Trypanosomiasis) and Leishmaniasis which are caused by Trypanosoma cruzi, 
Trypanosoma brucei and Leishmania species respectively. These diseases are reported 
to afflict more than 20 million people worldwide leading to an estimated 110,000 
deaths, with 500 million individuals living in areas deemed at risk (WHO, 2004). They 
are often considered neglected diseases since they attract relatively little research 
interest. Of the total amount of money spent worldwide on research, US$ 2.5 billion for 
2007, less than 5% was directed towards these three diseases combined (Moran et al., 
2009). This thesis will focus on the trypanosomes: T. brucei and T. cruzi, but will also 
feature Leishmania major. 
1.1.1 African sleeping sickness 
The first medical reports of African sleeping sickness were described by the physician 
Thomas Winterbottom. In 1734 he noted an infection whose early stage was 
characterized by swollen lymph glands at the back of the neck, a symptom apparently 
used by Arabian slave traders when discriminating between healthy and unfit slaves 
(Steverding, 2008). The next significant step in recognizing African sleeping sickness 
was made by the explorer David Livingstone who observed that cattle bitten by the 
Tsetse fly (Figure 1.1.1) went on to develop Nagana, an infection now known to be the 
cattle disease equivalent to African sleeping sickness. However, it took the 
microbiologist David Bruce to discover that a trypanosome infection was responsible for 
Nagana, and later to make the connection that the trypanosome was transmitted by the 
Tsetse fly vector. At the end of the 19
th
 century, this trypanosome was observed in 
human blood by Joseph Everett Dutton, and later in human spinal fluid by Aldo 
Castellani, prompting the first suggestions that African sleeping sickness was also 
16 
 
caused by the trypanosome. David Bruce further demonstrated that African sleeping 
sickness was spread by the Tsetse fly, the same way as Nagana (Steverding, 2008). The 
trypanosome species responsible for African sleeping sickness and Nagana was named 
Trypanosoma brucei, in honour of the scientific contribution made by David Bruce.   
 
 
Figure 1.1.1.  African sleeping sickness insect vector: the Tsetse fly  
Image from The Science Photo Library Ltd.  
 
 
The Tsetse fly (Glossina spp.) vector is critical to the epidemiology of African sleeping 
sickness. The Tsetse are restricted to the African continent, ranging from south of the 
Sahara to north of the Kalahari desert (Barrett et al., 2003). This in turn confines the 
transmission of T. brucei, and hence the regional distribution of the disease. Historically, 
the level of disease prevalence has fluctuated greatly. During the 1920s a major 
epidemic was recorded in the region of what is now the Democratic Republic of Congo, 
with up to 60,000 cases reported per year (WHO, 2000). The response of the governing 
colonial powers was to introduce new medical services, coupled with a significant 
improvement in living standards. This resulted in a dramatic reduction in the numbers of 
infected cases over a period up until the 1960s (Steverding, 2008). Unfortunately the 
social upheaval and political instability that followed the independence of many African 
countries resulted in a significant reduction in public health services and control 
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programmes. This led to the last major epidemic of African sleeping sickness which 
peaked in the late 1990s, with at its height in 1997 over 37,000 new cases reported 
(WHO, 2000). Since then, the number of new cases reported has steadily been declining, 
with the latest statistics showing that 9,689 new cases of African sleeping sickness were 
diagnosed in 2009, in the context of a significant improvement in passive screening for 
the disease (Simarro et al., 2011). The late 20
th
 century epidemic prompted a 1997 WHO 
resolution to raise international awareness of the disease. It is believed that following 
this resolution, the intensified political cooperation between African nations towards 
improved surveillance and control, combined with the successful distribution of drugs 
made available through benevolent agreements with pharmaceutical companies, is 
predominantly responsible for the decline in reported cases of African sleeping sickness.   
The important lesson here, emphasized by a World Health Organization report (WHO, 
2006), is that the development of safer, more effective, orally administered drug 
therapies should be coupled with the continuation of the socio and political collaboration 
between African States against African sleeping sickness. 
The African trypanosome responsible for African sleeping sickness, T. brucei, has two 
human infectious sub-species, each with distinct disease pathologies. T. brucei 
gambiense occurs within the western and central regions of the Tsetse fly‟s habitat of 
Africa, while T. brucei rhodesiense is endemic to east Africa (Brun et al., 2010). 
Although this discreet divide has often been referred to in the literature, there now 
appears to be an emerging overlap of endemic areas within Uganda between the T. 
brucei sub-species, potentially as the animal reservoirs of T. brucei rhodesiense move 
into the predominantly non-zoonotic T. brucei gambiense endemic region (Picozzi et al., 
2005). The third sub-species of T. brucei, named T. brucei brucei, is non-pathogenic to 
humans and only infects cattle, causing the disease Nagana. 
Infection by T. b. gambiense results in a slow chronic disease, estimated to last on 
average around 3 years (Checchi et al., 2008).  Conversely T. b. rhodesiense results in a 
rapid onset acute disease lasting from only weeks to a couple of months. Both types of 
disease progress in two distinct stages. In the first haemolymphatic stage, the parasites 
begin to replicate around the site of infection and gradually spread to the lymph and 
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blood system, resulting in general symptoms such as headaches and fever, as well as 
potentially swollen lymph glands at the back of the neck (Winterbottom‟s sign). The 
second encephalitic stage develops as parasites enter the central nervous system, by 
what appears to be an active migration process (Masocha et al., 2007; Nikolskaia et al., 
2006), as opposed to an opportunistic exploitation of any breakdown in the blood-brain 
barrier. During this stage, patients exhibit disrupted sleep patterns as the circadian 
rhythm becomes disrupted (Lundkvist et al., 2004), the clear symptom that gives this 
disease its name. The various symptoms of the two separate stages are significant, as 
while the first stage is much easier to treat, the general symptoms are easily mis-
diagnosed or ignored by the patient. Symptoms of the disease‟s second stage are much 
more obvious, although the treatment is less effective, and with a greater risk of adverse 
side-effects (see Section 1.2.1). If this disease remains untreated it will be fatal (Barrett 
et al., 2003).  
This thesis will focus solely on T. brucei brucei as a representative model of the two 
human pathogenic sub-species, due to the ease of culturing the physiologically relevant 
lifecycle stage, the number of reliable genetic tools available for the functional 
dissection of the parasite, together with a completed genome sequencing project 
(Berriman et al., 2005). Therefore the implications of any observations reported here 
should be considered in the wider context of applicable disease research.  
1.1.2 Chagas Disease 
Evidence of Chagas disease, also known as American trypanosomiasis, appears to date 
back 9 millennia, as indicated by samples taken from preserved 9000 year old mummies 
excavated from coastal regions of South America testing positive for DNA remnants of 
the disease causing T. cruzi parasite (Aufderheide et al., 2004). It has also been 
suggested Charles Darwin may have suffered from the disease, given his diary account 
of an encounter with the parasite‟s insect vector, alongside the pattern and nature of the 
symptoms he displayed for many years before his death (Bernstein, 1984). The first 
recorded case of Chagas disease was made by Dr. Carlos Chagas in a 2-year old girl, in 
1909 (Chagas, 1909). Dr. Chagas was also first to describe the T. cruzi parasite, which 
he named after his mentor, Oswaldo Cruz, and first to identify the insect vector and the 
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transmission life-cycle of the parasite. Surprisingly, despite being nominated twice, 
Chagas never won the Nobel Prize. 
 
 
 
Figure 1.1.2.  Chagas disease insect vector: Rhodnius prolixus.  
Image from The Science Photo Library Ltd.  
 
A significant animal reservoir exists for T. cruzi in wild animals, for example in rodents, 
bats, and armadillos, as well as domesticated animals such as cats and dogs. The T. cruzi 
parasite is predominantly transmitted by blood-sucking bugs from the Reduviidae 
family, with Triatoma infestans, Rhodnius prolixus (Figure 1.1.2), and Triatoma 
dimidiata considered 3 of the most important vector species to man (Rassi et al., 2010). 
Chagas disease is endemic to Latin America, reflecting the distribution of the various 
insect vectors. T. infestans is found mainly in sub-Amazonian regions, while R. prolixus 
and T. dimidiata occur further north beyond the Amazon basin, through Central 
America, reaching Mexico (WHO, 2002). Alternative mechanisms of transmission are 
also worth noting. Vertical transmission of the parasite between a mother and her baby 
is a risk (Azogue et al., 1985), as well as blood transfusions from T. cruzi contaminated 
samples (Dias, 1984).  
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In 2004 it was estimated that in Latin America, 7.7 million people were infected with 
Chagas disease (PAHO/WHO, 2007) with a resulting 11,000 deaths per year (WHO, 
2004). This is a significant decrease in the incidence reported for 1985 where 17.4 
million people were estimated to be infected with Chagas disease (WHO, 2002). A 
major factor in the reduction of cases was the initiation of the „Southern Cone Initiative‟ 
vector control programme in Argentina, Bolivia, Brazil, Chile, Paraguay, Peru and 
Uruguay. This political collaboration introduced a widespread insect control programme 
designed around extensive use of insecticides to clear the insect vector from infested 
rural and urban dwellings, coupled with co-ordinated blood screening to prevent any 
medically derived transmission (Moncayo, 1999). Following its inception, Chile and 
Uruguay, with parts of Argentina, Paraguay and Brazil, are now classed as free of 
vectorial transmission (Miles et al., 2003; Moncayo and Silveira, 2009). In contrast, 
arguably complacency and a lack of co-ordination in some regions such as Peru has led 
to a resurgence of the disease (Delgado et al., 2011), as investment towards control 
projects is diverted. Chagas disease is also an emerging problem in non-endemic regions 
as increased globalization leads to mass worldwide migration. For example, estimates in 
the United States indicate that approximately 300,000 people suffer from Chagas disease 
(Bern and Montgomery, 2009), with numerous cases reported in regions ranging from 
Canada and Japan to Australia and Europe (Rassi et al., 2010). 
The pathologies associated with Chagas disease can be divided into three phases. The 
initial, acute stage develops over a 4-8 week period and is often asymptomatic (Rassi et 
al., 2010). Possible signs of the disease can arise after 1-2 weeks for an infection 
originating from a bug bite, or after a couple of months from infection via a blood 
transfusion. These potential symptoms can include a swelling at the site of infection 
and/or a rapid onset fever, either of which can be easily missed or mis-diagnosed. 
Approximately 10% of acute cases results in death from either myocarditis 
(inflammation of the heart) or meningoencephalitis (inflammation of the brain) (Barrett 
et al., 2003). Beyond the acute stage, the disease progresses into an indeterminate stage, 
a pathology that can last the rest of the patient‟s natural life. Here, the disease remains 
latent and no obvious signs of infection are felt or observed by the patient. In 15-30% of 
patients, the so-called chronic form of the disease can occur. This is characterized by 
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premature heart disease and enlargement of the oesophagus and colon (mega 
syndromes) often resulting in heart failure and sudden death. The length of time a 
patient is in the indeterminate stage varies, with some individuals not entering the 
chronic disease state decades after the initial infection (Barrett et al., 2003). While drug 
treatment (see Section 1.2.2) for the acute stage is usually successful (Bahia-Oliveira et 
al., 2000), chemotherapy for the chronic stage remains ineffective (Cancado, 2002), 
placing an even greater emphasis on the importance of early diagnosis. 
Although there is only a single defined species of T. cruzi, a significant degree of 
variation between strains exists, amounting to greater intra-species diversity than even 
that observed between some classified species of Leishmania (Tibayrenc, 1998). The 
current classification system describes the sub-division of T. cruzi strains into six 
discrete groups: TcI - TcVI (Zingales et al., 2009). It has been reported that T. cruzi 
TcII, TcV, and TcVI strains are predominantly the cause of Chagas disease (Di Noia et 
al., 2002; Freitas et al., 2005), however T. cruzi Type I strains appear in patients in 
northern South America (Anez et al., 2004). It has been shown that clonal T. cruzi 
populations can undergo genetic exchange (Gaunt et al., 2003; Ocana-Mayorga et al., 
2010). This makes it difficult to interpret the full implications of genetic diversity 
between T. cruzi strains towards its epidemiology and human pathogenicity.  
1.1.3 Leishmaniasis 
The earliest medical reports of Leishmaniasis date back to 1903 where two military 
doctors, Dr. William Boog Leishman and Dr. Charles Donovan, independently 
identified a species, subsequently named Leishmania donovani, in spleen samples taken 
from patients in India (Herwaldt, 1999). Recent estimates indicate that there are nearly 2 
million new cases of Leishmaniasis each year (WHO, 2010) resulting in approximately 
50,000 deaths per year (WHO, 2004). Leishmaniasis is endemic at multiple geographic 
locations, encompassing 88 countries, ranging from South America, to southern Europe, 
northern Africa and across much of Asia (WHO, 2010). Given that 72 of these 88 
endemic countries are in the developing world, this infection represents yet another 
neglected parasitic disease associated with poverty.  
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Figure 1.1.3.  Leishmaniasis insect vector: the Sand fly.  
Image from The Science Photo Library Ltd.  
 
Transmission of Leishmania parasites from animal reservoirs to human hosts occurs via 
the bite of various species of the Sand fly (Figure 1.1.3), commonly of either the 
Phlebotomus (Old World) or Lutzomyia (New World) genus (Murray et al., 2005). 
There are numerous defined species of the Leishmania parasite responsible for the 
human disease (Desjeux, 1996), which creates a complex and diverse variety of disease 
pathologies. Reminiscent of Chagas disease, many cases of Leishmania infection remain 
asymptomatic, however this disease may manifest itself in a variety of forms depending 
on the infective species. For instance L. donovani and L. infantum are two examples of 
species that cause visceral Leishmaniasis, the most dangerous form of the disease. If 
symptoms are presented by a patient and remain untreated, this disease is often fatal 
(Desjeux, 1996). Symptoms of this form of disease may show as part of the acute phase 
weeks post infection, and can be severe such as developing splenomegaly, 
hepatomegaly, immunosuppression, anaemia and fever (Herwaldt, 1999). The cutaneous 
form of Leishmaniasis represents a milder form of disease and is often the result of 
infection by L. major (Old World) or L. mexicana (New World) species. Skin lesions 
may appear weeks after infection, which may further develop into scarring, or 
potentially self-cure over the long-term. Occasionally (less than 5% of cases) the 
cutaneous form can resurge as a form termed Mucocutaneous Leishmaniasis, possibly 
years after the initial cutaneous infection has cleared. An example of a species 
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associated with this type of disease progression is the New World L. braziliensis, where 
infection can result in significant damage to the larynx, nasal cavities, and other parts of 
the face through the formation of major destructive inflammatory lesions (Murray et al., 
2005). This thesis will feature L. major as a model species for Leishmaniasis, due to the 
availability of its completed genome project (Ivens et al., 2005).  
A vaccine against either African sleeping sickness and Chagas disease appears unlikely 
anytime soon (Barrett et al., 2003; Rassi et al., 2010), while a Leishmaniasis vaccine 
based on live L. major once existed, but was discontinued in the 1990‟s. This was due to 
the development of serious lesions on a number of recipients. The development of a 
vaccine for Leishmaniasis is still considered possible (Handman, 2001), however for the 
foreseeable future tackling African sleeping sickness and Chagas disease will rely on 
accurate and effective diagnosis, vector control and chemotherapy.  
1.2 Current Diagnostics and Therapies 
1.2.1 Treating African sleeping sickness 
The standard detection method for T. brucei is the card agglutination test for 
Trypanosomiasis (CATT) (MSF, 2010), which was developed in the 1970‟s and detects 
the presence of anti- parasite antibodies in the host‟s blood. It is both a simple and fast 
test to perform, with a ~95% degree of sensitivity and specificity towards the parasite 
(Truc et al., 2002), and is widely used for mass population screening (Lutumba et al., 
2005). The drawback of this high-throughput diagnostic is that it is only reliable in 
detecting T. b. gambiense (Brun et al., 2010); consequently diagnosing T. b. rhodesiense 
infection relies on the identification of symptoms presented by patients. Confirmatory 
detection of the parasite is strongly recommended before the administration of 
chemotherapy due to the associated toxicity.  
Two effective chemotherapies are available for the treatment of early stage African 
sleeping sickness: pentamidine and suramin. The sub-species T. b. gambiense is treated 
with pentamidine, which is administered either by injection into muscle over a week or 
intravenously as a saline solution for 2 hours. The side-effects of pentamidine are often 
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mild relative to alternative trypanosomatid chemotherapy, and include diarrhoea, 
nausea, and pain at the site of injection (Barrett et al., 2007). Also preventative measures 
are taken to reduce the potential of induced hypoglycaemia (MSF, 2010). Suramin is 
used to treat T. b. rhodesiense, and is administered through a slow intravenous injection, 
as a course of 6 injections over 31 days (MSF, 2010). Although pentamidine is easier to 
administer, the increased possibility of severe allergic reactions to pentamidine as a 
consequence of more frequent parallel infection by Onchocerca species in T. b. 
rhodesiense endemic regions (Brun et al., 2010) precludes its use against this sub-
species. Additional side-effects include rash, fatigue, anaemia, peripheral neuropathy, 
and bone marrow toxicity, plus the possibility of acute and severe anaphylactic shock 
(Brun et al., 2010). Neither drug is particularly effective against the second stage of the 
disease, as the charged nature of the compounds means they do not easily traverse the 
blood-brain barrier (Barrett et al., 2007) 
For the last 60 years second-stage encephalitic African sleeping sickness was treated 
with melarsoprol, an arsenical compound. However it is no longer the standard drug of 
choice (but does present a cheaper option) for second stage T. b. gambiense, although it 
still remains in clinical use for second-stage T. b. rhodesiense infection and for T. b. 
gambiense relapse cases. Its administration is complex, comprising a course of 3-4 slow 
intravenous injections given on consecutive days, with 3-4 repeats of this course 
separated by 7-10 day intervals; though for T. b. gambiense relapse patients a shorter 10 
day course is prescribed (MSF, 2010). Melarsoprol generates significant side-effects 
including an encephalopathic syndrome that affects 5-10% of treated patients, with 
~50% of those affected dying as a result (Barrett et al., 2007). Evidence is also emerging 
of possible melarsoprol resistance in the field. Melarsoprol uptake by T. brucei has 
previously been shown to occur via an adenosine transporter (TbAT1) (Carter and 
Fairlamb, 1993; Maser et al., 1999). Genetic mutations in this transporter have been 
observed in clinical parasite isolates taken from a region where patients are refractory to 
melarsoprol treatment (Matovu et al., 2001). Re-sampling this region years later, after 
melarsoprol treatment had been discontinued, revealed that all clinical isolates possessed 
the wild-type transporter allele, losing the acquired genetic mutations, and suggesting 
the occurrence of drug pressure drives selection of melarsoprol resistant T. brucei 
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(Kazibwe et al., 2009). The preferred alternative to melarsoprol treatment for T. b. 
gambiense is nifurtimox-eflornithine co-therapy (NECT). While sole treatment with 
eflornithine is possible and has been used previously (Burri and Brun, 2003), this 
strategy has now been superseded by the co-therapy regime. This requires a 10 day 
course of the orally administered nifurtimox and intravenously dosed eflornithine (MSF, 
2010). Nifurtimox originated as a chemotherapy to Chagas disease (see later), while 
eflornithine was developed as an anti-cancer treatment and first trialled against African 
sleeping sickness in the 1980‟s (Van Nieuwenhove et al., 1985). While the side-effects 
of eflornithine are not as severe as melarsoprol, its use may still result in convulsions, 
gastrointestinal symptoms such as nausea, vomiting and diarrhoea, and bone marrow 
toxicity (Burri and Brun, 2003). However, by combining its use with nifurtimox, the 
number of injections and side-effects have been reduced (as well as cost) with no loss to 
efficacy (Yun et al., 2010). Recently, an eflornithine uptake transporter has been 
identified in T. brucei (TbAAT6), which during in vitro selection with eflornithine can 
easily be lost, leading to induced drug resistance (Vincent et al., 2010). It will be 
interesting to see if this observation is reflected in the field.   
In summary, early stage African sleeping sickness chemotherapy is effective though 
limited, while significant side-effects are associated with late stage disease treatments. 
All of the current therapies are difficult to administer and require professional medical 
supervision. This, together with the potential of emerging resistance, emphasizes the 
need for safer, preferably orally administered drugs, particularly for the late stage of 
African sleeping sickness.  
1.2.2 Treating Chagas disease 
Diagnosis of Chagas disease in the acute stage is performed by the straightforward 
detection of parasites in a patient‟s blood sample (WHO, 2002). Difficulty arises in 
diagnosing chronic stage Chagas disease due to the very low abundance of parasites in 
the peripheral blood. Diagnosis relies on detecting specific antibodies in the blood 
instead, which only has around a 20-50% sensitivity for indicating the presence of the 
parasite (Gomes et al., 2009).   
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Only two drugs are available to treat Chagas disease: nifurtimox and benznidazole. Both 
are nitroheterocyclic compounds and are only effective at treating the early acute stage 
of the disease. Neither is ideal. A nifurtimox treatment regime lasts for 30-60 days and 
is administered orally 2-3 times a day (MSF, 2010). Side-effects of nifurtimox are 
common and include nausea, gastric pain, sleeping disorders and seizures (Jackson et 
al., 2010). Benznidazole treatment is also delivered orally over a period of 30-60 days 
(MSF, 2010), with side-effects occurring in up to 50% of patients, ranging from nausea 
and skin rash to fever and peripheral polyneuritis (Pinazo et al., 2010). Both drugs are 
based on a nitroheterocyclic chemical structure, and function as pro-drugs through 
activation by a type I nitroreductase enzyme (see Section 6.1). Parasites cross-resistant 
against nifurtimox and benznidazole can be generated through in vitro drug pressure, 
resulting from the selected loss of the type I nitroreductase gene (Wilkinson et al., 
2008). Therefore, resistance to either drug usually equates to resistance to both (all) 
drugs available to treat Chagas disease, and would be gravely significant if observed in 
the clinic. With an absence of chemotherapies available towards the chronic stage of 
Chagas disease and the potential for resistance to the existing remedies, new treatments 
are again urgently required.   
1.2.3 Treating Leishmaniasis 
Diagnosis of Leishmaniasis is achieved by the microscopic identification of parasites 
from tissue biopsies or skin scrapings taken from the site of infection (MSF, 2010). 
Further identification of the Leishmania specific species can be made with a PCR based 
assay. This process is considered 100% sensitive and specific (Vega-Lopez, 2003), and 
is important as different medications are prescribed for different species. The visceral 
form caused by L. donovani and L. infantum, and the mucocutaneous form of L. 
braziliensis is treated with either daily intravenous or intramuscular injections of 
meglumine antimoniate or sodium stibugluconate for 30 days (MSF, 2010). As the 
cutaneous form of Leishmaniasis can self-cure, the intervention with treatment is made 
only if the lesions are severe. Suitable chemotherapies include: meglumine antimoniate 
or sodium stibogluconate (1-2 week intravenous treatment), fluconazole (6 week oral 
treatment) or paromomycin (2 week topical treatment). Only then, if these therapies fail 
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the treatment of Leishmaniasis may resort to pentamidine (5-25 weeks, intramuscular 
injections) (MSF, 2010).  
1.3 The Trypanosomatid Life-Cycles 
Trypanosomatids are well adapted to live in the different environments of their 
mammalian host and insect vector, and possess a variety of life-cycle stages to thrive in 
their diverse surroundings. From the perspective of drug development it is clear that 
focusing research towards the disease causing human host stages is imperative, whether 
exploring potential drug targets or developing improved chemotherapies. 
Unsurprisingly, notable differences have been observed between the insect and 
mammalian parasite stages. In T. brucei for example, 6% of genes appear to be life-
cycle regulated (Siegel et al., 2010), while 9% of genes are stage regulated in L. major 
(Rochette et al., 2008). For T. cruzi, proteomic studies have highlighted many 
differences in protein abundance between life-cycle stages (Atwood et al., 2005). Much 
of the work discussed here concentrates on the clinical parasite forms. Often however, 
utilizing the insect stages provides technical advantages, which may be useful when 
studying particular parasite features conserved across all life-cycle stages. 
1.3.1 The T. brucei life-cycle 
In the mammalian host T. brucei lives free within the bloodstream and replicates as 
morphologically slender trypomastigote forms (Figure 1.3.1a). Then as parasite numbers 
increase, these shift into non-replicative morphologically stumpy forms. This is believed 
to prevent parasite numbers reaching a critical mass that would be fatal for the host, 
therefore prolonging the host lifespan and increasing the probability of transmission to 
the insect vector (Matthews et al., 2004). To shield the mammalian parasite stages from 
the host adaptive immune response, the pathogen‟s cell surface is covered with a single 
antigen, the variant surface glycoprotein (VSG) coat, which acts to thwart consistent 
antibody recognition of the foreign invasive organism. This dense masking of the 
accompanying invariant proteins on the cell surface membrane prevents recognition of 
the parasite by host specific antibodies. A parasite infection consists of a dominant 
population of a single variant surface glycoprotein structure (Cross, 1975). However, a 
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random genetic switching event facilitates the formation of tiny sub-populations of T. 
brucei equipped with alternative variant surface glycoproteins (Stockdale et al., 2008). 
Once the original dominant population of the infection has been eradicated by the 
acquired host immune response, this minor sub-population establishes itself as the new 
dominant population, evading the current antibody response (McCulloch, 2004; Pays et 
al., 2004). It is this feature of T. b gambiense and T. b. rhodesiense pathogenesis that 
makes the development of a vaccine against these organisms particularly unlikely.         
 
 
Figure 1.3.1.  Images of the trypanosomatid clinical parasite forms.  
(A) A blood film showing the human bloodstream form of T. brucei  (Barrett et  al. ,  2003). 
(B) A heart  biopsy specimen co ntaining the intracellular T. cruzi  parasites (Kun et al. , 
2009).  (C) A mouse macrophage iso late infected with the intracellular form of L. 
donovani (Murray et al. ,  2005).   
 
Even though T. b. brucei could evade the adaptive immune response, this sub-species 
remains non-pathogenic to humans due to the additional protective properties of the 
immune system. Standard human serum contains an effective trypanolytic factor, 
apolipoprotein L-I that, in tandem with a haptoglobin-related (Hbr) protein, (Rifkin, 
1978; Shiflett et al., 2007; Vanhamme et al., 2003) lyses the parasite via the formation 
of destructive pores in lysosomal membranes (Perez-Morga et al., 2005). Both T. b. 
gambiense and T. b rhodesiense sub-species are resistant to this trypanosome lytic factor 
by different mechanisms. In T. b rhodesiense, a Serum Resistance Associated (SRA) 
protein appears to reduce the level of the trypanolytic complex successfully targeting the 
(A) (B) (C)
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lysosome, inhibiting the parasite lysis mechanism (Hager and Hajduk, 1997; Oli et al., 
2006). In T. b. gambiense SRA is absent and another mechanism is employed. It has 
been suggested that in this sub-species, the conserved haptoglobin-related protein 
receptor is down-regulated and altered in amino acid sequence, thus inhibiting the 
internalization of the trypanolytic complex (Kieft et al., 2010). This highlights the fact 
that although T. b. gambiense and T. b rhodesiense are of the same species, they are not 
equivalent in basic biology, implying that from the perspective of research and drug 
development, African sleeping sickness should not necessarily be considered a single 
disease. It is also worth noting the T. b. brucei strain used in many laboratory 
experiments (Section 3.1.3) have lost the ability to differentiate into the stumpy forms, 
and remain monomorphic in culture as the slender forms (Hendriks et al., 2000). A 
small proportion of  these can differentiate directly into the insect forms though 
(Matthews and Gull, 1994). 
Once a Tsetse fly feeds on a host infected with T. brucei, short stumpy form parasites 
residing in the blood meal become deposited in the fly mid-gut. Here, they differentiates 
into the replicative procyclic forms, shedding the variant surface glycoprotein coat and 
replacing it with a less dense covering of procyclin proteins (Roditi et al., 1987). These 
procyclic parasites later migrate to the salivary gland and differentiate into replicative 
epimastigotes, which then mature into the metacyclic infectious forms, now equipped 
with a variant surface glycoprotein coat (Fenn and Matthews, 2007; Lenardo et al., 
1984) in preparation for re-infection into the mammalian host, completing the life-cycle 
(Figure 1.3.2). It is believed that at the epimastigote stage, genetic exchange between 
parasites is possible (Peacock et al., 2011).  
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Figure 1.3.2.  A diagram of the life-cycle stages of T. brucei.  
Image from the Centre for Disease Control and Prevent ion.  
 
1.3.2 The T. cruzi life-cycle 
T. cruzi enters the human host as an infectious metacyclic trypomastigote through skin 
wounds or mucosal membranes of the eyes and mouth. This parasite stage is covered in 
various mucin glycoproteins (Di Noia et al., 1995). Some mucins are involved in 
protecting the parasite from digestion by host proteases (Mortara et al., 1992), while 
others are important in host cell invasion (Yoshida et al., 1989) through interactions 
with host cell molecules (Ruiz et al., 1993). T. cruzi metacyclic forms are capable of 
invading both phagocytic and non-phagocytic cells through a subversive cell signalling 
mechanism. The full repertoire of molecular interactions between parasite and host that 
triggers this mechanism is varied and complex, and also depends on the particular T. 
cruzi strain and tissue cell-type (de Souza et al., 2010). These interactions consequently 
result in the activation of a Ca
2+
 signalling cascade (Ruiz et al., 1998) that leads to 
internalization of the metacyclic trypomastigotes within a lysosome (Rodriguez et al., 
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1997). Once inside, the metacyclic trypomastigotes are temporarily contained within a 
vacuole compartment, which they then disrupt by secreting a porin-like molecule (Tc-
TOX)  (Andrews et al., 1990). Upon release into the cytoplasm the parasites 
differentiate into the smaller rounded amastigotes (Figure 1.3.1b), which replicate by 
binary fission. It is this stage that genetic exchange between parasites appears to occur 
(Gaunt et al., 2003). Once these amastigotes reach a high density they differentiate into 
bloodstream trypomastigotes and rupture the host cell plasma membrane, releasing them 
to infect neighbouring cells (Tyler and Engman, 2001).  
 
 
Figure 1.3.3.  A diagram of the life-cycle stages of T. cruzi.  
Image from the Centre for Disease Control and Prevent ion.  
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Some free T. cruzi bloodstream trypomastigotes are taken up by the invertebrate vector 
during a blood meal. As these parasites traverse the insect‟s gut, the trypomastigotes 
differentiate into the epimastigote stage that then adheres to gut epithelial cells. This 
form begins to replicate by binary fission, occasionally releasing parasites into the 
lumen of the digestive tract gut. These then pass through into the hind-gut, eventually 
differentiating into the metacyclic trypomastigotes ready to be excreted in the 
invertebrate‟s faeces (Figure 1.3.3) (Kollien and Schaub, 2000). 
1.3.3 The Leishmania life-cycle 
Infectious metacyclic promastigote Leishmania enter the human host through the bite of 
the sand fly. The metacyclic promastigotes are capable of residing within a selection of 
phagocytic cell types, with the macrophage being the most common. Once in the 
bloodstream they covertly invade macrophages to prevent activation of the full immune 
response. However, unlike T. cruzi, which manipulates host cells to internalise the 
parasite via lysosomes, Leishmania rely on the active phagocytic uptake of the target 
macrophages. The metacyclic promastigotes express a variety of surface molecules to 
purposefully induce phagocytic uptake by macrophages, without specifically activating 
the macrophage‟s respiratory burst response (Alexander et al., 1999). When inside the 
macrophage vacuole, Leishmania also suppress specific cytokine signals, preventing the 
immune system from being alerted to their presence (Sacks and Sher, 2002). It is within 
the macrophage vacuole that the metacyclic promastigotes differentiate into the 
replicative amastigotes (Figure 1.3.1c). These increase in number inside the vacuole (in 
contrast to T. cruzi) until they are released from the macrophage, and further invade new 
phagocytic cells.    
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Figure 1.3.4.  A diagram of the life-cycle stages of Leishmania.  
Image from the Centre for Disease Control and Prevent ion. 
 
When a sand fly then feeds on a Leishmania host, a few infected macrophages may be 
taken up as part of the blood meal. As the meal passes down into the gut, the sand fly 
internally forms a peritrophic matrix made of proteins and glycoproteins, held together 
by microfibrils. This generates a protective sac that is designed to protect the sand fly 
gut from abrasive food particles and other infectious microbes. However, since the 
transitory differentiation stages are susceptible to destruction by digestive proteases, it 
also provides the time window required for the amastigotes once contained within the 
macrophage to fully differentiate into the promastigotes, (Pimenta et al., 1997). 
Eventually this sac is degraded by both the host and the parasite (Kamhawi, 2006) 
releasing the parasites to the gut. To prevent the free promastigote parasites being 
excreted by the fly, the parasites attach themselves through lipophosphoglycan 
molecules present on the pathogen‟s flagella to the epithelium lining of the gut (Sacks 
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and Kamhawi, 2001). These free promastigotes replicate intensely and by the 7
th
 day 
begin to differentiate into the short and slender infectious metacyclic promastigotes. 
These are believed to be regurgitated by the fly into the new host next time it takes a 
blood meal (Rogers et al., 2004), establishing a new human infection (Figure 1.3.4).      
1.4 Cell Biology 
Trypanosomatids possess many cellular features common in eukaryotic cells, containing 
for example a membrane bound nucleus, an endoplasmic reticulum and Golgi apparatus. 
In addition, they also have less typical structures, some of which are unique to this 
group of organisms. A few notable features are summarized below. 
One of the most striking features of trypansomatid parasites is their single flagellum. 
This is comprised of the classical axoneme of nine peripheral microtubule doublets 
circling a central pair of single microtubules, coupled with a large paraflagellar rod that 
runs the full length of the axoneme (Bastin et al., 1996). This rod appears to be involved 
in increased flagellar motility (Portman and Gull, 2010). Beyond its role in motility, the 
flagellum also has a role in attachment such as for Leishmania promastigote attachment 
to the fly gut wall, as well as being implicated in several other processes including cell 
division and immune evasion (Ralston & Hill 2008). At the base of the flagellum lies the 
flagellar pocket, which acts as the focal point of vesicular trafficking in trypanosomatids 
(Field and Carrington, 2009). 
Trypanosomatids possess a single mitochondrion which varies in size, structure and 
function during the parasite‟s life-cycle. The mitochondrial genome (kDNA) is 
composed of thousands of circular, inter-linked DNA molecules that form a network 
referred to as the kinetoplast. This structure is characteristic of all organisms in the 
Order Kinetoplastida. The kinetoplast is located within the mitochondrial matrix, and for 
most life-cycle stages of T. brucei, T. cruzi and Leishmania spp. appears as a rounded 
bar, although in T. cruzi trypomastigotes this takes on a more circular morphology (de 
Souza et al., 2009). The DNA network consists of two types of DNA molecule, the large 
(~20 kb) maxi-circles, which are few in number (copy number between 20-45) and 
encode for certain mitochondrial proteins, and the more numerous (up to 5,000), smaller 
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mini-circles (0.1-10 kb), which encode for various RNA molecules (Lukes et al., 2005; 
Stuart, 1979). Bizarrely, the genes encoded in the maxi-circle DNA are flawed and in a 
process known as RNA editing, require post-transcriptional modification by addition or 
removal of uridine nucleotides to the mRNA in order to generate the functional coding 
sequences (Benne et al., 1986; Simpson et al., 2003). This process is catalyzed by the 
editosome protein complex, and directed by guide RNAs, which are encoded on both the 
DNA maxi- and mini- circles (Stuart et al., 2005). Another unusual mitochondrial 
property of bloodstream form T. brucei is their ability to effectively shutdown ATP 
production by this organelle by down-regulating the expression of cytochrome-
dependent respiratory electron chains. In this situation the parasites become reliant on 
glycolysis for energy needs (Tielens and Van Hellemond, 1998).          
To facilitate the above need for energy production via glycolysis, trypanosomatids have 
compartmentalized this system within the glycosome, a dedicated membrane bound 
organelle unique to the kinetoplastids. This organelle, related to peroxisomes found in 
many other eukaryotic cells, was first identified in T. brucei and contains the first nine 
enzymes involved in glycolysis (Michels et al., 2006). The reasons for localizing this 
pathway in a specialised organelle are unclear but could be an adaptation event that 
allows the cellular energy demands of certain life cycle forms to be met solely via 
substrate level phosphorylation. In addition to glycolysis, glycosomes also contain a 
number of other enzymes involved in processes as diverse as sterol biosynthesis (Urbina 
et al., 2002), -oxidation of fatty acids and purine salvage (Michels et al., 2006) plus 
ancillary systems involved in detoxification of unwanted by-products  (Wilkinson et al., 
2005).  
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1.5 Trypanosomatid Genome Architecture 
In 2005 an important landmark was reached with publication of the T. brucei, T. cruzi 
and L. major genome sequences (Berriman et al., 2005; El-Sayed et al., 2005a; Ivens et 
al., 2005). With ~50% of the genes identified as hypothetical and having no known 
function, this has provided an unparalleled opportunity in terms of drug discovery and 
represents a fantastic tool allowing scientists to understand the cellular processes of 
these pathogens at a greater detail than before. For the genome sequencing project, 
reference laboratory cultured strains were chosen of each parasite that were believed to 
best reflect the natural life-cycle and disease pathology processes specific to each 
species, whilst also being amenable to everyday research.   
1.5.1 The T. brucei genome 
Arguably the most common T. brucei strain used in research is T. b. brucei Lister 427 
MITat 1.2 clone 221a, however T. b. brucei TREU 927/4 is able to fulfil the complete 
life-cycle, and so was chosen for sequencing (van Deursen et al., 2001). Analysis 
revealed that T. brucei has a diploid genome with a haploid content of ~35 Mb. This is 
divided into three distinct classes of chromosome, which based on size are referred to as 
megabase chromosomes, intermediate chromosomes and mini-chromosomes. 
Both T. brucei strains contain 11 megabase chromosomes which range in size from 1 to 
5.2 Mb for T. brucei TREU 927/4, and 1 to  ~6 Mb for T. brucei Lister 427 MITat 1.2 
clone 221a (Melville et al., 1998; Melville et al., 2000). An unusually large size 
variation between some individual chromosome homologues within a single clone is 
observed. Chromosome 1 of the T. brucei Lister 427 MITat 1.2 clone 221a is a prime 
example, where homologue Ib (3.6 Mb) is twice the size of the Ia homologue (1.85 Mb) 
(Melville et al., 2000). Sequencing has shown that the T. brucei TREU 927/4 megabase 
chromosomes contain 9,068 protein coding genes in addition to 904 pseudogenes 
(Berriman et al., 2005). Of the full protein coding gene complement on the megabase 
chromosomes, around 800 of these encode for alternative VSGs, which are deployed to 
evade the mammalian host immune response (Section 1.3.1). These are found in large 
arrays on the megabase chromosomes at sub-telomeric sites, and it is currently thought 
that a large proportion of the intra-homologue size difference is due to varying lengths 
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of these sub-telomeric regions (Callejas et al., 2006). Most of the remaining genes are 
contained within the core central body of the megabase chromosomes in large 
directional gene clusters (Berriman et al., 2005). This type of gene arrangement for the 
standard “housekeeping” genes is common in all the trypanosomatids.   
In addition to the 11 megabase chromosomes, T. brucei 927 also appears to contain 2 
intermediate chromosomes around 350 kb in size (Melville et al., 1998). The function of 
this chromosome type is unclear but they may act as a dedicated reservoir of gene 
expression sites required for transcription of specific VSGs (Hertz-Fowler et al., 2008). 
Besides the presence of these sequences, the only other feature of note present on many 
of the intermediate chromosomes is a distinct 177 bp repeat unit (Wickstead et al., 
2004). 
Mini-chromosomes represent the third class of chromosome present in T. brucei. These 
are between 50–150 kb in size with a copy number estimated to be around 100 per cell 
(Van der Ploeg et al., 1984). This represents approximately 10% of the T. brucei total 
genome DNA content. The central core of the mini-chromosomes consists of the 177 bp 
repeat found on the intermediate chromosomes. This repeat is organized as a palindrome 
with the switch point at the chromosomal centre (Wickstead et al., 2004). Towards the 
edges of the chromosome are additional variant surface glycoproteins genes, further 
increasing the reservoir pool of these genes (Van der Ploeg et al., 1984). 
1.5.2 The T. cruzi genome 
T. cruzi CL Brener was selected for genome sequencing mainly because of its highly 
infectious nature (Zingales et al., 1997). However, assembly of its genome has been 
complicated as over 50% of its nuclear DNA content is composed of highly repetitive 
DNA sequences (El-Sayed et al., 2005a) and even today closure of the genome into 
large contiguous regions is problematic. A further challenge to accurate assembly is that 
T. cruzi CL Brener (group TcVI) is a genetic hybrid between two different strains from 
groups TcII and TcIII (El-Sayed et al., 2005a; Machado and Ayala, 2001). This has lead 
to a high level of allelic variation (~2%), and even trisomy (Obado et al., 2005). 
Together, this has made accurate sizing of chromosomes and the determination of 
chromosome copy number difficult, although estimates indicate that the haploid genome 
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size is around 67 Mb split across ~28 chromosomes (El-Sayed et al., 2005b). It is 
predicted that this haploid genome contains around 12,570 genes, with around 900 
mucin genes and an estimated 219 ribosomal RNA genes. The molecular dissection of 
particular genes is made challenging by the nature of the T. cruzi CL Brener hybrid 
genome and the consequential unknown gene copy number. Recently, the DNA 
„shotgun‟ sequence of the T. cruzi X10/1 strain (group TcI) has been released, which 
should help combat this issue, as the TcI group genome appears less corrupted by 
hybridizations (Franzen et al., 2011). 
1.5.3 The L. major genome 
The genome of L. major MHOM/IL/80/Friedlin is diploid, with the haploid genome 
containing 36 chromosomes ranging from 0.3 to 2.5 Mb in size (Ivens et al., 1998). 
These encode a predicted number of 8,272 protein-coding genes, with only 39 additional 
pseudogenes (Ivens et al., 2005). In contrast to T. cruzi, there is little allelic variation 
between homologues (~0.1%). Intriguingly, of the 36 chromosomes in the L. major 
genome, 20 of these are almost completely syntenic (conserved gene order) with the 
much larger T. brucei chromosomes. Around half of the breakpoints in synteny between 
L. major and T. brucei are observed at “strand-switch” regions, i.e. where there is a 
change in transcriptional orientation of the polycistronic gene arrays (El-Sayed et al., 
2005b). This suggests much of the chromosomal arrangement has been conserved since 
these species diverged, over 200 million years ago (Douzery et al., 2004). 
1.5.4 Gene expression 
Many trypanosomatid genes are arranged in large directional gene arrays. These are 
transcribed as long polycistronic units that are post-transcriptionally modified to 
generate individual mature mRNAs. The genes within an array generally have unrelated 
functions and thus do not constitute the operon arrangement observed in bacteria 
(Clayton, 2002). Unlike many eukaryotes, trypanosomal genes do not generally have an 
exon/intron structure, being solely made up of coding sequence: to date only two T. 
brucei genes have been shown to contain introns (Mair et al., 2000). Transcription of the 
large polycistrons is RNA polymerase II dependent, but surprisingly no RNA 
polymerase II promoters have been found. Instead, it seems that transcription initiation 
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is regulated at the chromatin level, a proposal made after it was noted that certain 
histone variants were enriched at the start of polycistronic arrays in T. brucei (Siegel et 
al., 2009). To generate mature mRNAs, each gene of the polycistronic unit is trans-
spliced with a standard 5‟ splice leader mRNA cap, and also cleaved and polyadenylated 
at the 3‟ end. These processes appear to be linked, and guided by the presence of a 
polypyrimidine tract marker within the intergenic regions (Matthews et al., 1994). 
Expression of the ribosomal RNA arrays is promoter driven and mediated by RNA 
polymerase I, as are some protein coding genes in T. brucei such as the variant surface 
glycoproteins (Kooter and Borst, 1984). 
1.5.5 Genetic manipulation 
Artificial DNA molecules can be successfully delivered into trypanosomes by 
electroporation, facilitating a range of reverse genetic techniques. Parasite populations 
that have taken up exogenous DNA can be selected through exerting drug pressure 
against parasites lacking the accompanying drug markers. To effectively express drug 
maker genes, plus any other additionally introduced genes, the transcript must be 
correctly processed by the parasite. To generate mature mRNA from the initial 
transcription product, accessory flanks commonly derived from „housekeeping‟ genes 
such as α- and β- tubulin, or glyceraldehyde 3-phosphate dehydrogenase (GAPDH), are 
included in DNA constructs to provide the necessary signals to guide RNA processing. 
Arguably the most straightforward form of transgenic gene expression is through a non-
integrative replicative circular episome. For reasons that have yet to be fully elucidated, 
this does not require inclusion of a promoter and is effective in T. cruzi and Leishmania, 
but not in T. brucei. The first trypanosomal episomal expression plasmid was pTEX, 
which contained a neomycin phosphotransferase (Neo) gene flanked with GAPDH 
untranslated sequences (a drug cassette), plus a multiple cloning site featuring an array 
of restriction endonuclease sites to facilitate the insertion of the desired gene (Kelly et 
al., 1992). Additional GAPDH untranslated sequences facilitate elevated expression of 
the desired gene. This basic vector has subsequently been modified to allow even higher 
levels of gene expression (e.g. pRIBO-TEX) (Martinez-Calvillo et al., 1997), epitope 
tagging of a given protein (e.g. pTEX-9E10) (Tibbetts et al., 1995) or fluorescent 
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localization (e.g. pTEX-eGFP and pTEX-RED) (Wilkinson et al., 2002). The major 
drawback of this system however, is that gene expression may not be stable or 
consistent, as episomes are not faithfully segregated during mitosis, instead relying on 
the random distribution between dividing cells, and transcription is stochastic rather than 
promoter driven. 
An alternative strategy, which provides greater stability of gene expression, is to 
integrate directly into the nuclear genome by homologous recombination. Linear DNA 
molecules can be inserted into a chromosome by using flanking regions composed of 
matching target DNA sequences, combined with a central drug marker cassette. This can 
be used to replace existing DNA (Rudenko et al., 1994), for example to effect a gene 
knockout, or to replace non-coding intergenic DNA with an exogenous gene. If these 
two targeting flanks are located adjacent to one another on the chromosome, no native 
DNA is deleted and instead the transgenic DNA sequence is looped into a single locus, 
effectively extending the chromosome marginally with an additional DNA sequence, 
such as an epitope tag (Schimanski et al., 2005). Unless an additional promoter is 
included in the transgenic sequence, constitutive expression of the drug marker and any 
accompanying genes depends on the native RNA polymerase II transcription.   
The next level of sophistication in transgenic gene expression is the development of an 
on-demand inducible gene expression system. This commonly involves using the 
tetracycline (Tet) repressor system from E. coli, which consists of a tetracycline 
repressor and a tetracycline operator sequence, combined with a RNA polymerase 
promoter. The presence of a powerful promoter effectively generates over-expression of 
the desired downstream target gene. An early example of this was developed for T. 
brucei, where a procyclic acidic repetitive protein (PARP) promoter becomes de-
repressed under tetracycline treatment conditions, facilitating expression of the 
luciferase reporter gene (Wirtz and Clayton, 1995). Other systems have been developed 
such as the inducible bacterial T7 promoter based system in T. cruzi (Taylor and Kelly, 
2006; Wen et al., 2001) and the designated ribosomal expression locus coupled to RNA 
polymerase I in T. brucei (Alsford and Horn, 2008). 
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A significant exploitable feature of T. brucei is that it is able to perform RNA 
interference (RNAi), an ability that is absent from T. cruzi and L. major (DaRocha et al., 
2004; Ngo et al., 1998; Robinson and Beverley, 2003). RNAi represents a form of post-
transcriptional gene silencing mediated by the production of double stranded RNA 
(dsRNA). This double stranded RNA molecule is cleaved into 21 – 26 nucleotide long 
RNA fragments by an RNase III endonuclease termed DICER (Shi et al., 2006). These 
small double stranded fragments become bound to an RNA induced silencing complex 
(RISC) by a direct interaction with an Argonaute protein (Shi et al., 2004), which 
induces the degradation of the target RNA template by site-directed cleavage. By 
generating double stranded RNA molecules through an inducible expression system, 
which are unique to a specific gene, it is possible to induce „knockdown‟ of the 
corresponding transcript, thus depleting the corresponding protein levels. Generally, this 
genetic approach is considered simpler than creating gene null mutants, although it can 
generate off-target effects and in many cases the desired protein may not be fully 
depleted. The double stranded RNA required for RNAi can be artificially generated by 
orientating two inverted copies of target DNA sequence downstream of a single RNA 
polymerase promoter so once transcribed the corresponding transcript folds to form a 
hairpin loop structure (Bastin et al., 2000), or by placing two inverted promoters at 
either side of the target DNA sequence to form a „head to head‟ arrangement (Wang et 
al., 2000). Recently, the „head to head‟ approach has been applied to generating a T. 
brucei RNAi library where RNAi inducing DNA fragments representative of the whole 
genome can be used in an unbiased approach to identify new metabolic pathways and 
processes to open up new areas for drug discovery (Alsford et al., 2011; Baker et al., 
2010). 
Many of the aforementioned strategies are employed in the work presented here, to 
investigate a variety of hypotheses on a range of gene targets.  
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1.6 Research Aims 
This thesis is split into two sections, with each section comprised of a separate research 
project. This is as a result of discontinuous funding for the initial project. In the first 
section of this thesis, the genetic nature and location of centromeres on T. brucei and L. 
major chromosomes is explored. The second section investigates pro-drug compound 
candidates functioning through a nitroreductase dependant activation mechanism in T. 
cruzi and T. brucei.      
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SECTION I: 
Topoisomerase-II mediated biochemical mapping of centromeres 
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2 Introduction to Centromeres 
The faithful segregation of replicated chromosomes is essential to the process of cell 
division for all eukaryotic cells. This area of biology has experienced much general 
interest, as a failure to control the process of cell division is thought to be a cause of 
many human cancers (Jallepalli and Lengauer, 2001; Kops et al., 2005). Central to the 
process of mitosis, is the mechanical separation of replicated sister chromatid DNA, 
which requires microtubules from opposing poles of the nucleus attaching to the 
chromosomes, and on the appropriate cellular trigger, physically pulling the sister 
chromatids apart in preparation for cytokinesis. These microtubules attach to the 
chromosomes through the kinetochore protein super-structure, and the chromosomal 
base upon which the kinetochore anchors to the DNA, is termed the centromere.  
Little is known about the participating components and cellular regulation involved this 
aspect of mitosis in trypanosomatids, beyond the observation that many of the genes 
encoding core mitosis proteins identified in a range of other organisms appear absent in 
the trypanosomatid genomes (Berriman et al., 2005). These essential proteins may either 
be highly divergent from their other eukaryote orthologues, or alternatively the whole 
process may proceed via a different mechanism requiring different protein protagonists. 
Any major differences between the human and trypanosomatid systems would create the 
potential to identify novel therapeutic targets, in an area of disease biology already 
established as viable for chemotherapy intervention (Weaver and Cleveland, 2005). An 
important first step in identifying novel or highly divergent proteins is to identify the 
centromeric DNA regions on the chromosomes, because the centromere lies at the heart 
of the chromosome segregation process of cell division. Understanding the centromere 
would facilitate the addressing of further important biological questions including what 
makes these DNA regions unique to a chromosome, and are there associated epigenetic 
features of a centromere in terms of constitutive chromatin structure and the components 
of the kinetochore?  
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2.1 Cell Division 
Cell division is a highly dynamic aspect of cell biology as every feature of the cell must 
be accurately duplicated and separated into daughter cells. The faithful segregation of 
the genomes is no exception to this, being critical in generating viable daughter cells. 
Aneuploidy occurs when aberrations in the chromosome segregation mechanism leads 
to cells with either a fewer or greater number of chromosome homologues than normal. 
In developing human embryos for example, this proves almost always fatal  except for 
certain arrangements of sex chromosomes (Kops et al., 2005), and a few rare cases such 
as a triploid chromosome 21, which causes Down‟s syndrome. In general, the approach 
to cell division in trypanosomatids is similar to most other eukaryotes, although there 
appears to be some differences in components such as for mitosis, as well as variations 
in the cell-cycle regulation process between the life-cycle stages (Hammarton, 2007).  
2.1.1 The cell-cycle: Interphase 
Of the trypanosomatids, probably T. brucei is the best studied in respect to the cell-cycle 
and so will be the reference here. The eukaryotic cell-cycle can be considered in two 
main stages: interphase and mitosis. These represent the period when a cell makes the 
preparations for cell division (interphase), and the actual process of cell division 
(mitosis). Interphase itself can be sub-divided into 4 phases (Figure 2.1.1): Gap 0 (G0), 
Gap
 
1 (G1), DNA Synthesis (S), and Gap 2 (G2). The G0 stage represents a resting 
quiescent period in the cell-cycle where the process of cell division is effectively 
suspended, and is reflected by specific trypanosomatid life-cycle stages such as the T. 
brucei bloodstream non-dividing stumpy forms, and the infectious metacyclic forms 
(Section 1.3.1) (Seed and Wenck, 2003). This relationship illustrates the complexity for 
trypanosomatids in co-ordinating their cell-cycle processes with the various life-cycle 
stages of parasitic infection. The first active period of a dividing life-cycle stage cell, 
such as the T. brucei long slender bloodstream form or procyclic form, is the G1 phase. 
As for most other eukaryotes, this is the point when the cell prepares for the replication 
of the nuclear genome. At this time, trypanosomatids must also prepare to replicate the 
single concatenated network of the kinetoplast DNA. Physically associated with the 
trypanosome kinetoplast is the basal body of the characteristic flagellum. This cellular 
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component appears to be the first feature to replicate during S phase, allowing for the 
further development of a duplicate flagellum (McKean et al., 2003). This is soon 
followed by the DNA replication of a two-part trypanosome S phase, where first the 
kinetoplast DNA (SK phase), and then the nuclear DNA (SN phase), is replicated 
sequentially (Woodward and Gull, 1990). Microscopy of DNA stained procyclic T. 
brucei cells suggests that while the cell proceeds to replicate the nuclear DNA, the 
segregation of the previously duplicated kinetoplast DNA is performed (Siegel et al., 
2008). Coinciding with the separation of the kinetoplast DNA, is the coupled 
segregation of the duplicated flagellar basal bodies (Robinson and Gull, 1991). Once 
this is completed and the nuclear genome has been replicated, the cell exits S phase. 
Now in the G2 phase, preparations are made for mitosis, where the complex task of 
separating sister chromatids, that can be megabases of DNA in length, is enacted.    
 
Figure 2.1.1.  A scheme showing the basic phases of the cell -cycle .  
Eukaryot ic cells may either reside in the G 0  phase,  or progress through the cell-cycle:  
fir st  preparing to replicate the genomes (G1), and then duplicat ing the DNA (S), before 
preparing to  segregate the DNA (G2).  Collect ively these phases are referred to  as 
interphase.  Mitosis fo llows interphase,  and can be sub -divided into four stages: prophase, 
metaphase,  anaphase,  and telophase.  Once mitosis completes,  the separate process of 
cytokinesis is performed, generat ing two daughter cells.  Arrows are for illust rat ion only 
and do not reflect  the durat ion of individual phases.     
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2.1.2 The cell-cycle: Mitosis 
The period of segregating the replicated chromosomes is mitosis. For general 
eukaryotes, this can be sub-divided into four stages: prophase, metaphase, anaphase, and 
telophase (Figure 2.1.1). The timings and specific processes varies between organisms, 
however the themes mostly remain constant, and are outlined below.  
In prophase, the sister chromatids that were replicated previously in S phase remain held 
together by a protein complex called cohesin. The number of components varies, but at 
least four common core components have been identified: two Structural Maintenance 
of Chromosome proteins (Smc) – Smc1 and Smc3, plus Sister Chromatid Cohesion 
proteins (Scc) - Scc1 and Scc3 (Haering and Nasmyth, 2003). The protein complex of 
Smc1 and Smc3 forms a „V‟ structure, and is assembled on chromatids during S phase. 
This binds with the Scc1 protein, forming a conjoined ring structure around both sister 
chromatids, binding them together (Haering et al., 2008). In yeast, this enclosing ring 
structure is maintained through prophase and metaphase, until the chromosomes are 
prepared for segregation. In vertebrates though, much of the cohesin complexes are lost 
during prophase (Darwiche et al., 1999), and only a concentration at the centromeres 
remain, along with a small amount along the chromosomal arms (Waizenegger et al., 
2000). The signal that makes the vertebrate cohesin complexes of the chromosome arms 
dissociate is unknown, although a shugoshin protein has been shown to block the 
dissociation of the concentrated cohesins specifically at the centromere (LeBlanc et al., 
1999; Tang et al., 2004).      
Ordinarily, the characteristic feature of eukaryotic prophase is the condensing of 
chromosomes, where they become easily visible under the microscope. This process 
appears to be driven by a condensin complex containing further Smc proteins:  Smc2 
and Smc4, along with three other proteins: CAP-D2, CAP-G and CAP-H (Losada and 
Hirano, 2001). The details and the mechanism of this process remains a mystery 
(Hudson et al., 2009), however recently it has been shown in Saccharomyces cerevisiae 
that condensin is heavily enriched at the centromere, for as yet unknown reasons 
(D'Ambrosio et al., 2008). In regard to trypanosomatids, putative orthologues of the 
Smc1, Smc3, Scc1 and Scc3 proteins of the cohesin complex have been identified in the 
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T. brucei genome (Gluenz et al., 2008), along with potential orthologues for Smc2, 
Smc4 and CAP-D2 of the condensin complex (Hammarton, 2007). The apparent 
presence of components of the condensin complex in the trypanosome genome is 
surprising, as trypanosomatid chromosomes appear not to condense during mitosis 
(Galanti et al., 1998), although it is worth noting condensin complexes also appear to 
have roles outside of mitosis (Wood et al., 2010). 
During the prophase of higher eukaryotes, the nuclear envelope breaks down, and 
mitosis is performed in the open (De Souza and Osmani, 2007), however for 
trypanosomatids and many other protists the nuclear envelope remains intact, and 
mitosis is performed within a closed nuclear environment (Vickerman and Preston, 
1970). The assembly of the large kinetochore structures at the centromeres of the 
individual chromosomes is finalized during prophase, in preparation for attachment to 
the microtubules (Chan et al., 2005). Commonly these microtubules are propagated from 
two opposing microtubule organizing centres, which are part of specialized bodies 
dedicated for mitosis, termed centrosomes (Bornens, 2002). Normally a single 
constitutive centrosome, or equivalent body, is present throughout the cell-cycle, which 
then duplicates in S phase in readiness for mitosis (Lim et al., 2009). No centrosome or 
similar feature has been identified in T. brucei, although during mitosis it appears that 
microtubules are still seeded from two opposing points near the intact nuclear envelope, 
suggesting the existence of some form of microtubule organizing centre that can form 
the mitotic spindle and attach microtubules to kinetochores (Ogbadoyi et al., 2000). 
Another unresolved question in T. brucei is that so far only eight kinetochore-like 
plaques have been identified by using electron microscopy (Ogbadoyi et al., 2000), 
which doesn‟t correlate with the 22 megabase chromosomes of the duplicated genome 
that requires segregation. This however, assumes that T. brucei follows the classical 
segregation mechanism of each chromosome attaching separately to microtubules 
through their own kinetochore. It also raises the further question of how do the 
approximately 100 mini-chromosomes of T. brucei also become faithfully segregated, 
given the limited number of kinetochores (Gull et al., 1998). These issues are not 
restricted to T. brucei, as there appears to be a shortfall in the number of kinetochore-
like plaques observed in T. cruzi and also L. major (Solari, 1980; Urena, 1988). 
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The metaphase procedure whereby microtubules propagate from centrosomes seeking 
out the kinetochores assembled on centromeric DNA is thought to be random (Haering 
and Nasmyth, 2003). For many eukaryotes, after a chromosome has been successfully 
connected to mitotic microtubules from both of the opposing sides of the nucleus in a bi-
polar attachment, the resulting physical tension leads to the chromosome being drawn to 
the middle of the nucleus. As this migration is repeated across the full complement of 
chromosomes, they begin to line up spanning the nucleus equator (Figure 2.1.2). Cells 
are held in metaphase by the mitotic spindle checkpoint until all kinetochores have 
successfully attached to mitotic microtubules, ensuring that all sister chromatids can be 
faithfully segregated (Yu, 2002). It remains controversial what the actual signal is for 
reporting when a chromosome is correctly associated with mitotic microtubules. 
Whether the trigger is simply the tethering of the kinetochore to a number of 
microtubules, or alternatively the microtubule tension produced by pulling apart sister 
chromatids still bound together, is debated (Bloom and Yeh, 2010). 
 
 
Figure 2.1.2.  Immunofluorescence images of human chromosomes at metaphase . 
(A) Chromosomes of a HeLa cell stained with DAPI (blue) have condensed and aligned 
across the nuclear equator (Dynek and Smith,  2004).  The centromeres have been la belled 
with a specific ant ibody (green).  (B) A further ant ibody against  α-tubulin (red) highlights 
the microtubules emanat ing from the centrosomes towards the kinetochores assembled on 
the centromeres.  Images reproduced from Dynek and Smith,  2004.       
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While the sensor mechanism detecting the kinetochore attachment to microtubules 
remains unknown, more is known about the sophisticated signalling system. Mitotic-
arrest deficient (MAD) proteins MAD1, MAD2, and MAD3, plus budding uninhibited 
by benzimidazole (BUB) proteins BUB1 and BUB3 were first identified in S. cerevisiae 
as key components of a complex signalling pathway that inhibits the start of the 
chromosome segregation process while any chromosomes remain unattached to the 
microtubules (Hoyt et al., 1991). These key proteins have since been identified in a 
range of eukaryotes and appear to localize at the kinetochore (Yu, 2002), although of 
these, only MAD2 has been identified so far in T. brucei (Berriman et al., 2005). 
Collectively, they represent the spindle assembly checkpoint (Figure 2.1.3). It has been 
observed in S. cerevisiae that mutating centromeric DNA leads to a delay in mitosis, 
which is believed to be mediated by the spindle assembly checkpoint, despite the 
kinetochore correctly assembling on the mutated centromere (Spencer and Hieter, 1992). 
Once all of the chromosomes are ready for segregation, this inhibition pathway is 
retracted via the spindle assembly checkpoint proteins no longer binding to another 
protein, CDC20 (Hwang et al., 1998). The CDC20 protein is a co-factor of the anaphase 
promoting complex (APC), and a wealth of research has shown that when CDC20 is 
freed of the spindle assembly checkpoint proteins, it no longer represses the activity of 
the anaphase promoting complex (reviewed in Musacchio and Salmon, 2007). As the 
anaphase promoting complex becomes active, it begins the process of chromosome 
segregation, the period of anaphase. 
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Figure 2.1.3. Diagram showing key protein in teractions of the mitotic control 
checkpoint. 
During the t ransit ion from prophase to metaphase the spindle assembly checkpoint  
proteins MAD2, BUB3, and BubR1 (MAD3) inhibit  the act ivat ion of the chromosome 
segregat ion pathway by binding the anaphase promot ing complex (APC) via the protein 
CDC20. Once all kinetochores have attached to the mitot ic microtubules at  metaphase,  an 
unknown t rigger releases the spindle assembly checkpoint  proteins from CDC20, which 
act ivates the APC and promotes chromosome segregat ion and anaphase.  Diagram 
reproduced from Yu, 2002.  
  
 
The anaphase promoting complex is an E3 ligase, part of the ubiquitination system 
(King et al., 1995; Sudakin et al., 1995). It ubiquitinates a range of mitosis related 
proteins, targeting them for proteasome mediated degradation (Peters, 1999). One 
important protein is securin (Funabiki et al., 1996; Yamamoto et al., 1996), which acts 
as an inhibitory chaperone of the protein separase (Ciosk et al., 1998). Upon the 
degradation of securin, separase is free to sever the cohesin ring complex through 
cleavage of the Scc1 sub-unit (Uhlmann et al., 1999). In yeast, this frees both the 
chromosome arms and centromeres of their restrictive ties, while in vertebrates the 
remaining cohesin still located at the centromeres is finally removed. For all studied 
eukaryotes this separase activity triggers the segregation of the nuclear chromosomes, 
anaphase.  
Last in mitosis is telophase, during which the kinetochores disassemble as the cell tidies 
up from the segregation process. In organisms where chromosomes have condensed 
during prophase, these now de-condense, and for organisms that perform an open 
Prophase Metaphase Anaphase
52 
 
mitosis, new nuclear envelopes are constructed around the two daughter nuclei 
(Walczak et al., 2010).  
Cytokinesis, or mitotic exit, represents the final stage of the cell-cycle, and is a separate 
process from mitosis, involving the cell physically splitting into two daughter cells. 
While many genes involved in the exit from mitosis have been identified in model 
organisms, it has proved difficult to unravel the complex and often overlapping 
signalling systems (Bosl and Li, 2005). Even less is known in trypanosomes, where 
many potential candidates have been identified, but little experimental research has been 
performed (Hammarton, 2007). The various life-cycle stages of trypanosomes look set 
to complicate matters further, as it has been shown that a mitotic exit checkpoint present 
in the bloodstream form T. brucei appears absent in the procyclic form (Hammarton et 
al., 2003).    
2.2 Centromere structure 
2.2.1 Centromeric DNA 
As described previously, the centromere has a vital role in segregating the nuclear 
chromosomes, in both providing the kinetochore assembly site facilitating the tethering 
to mitotic microtubules, and binding sister chromatids together until the cell is ready for 
anaphase. Despite the conservation of the basic mechanism of mitosis in eukaryotes, the 
composition of centromeric DNA in both length and sequence varies considerably.  
The first centromere to be identified was in the budding yeast S. cerevisiae (Clarke and 
Carbon, 1980), and was shown to consist of a minimal „point‟ entity of only 125 bp of 
DNA, which was conserved across chromosomes (Cottarel et al., 1989). This small 
centromeric region is comprised of three conserved DNA elements: CDEI (14 bp), 
CDEII (~90 bp), and CDEIII (11 bp), notably with the DNA of element CDEII being 
90% AT-rich (Figure 2.2.1) (Fitzgerald-Hayes et al., 1982). Even at this early stage, 
experiments had shown that simply inserting this DNA sequence on a foreign piece of 
DNA was insufficient to generate an effective budding yeast centromere, suggesting a 
53 
 
role for chromatin in establishing a centromere, and the potential for epigenetic 
inheritance of centromeres (Bloom and Carbon, 1982).  
The „point‟ centromere of S. cerevisiae is far from mainstream, for instance the fission 
yeast Schizosaccharomyces pombe possesses a much larger, regional centromere 
spanning 40-100 kb in length (Chikashige et al., 1989; Fishel et al., 1988). At the centre 
of these centromeres is a non-repetitive 4-7 kb central core region, flanked by innermost 
repeats, and then outermost repeats (Figure 2.2.1). The central core region is not 
identical between chromosomes, but does share a high level of homology, with 
approximately a 70% AT codon bias (Wood et al., 2002). The innermost repeat region 
consists of divergent inverted repeat sequences, while the outermost repeats actually 
contain 3 separate types of repeat sequences. Different protein compositions were 
observed at the central core and innermost repeat region, compared with the outermost 
repeats (Partridge et al., 2000), for example the histone H3 variant, CENP-A was only 
found at the central core (Kniola et al., 2001), which is suggestive of multiple functional 
chromatin domains in the region. In S. pombe a centromeric enhancer DNA sequence, 
dispensable for native chromosomes, is required to establish a new centromere on 
artificial chromosomes (Marschall and Clarke, 1995). Further, as two completely 
different DNA sequences derived from centromeres have been used in conjunction with 
this enhancer to generate a new active fission yeast centromere on an artificial 
chromosome (Ngan and Clarke, 1997), it seems that specific DNA sequence does not 
define a fission yeast centromere. Instead it is suggested that only certain classes of 
DNA elements are required to form an active centromere, and once established the 
epigenetic features of an active centromere are inherited (Ngan and Clarke, 1997). 
Much larger regional centromeres than those of S. pombe were later found in Drosophila 
melanogaster. Here, the central centromeric core occurs in a region spanning 200 kb, 
flanked either side by a further 200 kb of repeat sequence (Figure 2.2.1) (Murphy and 
Karpen, 1995). Unlike the model yeast systems, the Drosophila centromeric region is 
contained within heterochromatin blocks. The flanking satellite repeats consist of only 
two types of 5 bp repeat sequence (Sun et al., 1997), which are heavily AT codon biased 
(AATAT & TTCTC). These satellite repeats are not unique to the centromeric regions, 
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suggesting they do not represent a centromere in themselves (Sun et al., 2003). At the 
centromere the 200 kb central core features multiple intact retrotransposons, 
interspersed with the AATAT satellite repeat, plus a single 16.2 kb island containing a 
single AT-rich sequence. This single sequence is not identical between centromeres of 
different chromosomes (Sun et al., 2003), fuelling the notion that DNA sequence itself 
does not define a centromere. The idea of epigenetic marking of centromeres is further 
supported in Drosophila where experiments showed that by first inserting a non-
centromeric test DNA sequence next to an existing centromere, then liberating the new 
test sequence by irradiation, a viable centromere on the test sequence was could be 
generated (Maggert and Karpen, 2001). The observation supported the concept of a 
protein based centromeric defining marker spreading to neighbouring DNA regions to 
establish a neocentromere.  
Human centromeric regions are larger still, spanning megabases of heterochromatin 
along a chromosome (Figure 2.2.1). They are made predominantly of 171 bp uniformly 
directed α-satellite repeats (Heller et al., 1996), which are approxiamtely 70% rich in 
AT content (Koch et al., 1989), and interspersed with retroelements (Schueler et al., 
2001). Since human centromeres span such large distances it has proved difficult to fully 
sequence these regions, meaning that it is possible that any small unique centromeric 
sequences could be easily missed (Murphy and Karpen, 1998). These α-satellite repeats 
are also not required for an active centromere, as neocentromers formed in alterative 
euchromatic regions of human chromosomes do not contain these sequences (Voullaire 
et al., 1993), again suggesting a role for epigenetic marking of centromeres. Plant 
centromeres also contain this satellite DNA, for example Arabidopsis thaliana 
centromeres contain a 180 bp satellite repeat, unrelated to the human sequence, but 
which is arranged in a similar fashion including the presence of intact retroelements 
(Copenhaver et al., 1999). These repeat regions range from around 1.4 to 4.4 Mb in size 
(Haupt et al., 2001), but unlike the human repeats, the AT/GC codon bias of the 
Arabidopsis centromeric repeats remains consistent with the genome average (~64% 
AT) (Copenhaver et al., 1999). The centromeres of rice chromosomes are again 
composed of retroelements and satellite repeats, this time of 155 bp units spanning 
between 65 kb to 2 Mb (Cheng et al., 2002). 
55 
 
 
 
Figure 2.2.1.  Structure of eukaryotic centromeres. 
The „point‟ centromere of S. cerevisiae  spans 125 bp and consists of 3  conserved DNA 
elements (CDE) that  are ident ical between all chromosomes (Clarke and Carbon, 1980; 
Cottarel et  al. , 1989).  The small regional centromere of S. pombe  contains a non-
repet it ive 4-7 kb central core region (cnt),  flanked by innermost  repeats (imr), and 
outermost  repeats (otr).  Unlike S. cerevisiae  the central core of S. pombe  is  not  conserved 
in sequence between chromosomes (Chikashige et  al. ,  1989; Fishel et  al. ,  1988) . 
Drosophila  centromeres span much larger regions,  and contain small satellite repeat  
sequences with a central core containing retroelements and a u nique AT-rich sequence 
„island„(Murphy and Karpen, 1995; Sun et  al. ,  2003) .  The human centromere spans 
megabases of 171 bp α-satellite repeats,  interspersed with retroelements (Heller et al. , 
1996; Schueler et al. , 2001) . Figure reproduced from Morris and Moazed, 2007. 
 
Although the mainstream centromere of fission yeast, metazoans and plants appear to be 
single regional centromeres of various lengths and compositions, the point centromere 
of S. cerevisiae is not alone in being unusual. The site of kinetochore assembly of the 
worm, Caenorhabditis elegans, is not a single centromere entity, as for all the 
previously described organisms, but instead is a series of centromeres that extend the 
full length of the chromosomes (Albertson and Thomson, 1982). Each centromere 
contains a fully functional kinetochore capable of attaching to mitotic microtubules and 
facilitating chromosome segregation (Oegema et al., 2001). Given the potential for the 
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introduction of neocentromeres in some of the previously discussed organisms 
containing the more common regional centromeres, the holocentric nature of C. elegans 
raises the question of how only one functional regional centromere can be actively 
maintained on these chromosomes at a time? 
2.2.2 Centromeric proteins 
Since there seems no consensus DNA sequence that constitutes a centromere between 
organisms, or indeed a conserved centromeric DNA sequence between chromosomes of 
a single organism, the evidence supports a significant role for epigenetics. Although the 
typical kinetochore consists of over 80 proteins, most of these are transiently assembled 
at the centromere during mitosis (Cheeseman and Desai, 2008). The known major 
constitutive protein elements are the DNA binding proteins CENP-A, CENP-B, and 
CENP-C (the antigens of the ACA antibody in Figure 2.1.2), although the levels of 
CENP-B and CENP-C fluctuate during the cell-cycle (Hemmerich et al., 2008). 
Therefore the prime candidate for epigenetically establishing centromeres is the histone 
H3 variant, CENP-A. This was first identified in humans, where it shares approximately 
60% sequence identity to that of the standard histone H3 at the C-terminal end (Palmer 
et al., 1987). The centromere specific CENP-A histone variant has now been found in 
almost all other studied eukaryotes including: S. cerevisiae (Meluh et al., 1998), S. 
pombe (Takahashi et al., 2000), Drosophila (Henikoff et al., 2000), C. elegans 
(Buchwitz et al., 1999), and Arabidopsis (Talbert et al., 2002), making it widely 
accepted as the key constituent of the centromere (Mellone et al., 2009). Further 
evidence for CENP-A regulating the centromere came from experiments analyzing 
neocentromeres on human chromosomes. These showed that only the new active 
centromere contained CENP-A, while the old inactive α-satellite repeat region now 
lacked CENP-A (Warburton et al., 1997). It is a surprise then, that a CENP-A 
orthologue has not yet been found in trypanosomatids (Berriman et al., 2005). Another 
constitutive candidate for regulating a centromere is the DNA binding protein, CENP-B, 
which was first identified as binding to short sequences of α-satellite repeats (Masumoto 
et al., 1989). CENP-B forms a complex with CENP-A and CENP-C, and also proteins 
of the inner kinetochore, suggesting that CENP-B has a role in connecting the 
kinetochore assembly to the centromere (Ando et al., 2002). While putative orthologues 
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of CENP-B have been identified in most model eukaryotes (Chan et al., 2005), it is not 
essential in establishing the kinetochore (Hudson et al., 1998), and is also not found at 
neocentromeres (Choo, 2001). As for CENP-A, no potential orthologues have been 
identified in trypanosomatids (Berriman et al., 2005). In fact this pattern continues, with 
the DNA binding protein CENP-C (Sugimoto et al., 1994) also apparently absent from 
the trypanosomatid genome.  
With no obvious DNA sequence that defines a eukaryotic centromere in 
trypanosomatids, and the absence of any constituent centromeric proteins, locating the 
centromeric loci on chromosomes is not straightforward. Even many transient 
kinetochore proteins have yet to be identified in trypanosomatids, making the eventual 
task of discovering novel or divergent proteins involved in mitosis challenging but full 
of potential. These missing key proteins include the microtubule motor protein of the 
kinetochore CENP-E (Wood et al., 1997), the kinetochore matrix protein CENP-F (Liao 
et al., 1995), the Mis12 protein of the inner kinetochore (Takahashi et al., 1994), and the 
kinetochore-microtubule linker complex Ndc80 (McCleland et al., 2004). However, an 
enzyme that is present in the nucleus of trypanosomatids (Fragoso et al., 1998) and has 
been shown to locate to centromeres of mammalian cells (Rattner et al., 1996) is the 
DNA topological manipulation enzyme, topoisomerase-II. 
2.3 Topoisomerase-II 
Topoisomerases are enzymes that cut and anneal DNA strands to regulate the 
topological properties of DNA during transcription and replication such as DNA super-
coiling and tangles. They can be separated into two types: topoisomerase-I enzymes cut 
only a single strand of DNA to aid the relaxation of super-coiled DNA by passing the 
intact strand through the gap in the cleaved strand and then re-sealing the single stranded 
break; topoisomerase-II cleaves both DNA strands allowing the passage of an intact 
DNA duplex through the gap, which is then re-annealed after the passage of the α-helix. 
Topoisomerase-II can either pass through a DNA duplex that is part of the same DNA 
molecule that has been cut by the enzyme to untangle a knot, or the cleaved DNA 
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duplex may be decatenated from a separate DNA molecule, such as sister chromatids 
following DNA replication. 
The first topoisomerase-II (DNA gyrase) was discovered in bacteria where it was shown 
to be ATP and magnesium dependent (Gellert et al., 1976). Later in Xenopus laevis the 
first eukaryotic topoisomerase-II was identified, sharing the same dependencies as its 
bacterial counterpart (Baldi et al., 1980). The bacterial DNA gyrase was shown to stay 
covalently bound to the cleaved DNA molecule through 2 phosphodiester bonds located 
4 bp apart on opposing strands (Morrison and Cozzarelli, 1979). This behaviour was 
found to be conserved in eukaryotic topoisomerase-II (Liu et al., 1983; Sander and 
Hsieh, 1983), with the interaction shown to be mediated via an N-terminal catalytic 
tyrosine residue (Horowitz and Wang, 1987). Based on a large body of biochemical 
data, a central mechanism of topoisomerase-II decatenation has been proposed. It begins 
with topoisomerase-II dimerizing, followed by the binding and cleavage of the first 
DNA molecule by the paired tyrosine residues of the dimerized N-terminal catalytic 
domains. Then the central ATPase domain of topoisomerase-II controls the passage of 
the second DNA molecule through the double stranded DNA break in an ATP 
dependent gate-regulated manner, before the double stranded DNA break is then re-
ligated (Champoux, 2001). The C-terminus of topoisomerase-II appears unnecessary for 
enzyme activity, as deletions up to around 240 amino acids from the C-terminal end 
resulted in no loss of in vitro activity in Drosophila (Crenshaw and Hsieh, 1993) and 
budding yeast (Caron et al., 1994).  
The lack of any obvious functional role for the C-terminus of topoisomerase-II has lead 
to much speculation that it may instead be involved in regulation of the enzyme. In S. 
cerevisiae topoisomerase-II is phosphorylated by casein kinase II in vivo at the C-
terminus (Cardenas et al., 1992). A later study in S. cerevisiae using affinity purification 
techniques has showed that casein kinase II is stably associated with topoisomerase-II 
even after phosphorylation, and that topoisomerase-II becomes more active following its 
phosphorylation (Bojanowski et al., 1993). Human topoisomerase-II has also been 
shown to be phosphorylated at the C-terminus by casein kinase II (Daum and Gorbsky, 
1998), as well as casein kinase I /  (Grozav et al., 2009). The phosphorylation of 
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topoisomerase-II also appears to be cell-cycle dependent and up-regulated during G2 
phase and mitosis (Escargueil et al., 2000; Wells and Hickson, 1995), potentially 
because at this stage in the cell-cycle, chromosomes have now been replicated and 
therefore may require decatenation before the beginning of the segregation process. In 
fact phosphorylation of topoisomerase-II by polo-like kinase 1 has been shown to be 
essential for sister chromatid segregation (Li et al., 2008). 
Topoisomerase-II has been shown to specifically accumulate at conventional 
centromeres and at neocentromeres during mitosis (Rattner et al., 1996; Saffery et al., 
2000), suggesting its recruitment to the centromere may not be DNA sequence based. 
This is supported by the finding that on human chromosomes with multiple centromeres, 
only the single active centromere contains topoisomerase-II (Andersen et al., 2002). 
With an artificial chromosome, centromere adjacent truncations which introduces a 
neighbouring telomere, also shifts cleavage loci of topoisomerase-II at the centromere, 
again suggesting an epigenetic guidance of topoisomerase-II activity (Spence et al., 
2002). This domain of topoisomerase-II activity also coincided with the presence of the 
centromeric proteins CENP-A, and CENP-C. It also seems that topoisomerase-II activity 
specifically at the centromere is important for mitosis, however not essential, as 
segregation of a small human artificial chromosome is perturbed by depletion of 
topoisomerase-II (Spence et al., 2007). Separation of Drosophila centromeres at 
anaphase is also inhibited by the depletion of topoisomerase-II, further supporting this 
observation (Coelho et al., 2008). It appears in human cells that centromeres are held 
together at anaphase by not only the cohesin ring complex, but also catenated DNA 
fibres that persist after the anaphase promoting complex mediated activity of separase, 
and which require the activity of topoisomerase-II to untangle (Baumann et al., 2007; 
Wang et al., 2008).    
There is now increasing evidence that topoisomerase-II localization at the centromere is 
controlled by the small ubiquitin-like modifier protein (SUMO). The SUMO protein 
conjugates to a target protein in a similar fashion to ubiquitin, through an E3 ligase 
pathway. In S. cerevisiae there is evidence that SUMOylation of topoisomerase-II 
coincides with the cohesion between sister chromatid centromeres and chromosome 
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segregation defects (Bachant et al., 2002). Experiments in Xenopus suggest that SUMO 
conjugation of topoisomerase-II is responsible for the localization to the centromere 
during mitosis (Azuma et al., 2005), with a similar observation made in human cells 
(Dawlaty et al., 2008). Intriguingly, in procyclic T. brucei cells, SUMO deficiency leads 
to cell-cycle arrest between G2/Mitosis. Therefore potentially, topoisomerase-II and 
SUMO may play an important role during chromosome segregation and centromeric 
specific activity in trypanosomatids.  
2.3.1 Biochemical mapping of centromeres with topoisomerase-II 
The anti-cancer drug etoposide was first licensed in the mid 1980s and targets 
topoisomerase-II. It has been used to treat Hodgkin‟s disease, non-Hodgkin‟s 
lymphoma, lung cancer, gastric cancer, breast cancer and ovarian cancer (Hande, 1998). 
It was shown to act as a poison by inhibiting only the DNA re-ligation step, once the 
DNA had been enzymatically cleaved, thus trapping the topoisomerase-II complex and 
generating permanent lesions in chromosomes (Chen et al., 1984). In etoposide treated 
mice, these DNA lesions were found concentrated in centromeric regions of 
chromosomes (Kallio and Lahdetie, 1996), which correlates with what is known about 
topoisomerase-II accumulation at centromeres. Following this observation, an 
experiment was performed in Drosophila where flies were treated with a topoisomerase-
II poison (VM-26), and then their genomic DNA was isolated and separated by pulsed 
field gel electrophoresis. By resolving the DNA lesion fragment sizes, the positions of 
the lesions were found to localize towards centromeric regions, similar to the 
experiments in mice, and hence topoisomerase-II poisoning was proposed as a method 
for mapping centromeric chromatin regions on chromosomes (Borgnetto et al., 1999). 
This technique was first implemented to map the centromeric region of the human Y 
chromosome (Floridia et al., 2000) to the α-satellite repeats, then the X chromosome 
(Spence et al., 2002) and later chromosome 11 (Spence et al., 2005). It has since been 
used to map the centromeres on the malaria parasite Plasmodium falciparum (Kelly et 
al., 2006).  
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2.4 Research Objectives 
The aim of investigating the nature and location of centromeres on trypanosomatid 
chromosomes can be defined by the following core objectives: 
 To biochemically map the centromeric locations of T. brucei megabase 
chromosomes using topoisomerase-II and etoposide mediated DNA cleavage. 
 To identify any signature DNA sequences or features indicative on a centromere 
between T. brucei chromosomes. 
 To extend the biochemical mapping technique to investigate the activity on the 
T. brucei mini-chromosomes. 
 To apply the biochemical mapping technique to L. major chromosomes. 
 To investigate potential centromeric specific activity of topoisomerase-II in 
bloodstream form T. brucei. 
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3 Materials and Methods 
3.1 Cell Culturing and Storage 
3.1.1 Bacterial strains 
The E. coli strains used in this project were DH5α (φ80dlacZΔM15, recA1, endA1, 
gyrAB, thi-1, hsdR17(rK-, mK+), supE44, relA1, deoR, Δ(lacZYA-argF) U169, phoA), 
XL1-Blue (recA1, endA1, gyrA96, thi-1, hsdR17(rK-, mK+), supE44, relA1, lac,  [ F', 
proAB, lacI
qZΔM15::Tn10(tetr)]) and SCS110 (rpsL (Strr) thr leu endA thi-1 lacY galK 
galT ara tonA tsx dam dcm supE44 Δ(lac-proAB) [F´ traD36 proAB lacIqZΔM15]). 
They were grown in NZCYM broth (10 g l
-1
 enzymatic casein digest, 1 g l
-1
 Casamino 
acids, 5 g l
-1
 yeast extract, 5 g l
-1
 NaCl, 0.98 g l
-1
 MgSO4: Sigma) or on plates 
supplemented with 1.5%  (w/v) agar (Sigma), containing 50 µg ml
-1 
ampicillin, where 
appropriate. 
3.1.2 Mammalian cells 
African Green Monkey Kidney epithelial (Vero C1008) cells (ATCC CRL-1586) were 
cultured in RPMI-1640 medium (Sigma) supplemented with 5 g l
-1
 HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid), 0.34 g l
-1
 sodium glutamate, 0.22 g l
-1
 
sodium pyruvate, 2500 U l
-1
 penicillin, 0.25 g l
-1
 streptomycin and 10% (v/v) foetal calf 
serum at 37 C with 5% CO2. To passage cells, the existing growth medium was 
removed and replaced with 10 ml UV-irradiated trypsin containing EDTA (PAA). After 
2 minutes at room temperature, the trypsin was removed, and the cells were incubated at 
37 C for a further 10 minutes, with gentle agitation. Detached cells were collected in 
fresh medium and transferred to a new flask containing fresh medium. Cultures were 
passaged once every 3-4 days, with a single Vero cell line maintained in culture for no 
longer than 6 months. Fresh medium was prepared at least once a month.  
The foetal calf serum used in all eukaryotic culturing was designated as tetracycline free 
by the manufacturer (Autogen Bioclear) and was heat treated (55
o
C for 30 min) to 
inactivate components of the complement cascade prior to use. 
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3.1.3 Trypanosoma brucei 
The procyclic form (PCF) of T. brucei TREU 927/4 was cultured in SDM-79 medium 
(Invitrogen) supplemented with 7.5 mg l
-1
 haemin and 10% (v/v) tetracycline-free foetal 
calf serum at 27 C (Brun and Schonenberger, 1979). In topoisomerase-II mediated DNA 
cleavage studies, T. brucei PCF cells (2 x 10
6
 cells ml
-1
) in the logarithmic phase of 
growth were treated with 500 µM etoposide (Sigma) dissolved in dimethyl sulfoxide 
(DMSO) for 1 hour. 
The bloodstream form (BSF) of T. brucei Lister 427 MITat 1.2 clone 221a was grown in 
HMI-9 (Invitrogen) supplemented with 3 g l
-1
 sodium bicarbonate, 0.014% (v/v) β-
mercaptoethanol and 10% (v/v) foetal calf serum at 37
o
C with 5% CO2 (Hirumi and 
Hirumi, 1989). A derivative of this cell line (designated 2T1/TAG
PURO
), that 
constitutively express the tetracycline repressor protein, was maintained in the above 
medium supplemented with 2 µg ml
-1
 phleomycin (Alsford and Horn, 2008). De-
repression of the tagged locus via removal of the DNA bound tetracycline repressor 
protein was initiated with 1 g ml
-1
 tetracycline. In topoisomerase-II mediated DNA 
cleavage studies, T. brucei BSF cells (2 x 10
6
 cells ml
-1
) in the logarithmic phase of 
growth were treated with 100 µM etoposide for 30 minutes. 
3.1.4 Trypanosoma cruzi 
All T. cruzi epimastigote cell-lines were cultured in RPMI-1640 medium (Sigma) 
supplemented with 5 g l
-1
 trypticase, 5 g l
-1
  HEPES pH 8.0, 20 mg l
-1
 haemin, 0.34 g l
-1
 
sodium glutamate, 0.22 g l
-1
 sodium pyruvate, 2500 U l
-1
 penicillin, 0.25 g l
-1
 
streptomycin and 10% (v/v) tetracycline-free foetal calf serum at 27 C (Kendall et al., 
1990).  
The amastigote form of T. cruzi (clones MHOM/BR/78/Sylvio-X10-6 and CL Brener) 
were cultured as follows.  T. cruzi epimastigote cultures (1 ml) in the stationary phase of 
growth (8-10 day old cultures) were transferred to a freshly passaged Vero culture and 
allowed to infect the mammalian cells overnight at 37°C under a 5% CO2 atmosphere. 
The following day, free parasites were removed by extensively washing the monolayer 
with fresh Vero cell growth medium. The infected Vero culture was maintained at 37°C 
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under a 5% CO2 atmosphere, and every 4 days the growth medium changed. Ten to 14 
days after the initial infection, bloodstream trypomastigotes were microscopically 
observed. These were collected and used to infect fresh Vero cell monolayers to 
propagate the infection. Amastigote cells were maintained in culture for no longer than 3 
months before being discarded. 
3.1.5 Leishmania major 
The promastigote form of L. major MHOM/IL/80/Friedlin was cultured in SDM-79 
medium supplemented with 3 g l
-1
 sodium bicarbonate, 7.5 mg l
-1
 haemin and 10% (v/v) 
foetal calf serum at 27 C. 
3.1.6 Cell storage  
For long term storage, bacterial strains and trypanosomatid lines were deposited as 
frozen stocks in liquid nitrogen (parasite lines) or at -80
o
C (prokaryotic strains) in fresh 
growth medium containing 20% (v/v) glycerol. For BSF T. brucei each 1 ml stock 
contained approximately 1 x 10
6
 parasites whereas for T. cruzi epimastigotes, L. major 
promastigotes and T. brucei PCF approximately 1 x 10
7
 cells ml
-1
 were used. Bacterial 
strains were frozen directly at -80
o
C in 1.2 ml cryogenic vials (Nunc). Trypanosomatid 
lines, in 1.2 ml cryogenic vials (Nunc), were frozen slowly (1-2 days) to -80
o
C using a 
Cryo 1°C Freezing Container (Nalgene) containing isopropanol, then transferred to 
liquid nitrogen for long-term storage. Mammalian (Vero) cells were frozen in fresh 
growth medium containing 20% (v/v) DMSO at a density of 1 x 10
5
 cells ml
-1
. Frozen 
stocks were generated as described for trypanosomatid lines using the Cryo 1°C 
Freezing Container (Nalgene). 
Eukaryotic cell lines were revived by quickly thawing the contents of the frozen vial. 
Thawed cells were washed in 10 ml of appropriate medium, pelleted by centrifugation 
for 5 minutes (parasites: 1640 g, Vero cells: 400 g), and the medium removed. Cells 
were then re-suspended in fresh medium as per normal culturing. 
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3.2  Nucleic Acid Extraction 
3.2.1 Plasmid DNA 
A tube of NZCYM (5 ml) containing 50 µg ml
-1
 ampicillin was inoculated with the 
desired E. coli strain and incubated overnight at 37
o
C with vigorous aeration. Plasmid 
DNA was then extracted from the culture using an AccuPrep® Plasmid Mini extraction 
kit (Bioneer), in accordance to manufacturer‟s instructions. The basis of this approach 
involves the alkali lysis of the bacteria followed by neutralisation of the extract. 
Chromosomal DNA and cell debris was then removed following centrifugation and the 
cleared lysate is applied to a DNA binding column. Under the salt concentrations 
derived from the neutralisation buffer, any DNA molecules bind to the silica membrane 
within the column. Salts and precipitates were then removed by a series of 
centrifugation and ethanol-based wash steps, before eluting DNA from the column into 
a low salt buffer such as TE (10 mM Tris-HCl, 1 mM EDTA). Plasmid samples were 
then stored at -20 C. 
3.2.2 Parasite genomic DNA 
Parasites (5 x 10
7
) in the logarithmic phase of growth were pelleted by centrifugation at 
1640 g for 10 minutes at room temperature, washed in PBS (137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.6), then harvested. The cell pellet was 
re-suspended in 2 ml lysis buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 100 mM 
NaCl, 1% (w/v) sodium dodecyl sulphate (SDS) containing 100 µg ml-1 proteinase K) 
and incubated at 37 C overnight. The lysis solution was then gently mixed with an equal 
volume of phenol. The aqueous/organic phases were partitioned by centrifugation at 
3555 g for 10 minutes and the aqueous phase collected. This was then mixed with an 
equal volume of phenol/chloroform (1:1), partitioned as described above and the 
aqueous phase retained. If required, the phenol/chloroform step was repeated. The DNA 
containing aqueous phase was finally transferred to a fresh tube and the nucleic acid 
precipitated using an equal volume of isopropanol. The resultant fibrous material was 
collected, transferred to a fresh 1.5 ml centrifuge tube and briefly dried under vacuum. 
The nucleic acid was re-suspended in TE buffer containing RNase A (Sigma), added to 
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a final concentration of 1 µg ml
-1
, and incubated for 1 hour at 37 C. Samples were 
stored at 4 C.  
3.2.3 Intact trypanosomatid chromosomes 
Parasites in the logarithmic phase of growth were pelleted by centrifugation at 1640 g 
for 10 minutes at room temperature, washed in PBS, and the cells harvested. The pellet 
was re-suspended at a density of 2 x 10
7 
cells ml
-1
 in 1.4% Low Melting Point Agarose 
(BioRad) in PBS held at 42 C, and dispensed into a mould (BioRad): the cell density 
used equated to 5 x 10
7 
parasites per agarose block. The agarose was allowed to solidify 
for 30 minutes on ice, before transferring the blocks to digestion buffer (3% sarkosyl, 
0.5 M EDTA) supplemented with 100 µg ml
-1
 proteinase K (Van der Ploeg et al., 1984). 
Samples were then incubated at 56 C for 24 hours.  
3.2.4 Total RNA extraction 
Parasites (2 x 10
8
) in the logarithmic phase of growth were pelleted by centrifugation at 
1640 g for 10 minutes at room temperature and washed in PBS. The cells were 
harvested and RNA from the pellet extracted using the RNeasy kit (Qiagen), in 
accordance to manufacturer‟s instructions. Briefly, cells were lysed by re-suspension of 
the pellet in an RNA stabilization solution containing guanidine-thiocyanate: this 
inactivates endogenous RNases. The extract was then homogenized through a 
QIAshredder column (Qiagen), shearing the parasite genomic DNA. Ethanol was then 
added to the resultant, homogenised lysate and the material added to an RNeasy spin 
column: addition of ethanol promotes selective binding of RNA to a silica membrane 
within the centrifuge column. Following centrifugation, any contaminating residual 
genomic DNA was degraded using an RNAase-free DNase kit (Qiagen), applied directly 
to the silica membrane. Residual salts and precipitates were then removed by a series of 
centrifugation and ethanol-based wash steps, before eluting RNA off the column into 
RNase-free water. Samples were then stored at -20 C. 
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3.3  Restriction Endonuclease analysis 
3.3.1 Restriction of DNA in solution  
A typical restriction digestion was set up as follows. In a total volume of 50 µl, the DNA 
(5 µl) sample was mixed with x10 restriction buffer (5 µl), appropriate for the particular 
enzyme under study, and sterile distilled water (39 µl). Restriction enzyme (1 µl: 10-20 
units, Table 3.3.1) was added and the tube contents consolidated by centrifugation. The 
tube was then placed at an appropriate incubation temperature, generally 37 C, for 2 
hours. The reaction was halted by addition of a 1/10th volume (5 µl) of loading dye (10 
mM Tris-HCl pH 7.6, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol, 
60 mM EDTA) to the mixture. 
 
 
Enzyme  Sequence  
AgeI A^CCGGT 
ApaI GGGCC^C 
AscI GG^CGCGCC 
BamHI G^GATCC 
EcoRI G^AATTC 
HindIII A^AGCTT 
KpnI GGTAC^C 
NcoI C^CATGG 
NotI GC^GGCCGC 
NruI TCG^CGA 
SbfI CCTGCA^GG 
StuI AGG^CCT 
XbaI T^CTAGA 
XhoI C^TCGAG 
XmaI C^CCGGG 
  
Table 3.3.1. The restriction endonucleases and associated recognit ion sites. 
The ^ symbol corresponds to  the specific  site of DNA cleavage of the single strand 
shown. This site occurs in the same posit ion of the palendromic sequence in the 
complementary strand.  
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3.3.2 Restriction of DNA in agarose embedded chromosomes 
For the in-situ restriction digest of intact chromosomes, the agarose blocks were washed 
3 times in 10 ml TE buffer containing 1 mM PMSF (phenylmethanesulphonylfluoride) 
at 25 C for 1 hour. Restriction digests on the entire block were performed overnight at a 
temperature appropriate for particular enzyme using excess enzyme (100-200 units) in 
500 µl of appropriate 1x restriction buffer. Prior to analysis, the blocks were cooled on 
ice. 
3.4 Nucleic acids separation 
3.4.1 DNA by conventional gel electrophoresis 
Conventional agarose gel electrophoresis was used to fractionate DNA molecules in the 
size range of 200 bp to 10 kbp. The agarose concentration, voltage and run times were 
altered to optimise separation in the desired range. A standard agarose gel was made by 
dissolving an appropriate amount of molecular grade agarose (Bioline) in 1x TAE buffer 
(40 mM Tris base, 40 mM acetic acid, 1 mM EDTA) containing ethidium bromide (0.1 
mg l
-1
). Generally, an agarose concentration of 0.6-1.0% (w/v) was used. Following 
casting, the solidified gel was placed in electrophoresis buffer (1x TAE containing 
ethidium bromide), samples loaded into the wells, including a GeneRuler™ 1 kb DNA 
ladder marker (Fermentas), and a constant voltage then applied across the gel for 
varying time periods. Generally, a run time of 1-2 hours was employed when using a 
constant voltage of between 3-5 V cm
-1
. Migration of the sample through the agarose 
matrix was followed by monitoring the bromophenol blue/xylene cyanol dye fronts. 
When the DNA had migrated the desired distance, the gel was analysed on a UV 
transilluminator and documented (Syngene).  
3.4.2 Contour clamped homogeneous electric field electrophoresis 
Contour Clamped Homogeneous Electric Field Electrophoresis (CHEFE) was used to 
separate DNA molecules greater than 10 kb, with the CHEF Mapper II System 
(BioRad). The agarose concentration, voltage, electric field switching time, angle of the 
electric field, the run times, electrophoresis buffer and its temperature can all be altered 
69 
 
to optimise separation in the desired range. Agarose gels were prepared by dissolving an 
appropriate amount of High-Strength Megabase Agarose (BioRad) in 0.5x TBE (45 mM 
Tris-HCl, 45 mM boric acid, 1 mM EDTA). Following casting, DNA-containing 
agarose blocks were loaded into the wells of the gel and fixed into position using 
residual low melting point agarose. When solidified, the gel was placed in the 
electrophoresis chamber of the CHEF Mapper II and submerged in 2 l of 0.5x TBE, pre-
cooled to the desired temperature. 
To separate DNA molecules between 0.2–2.0 Mb (megabase chromosomes), a 0.8% 
strength gel was made with 0.5x TBE and electrophoresis carried out using a 0.5x TBE 
buffer maintained at 18 C. The CHEF Mapper II was programmed to give a linear pulse 
ramp from 90-300 s over a 36 hour time period using a constant voltage of 2.9 V cm
-1
, 
followed by a second linear pulse ramp from 300-720 s over a 36 hour time period using 
a constant voltage of 2.6 V cm
-1
. The angle between the 2 electric field, the switch 
angle, was set at 120  (-60  to + 60 ) throughout the entire run. Samples were run along 
with S. cerevisae chromosomes (0.2–2.2 Mb) (Biorad). 
To separate DNA molecules between 20 kb–1.6 Mb (intermediate and mini-
chromosomes), a 1% strength gel was made with 0.5x TBE and electrophoresis carried 
out using a 0.5x TBE buffer maintained at 14 C. The CHEF Mapper II was programmed 
to give a linear pulse ramp from 3-136 s over a 27 hour time period using a constant 
voltage of 6 V cm
-1
 and a 120  switch angle. Phage lambda DNA concatemers (0.05–1.0 
Mb) (Biorad) were used as DNA markers. 
Restriction digested chromosomes were separated between 10 and 250 kb by an 
automated programmed size separation. This used the automated Field Inversion Gel 
Electrophoresis (FIGE) mode of the CHEF Mapper II system, with a 1% gel with 
running temperature maintained at 14 C. A constant forward voltage of 6 V cm
-1
 was 
programmed for 20 hours 18 minutes. Markers were 8.3–48.5 kb mixed digests of phage 
lambda DNA (Biorad).  
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Following electrophoresis, the gels were stained for 30 minutes in electrophoresis buffer 
containing ethidium bromide (1 mg l
-1
), then de-stained in electrophoresis buffer for 45 
minutes. Gels were then analysed on a UV transilluminator and documented (Syngene).  
3.4.3 RNA 
Prior to electrophoresis and gel/sample preparation, all glass and plastic ware was 
autoclaved and the electrophoresis tank treated with 3% H2O2 for 30 minutes. RNA 
samples were run on 1.2% agarose gels, prepared in 1x running buffer (5 mM sodium 
oxaloacetate, 20 mM MOPS (3-morpholinopropanesulfonic acid) pH 7.0, 1 mM EDTA) 
containing 2% (v/v) formaldehyde. Before loading the samples, the gel was subject to a 
constant voltage of 5 V cm
-1
 for 5 minutes in 1x running buffer. Prior to loading on the 
gel, 1 volume of RNA sample (10 µg in 10 µl) was mixed with 2 volumes of loading 
buffer (20 µl) (75% (v/v) formamide, 2.5% (v/v) formaldehyde, 1.5x running buffer, 7.5 
mg ml
-1
 ethidium bromide) and incubated at 65 C for 5 minutes then cooled on ice. 
Sterile loading dye (0.03% bromophenol blue, 35% glycerol, 1x running buffer) was 
then added to the RNA mixture, the sample loaded on to the gel and a constant voltage 
applied across the gel for varying time periods. Generally, a run time of 3-4 hours was 
employed when using a constant voltage of between 3-5 V cm
-1
. Migration of the 
sample through the matrix was followed by monitoring the bromophenol blue dye front. 
When the RNA had migrated the desired distance, the gel was washed twice in distilled 
water then once in 10X SSC (1.5 M NaCl, 0.15 M Sodium Citrate, pH 7.0), each wash 
was carried out for 15 minutes, and the gel was analysed on a UV transilluminator and 
documented (Syngene).  
3.5 Nucleic Acid Manipulations 
3.5.1 DNA purification 
DNA products in solution were purified using an AccuPrep® PCR and Gel Purification 
Kit (Bioneer), in accordance to manufacturer‟s instructions. Briefly, DNA samples in a 
high salt buffer were applied to a DNA binding column. Under these conditions, the 
DNA binds to the silica membrane within the column. Salts and precipitates are then 
removed by a series of centrifugations and ethanol-based wash steps, before eluting 
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DNA off the column into a low salt buffer such as TE (10 mM Tris-HCl, 1 mM EDTA). 
Samples were then stored at -20 C. 
To purify a DNA fragment fractionated on an ethidium bromide stained agarose gel, the 
gel was inspected on a UV transilluminator and the required DNA band excised with a 
scalpel. The DNA was extracted from the agarose slice using the AccuPrep® PCR and 
Gel Purification Kit (Bioneer), in accordance to manufacturer‟s instructions. The 
weight, hence volume, of the agarose slice was determined. This was then solubilised in 
3 volumes of Gel Binding Buffer at 50 C until the agarose had completely dissolved. 
One volume of isopropanol was added to the solution to increase the purification yield 
and the mixture applied to a DNA binding column. The sample was then treated as 
described above when purifying DNA fragments in solution. 
3.5.2 DNA amplification 
A set of 2x stock buffers were prepared containing 2x polymerase chain reaction (PCR) 
buffer (40 mM Tris-HCl, 20 mM (NH4)2SO4, 20 mM KCl, 0.2% Triton X-100 (New 
England Biolabs)), 200 M deoxynucleoside triphosphates (dNTPs) (New England 
Biolabs), 10% DMSO and different magnesium concentrations (at either 2, 4, 6, 8 or 10 
mM).  
A typical DNA amplification reaction was set up as follows. In a reaction with a total 
volume of 20 µl, 2x stock buffer (10 µl) was mixed with the forward and reverse primer 
(both at 0.5 M) and template DNA (approximately 0.2 µg). The volume of the reaction 
was adjusted to 19 µl with sterile distilled water to which 1 µl (2 units) of DNA 
polymerase was added. For low fidelity amplification, Taq DNA Polymerase (New 
England Biolabs) was used whereas Vent (New England Biolabs) DNA polymerase was 
employed when high fidelity was required. 
Using a Techne TC-412 thermal cycler, a standard DNA amplification programme 
consisted of 1 cycle at 96 C for 1 minute (initial melting stage), then 30 cycles of the 
following: 96 C for 30 seconds (denaturing stage), 55 C for 30 seconds (annealing 
stage), 72 C for 1:30 minutes (extension stage). Based on the properties of the 
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oligonucleotide primers, the annealing temperature and extension times were varied as 
necessary. 
3.5.3 A-tailing of DNA amplification products 
DNA fragments generated by DNA amplification using high fidelity DNA polymerase 
were occasionally cloned into the pGEM-T Easy vector (Promega). To facilitate ligation 
into this vector, an additional adenosine residue was added to the 3‟ end of the DNA 
products. In a total reaction volume of 20 l, Taq DNA Polymerase (New England 
Biolabs) (2 units), 200 M dATP and 2x polymerase chain reaction (PCR) buffer (New 
England Biolabs) containing 2 mM MgCl2 was mixed with the DNA sample. The 
sample was incubated at 70
o
C for 15-30 minutes and the DNA purified. 
3.5.4 DNA ligation 
A typical DNA ligation reaction was set up as follows. In a total volume of 20 µl, 
varying amounts of vector and insert DNA were mixed with 2 μl x10 T4 DNA ligation 
buffer (500 mM Tris-HCl pH 7.5, 100 mM MgCl2, 10 mM ATP and 100 mM 
dithiothreitol) (New England Biolabs) and the volume adjusted to 19 µl with sterile 
distilled water. T4 DNA ligase (1 µl: 400 units) (New England Biolabs) was then added 
to the mixture and the reaction consolidated by centrifugation. The reaction was then 
incubated at a room temperature for 2-4 hours, then placed at 4ºC overnight. The 
amount of vector and insert used in the ligation was judged by visualisation on an 
ethidium bromide-stained agarose gel and a ratio of 5-10:1 insert to vector molecules 
used in each reaction. 
3.5.5 Bacterial DNA transformation 
Competent bacteria were prepared the day of transformation. An overnight culture of E. 
coli was diluted 1:50 into NZCYM medium and grown for around 4-5 hours at 37ºC. 
The cells (5 ml culture) were pelleted at 3555 g for 5 minutes, re-suspended in 10 ml 
ice-cold 0.1 M CaCl2 and then incubated on ice for 30 minutes. Cells were harvested 
and the pellet re-suspended in an appropriate amount of ice-cold 0.1 M CaCl2. An 
aliquot (100 l) of competent cells was taken, to which the DNA to be transformed was 
added. The bacteria/DNA mix was incubated on ice for 30 minutes, then heat shocked at 
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42ºC for 3 minutes, before being placed back on ice. Transformation mixes were then 
transferred on to NZCYM agar plates containing appropriate antibiotic selection. Agar 
plates were then incubated overnight at 37ºC to allow colonial growth. In certain 
instances, for example when using the T-easy vector (Promega), a blue/white selection 
was performed. Here, NZCYM agar was supplemented with 250 M isopropyl β-D-1-
thiogalactopyranoside (IPTG) and 60 mg l
-1
 bromo-chloro-indolyl-galactopyranoside 
(X-gal). 
3.5.6 DNA sequencing 
DNA was sequenced using either the BigDye® terminator cycle sequencing kit 
(Applied Biosystems) according to instructions, or by a custom DNA Service 
(Eurofins).  
For the BigDye® terminator cycle sequencing (10 µl total volume), approximately DNA 
template (0.2 µg) was mixed with the appropriate primer (3.2 pMol), Terminator Ready 
Reaction Mix (1 µl) and 5x sequencing buffer (2 µl). Using a Techne TC-412 thermal 
cycler, the sample was subject to DNA amplification conditions consisting of 1 cycle at 
96 C for 1 minute (initial melting stage) followed by 25 cycles of 96 C for 10 seconds, 
50 C for 5 seconds, 60 C for 2 minutes. The DNA was ethanol precipitated by addition 
of 2 volumes of 100% ethanol and EDTA to a 25 mM final concentration, then 
incubated at room temperature for 15 minutes. The DNA was pelleted at 16,000 g for 10 
minutes and residual supernatant removed with a pipette. The pellet was washed twice 
in 250 µl 70% ethanol, residual supernatant being removed with a pipette and dried by 
heating at 98ºC. Samples were stored at -20ºC and sequenced using an ABI3730 
sequencer (Applied Biosystems). 
For the Custom DNA Service (Eurofins), 0.75-1.5 µg of template DNA and 30 pmol of 
accompanying primer were used for sequencing by the supplier. 
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3.6 Plasmids 
3.6.1 Probes for Southern blots of CHEFE gels 
Individual probes were amplified from T. brucei 927 (Tb probes) or L. major Friedlin 
(Lmf probes) genomic DNA, using the appropriate pairs of primers (Appendix Table 
10.2.1), and low fidelity Taq Polymerase. The resulting A-tailed PCR fragments were 
cloned into pGEM-T-easy (Promega), utilising the vector‟s incorporated T-overhangs. 
Cloned probes were excised from their vector by EcoRI digest, and gel purified. 
3.6.2 Construction of pRPaiSL-TopoIIβ 
This vector facilitates the tetracycline-inducible RNAi mediated knockdown (Section 
1.5.5) of topoisomerase-IIβ in T. brucei. It is used in conjunction with the hygromycin-
tagged ribosomal spacer locus (2T1/TAG
PURO
) cell-line (Alsford and Horn, 2008) 
discussed earlier (Section 3.1.3). A 626 bp fragment specific to topoisomerase-IIß 
(Genbank: DQ309463.1, nucleotide positions: 3743 – 4369) was amplified from T. 
brucei 427 genomic DNA with the TbTopo-IIß RNAi primers (Appendix Table 10.2.2) 
and low fidelity Taq polymerase. The forward and reverse primers both contained 2 
restriction sites (XbaI/ BamHI and XhoI/ KpnI respectively) to facilitate the head-to-
head cloning of the same PCR fragment into either of the multiple cloning sites of the 
pRPa
iSL
 stem-loop plasmid (Figure 5.1.2). The final construct: pRPa
iSL
-TopoIIβ, was 
linearized with AscI, and DNA purified, ready for transfection. 
The plasmid pRPa
iSL
-TopoIIβ was used in parallel with the plasmid pRPaiSL-TopoIIα 
(Obado et al., 2007) to generate isoform specific RNAi of topoisomerase-II. The 
plasmid pRPa
iSL
-TopoIIα had previously been developed by Dr Obado using a 657 bp 
fragment specific to topoisomerase-IIα (Genbank: DQ309462.1, nucleotide positions: 
3629 – 4286). These cloned fragments were also used to probe Southern and northern 
blots to detect the specific isoforms.  
3.6.3 Cloning the topoisomerase-II intergenic region 
The intergenic DNA sequence between topoisomerase-IIα and topoisomerase-IIβ of T. 
brucei is not present in the genome database due to the 2 isoforms being mistakenly 
assembled as a single fusion protein of the 2 paralogues (Kulikowicz and Shapiro, 
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2006), so therefore the region was cloned for DNA sequencing.  This sequence would 
allow the design of gene knock-out vectors. The TbTopoII Intergenic primers (Appendix 
Table 10.2.2) hybridize to the 3‟ end of the topoisomerase-IIα gene and the 5‟ end of the 
topoisomerase-IIβ gene. Using these primers, the intergenic DNA fragment was 
amplified from T. brucei 427 genomic DNA using high fidelity VENT polymerase. 
These PCR products were A-tailed using low fidelity Taq polymerase (Section 3.5.3) 
and cloned into the T-easy vector. This 1.5 kb fragment was sequenced using primers to 
the T7 and SP6 promoters (Promega) of the T-easy cloning vector. 
3.6.4 Construction of pNATx12M-HYG-TopoIIα 
This vector allows in situ tagging of a native allele with 12 c-myc tags in an array, for 
either immunofluorescence localization or immunoprecipitation experiments in T. 
brucei. The plasmid pNAT
x12M
 (Alsford and Horn, 2008), which features a blasticidin 
resistance gene, was modified by replacing the existing targeting fragment plus the 12 c-
myc tag into pNAT
xG-HYG
 (Alsford and Horn, 2008), to effectively replace the GFP tag 
with the 12 c-myc tag equivalent. This was achieved with a HindIII and BamHI digest. 
Then a 1324 bp targeting sequence of the 3‟ end of topoisomerase-IIα (Genbank: 
DQ309462.1) featuring a unique AgeI restriction site, and deleted stop codon 
(nucleotides: 3041-4365; removing the stop codon), was amplified from T. brucei 427 
genomic DNA using high fidelity VENT polymerase with the TbTopo-IIα 12-Myc tag 
primers (Appendix Table 10.2.2). The products were cloned into the new pNAT
x12M-Hyg
 
with a HindIII and XbaI digest to generate pNAT
x12M-HYG
-TopoIIα (Figure 5.1.5). The 
primers used for amplification were also used to confirm the correct protein sequence 
(Section 3.5.6). This plasmid was linearized with AgeI and DNA purified, in preparation 
for transfection. 
3.6.5 Construction of pKOBLA-TopoIIα 
A blasticidin resistance cassette with adjacent α/β tubulin intergenic regions, and 
flanking cloning sites (Rudenko et al., 1994), can be used to target the drug marker into 
a specific part of the T. brucei genome by double homologous recombination. Here, this 
vector is used for gene disruption of topoisomerase-IIα. A 317 bp fragment of the 5‟ end 
of topoisomerase-IIα (nucleotides: 25-342), and a 933 bp fragment of the 3‟ end 
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(nucleotides: 3361- 4294), was amplified from T. brucei 427 genomic DNA. The 
amplification used high fidelity VENT polymerase with the TbTopo-IIα 5‟ Disruption 
and TbTopo-IIα 3‟ Disruption primer pairs to generate the 2 PCR fragments (Appendix 
Table 10.2.2). The 317 bp fragment was cloned into the 5‟ end of a blasticidin resistance 
cassette with NotI and BamHI, while the 933 bp fragment was cloned into the 3‟ end 
with ApaI and KpnI forming pKO
BLA
-TopoIIα (Figure 5.1.5). The flanks were 
sequenced using the PCR amplification primers. This construct was linearized with NotI 
and KpnI, and DNA purified for transfection.  
3.6.6 Construction of pKOHYG-TopoIIα 
To disrupt the second topoisomerase-IIα allele, a hygromycin version of pKOBLA-
TopoIIα was developed. The 2 gene disruption targeting fragments were directly cloned 
from pKO
BLA
-TopoIIα (Figure 5.1.5b) to a hygromycin resistance cassette with NotI and 
BamHI (the 5‟ fragment), plus ApaI and KpnI (the 3‟ fragment). This generated the 
plasmid pKO
HYG
-TopoIIα (Figure 5.2.4a). This construct was also linearized with NotI 
and KpnI, and prepared as standard. 
3.6.7 Construction of pTub-ExBLA-LmfTopoII 
The purpose of this vector was to allow high levels of constitutive expression of a gene 
inserted into the α/β tubulin array of T. brucei. The original vector, pTub-EXPHLEO 
(Cross et al., 2002) had been modified in our laboratory to possess a blasticidin drug 
resistance marker, forming pTub-EX
BLA
 (Obado et al., 2011). This allowed the vector to 
work in the 2T1/TAG
PURO
 cell-line (Alsford and Horn, 2008) without a conflict of drug 
markers. The full length L. major topoisomerase-II (Genbank: XM_001684460.1) was 
amplified from L. major Friedlin strain genomic DNA with high fidelity VENT 
polymerase and LmfTopo-II Complement primers (Appendix Table 10.2.2). The PCR 
fragment was cloned with SbfI at the 5‟ end, and AscI at the 3‟ end to construct pTub-
Ex
BLA
-LmfTopoII (Figure 5.2.1). The plasmid was linearized with BamHI and KpnI, as 
before. 
By performing a NotI and AscI restriction digest of the pTub-Ex
BLA
-LmfTopoII plasmid, 
an 855 bp fragment of the 3‟ end of L. major topoisomerase-II could be excised 
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(nucleotide positions: 3639 – 4494) for the generation of specific radio-labelled DNA 
probes. These could be used for analysis of Southern and northern blots.   
3.6.8 Construction of pTub-ExPURO-LmfTopoII 
This vector was developed to allow constitutive expression of L. major topoisomerase-II 
in a null mutant T. brucei topoisomerase-IIα background, which would be generated 
under blasticidin and hygromycin selection. Therefore L. major topoisomerase-II was 
cloned from the blasticidin based pTub-Ex
BLA
-LmfTopoII, and inserted into pTub-
Ex
PURO
 developed by Dr Obado (unpublished), with SbfI at the 5‟ end and AscI at the 3‟ 
end, forming pTub-Ex
PURO
-LmfTopoII (Figure 5.2.4b). The plasmid was linearized with 
BamHI and KpnI, and prepared as standard.  
3.6.9 Construction of pTub-ExPURO-TcTopoII 
This vector allows the constitutive expression of the T. cruzi topoisomerase-II for 
experiments as per section 3.6.8. Full length T. cruzi CL Brener topoisomerase-II was 
cloned from pTub-Ex
BLA
-TcTopoII (Obado et al., 2011) into pTub-Ex
PURO
 with SbfI (5‟ 
end) and AscI (3‟ end). The plasmid pTub-ExPURO-TcTopoII (Figure 5.2.4c) was 
linearized with BamHI and KpnI, and prepared as before. 
A specific radio-labelled DNA probe for use with Southern and northern blots was 
provided, which was derived from pTub-Ex
BLA
-TcTopoII (Obado et al., 2011), and 
encompassed the T. cruzi topoisomerase-II nucleotides 3678 to 4452. 
3.6.10 Construction of pC-PTPNEO-TopoIIα 
The purpose of this vector is to facilitate a high yield of tandem affinity purified 
topoisomerase-IIα by tagging the native allele with a tandem epitope tag. The plasmid 
pC-PTP
NEO
 (a gift from the Günzl laboratory) contains  a variant of the traditional TAP-
tag (Rigaut et al., 1999), where the calmodulin-binding peptide of the original is 
replaced with a protein C epitope (ProtC), leaving the remaining protein A epitope 
(ProtA) unchanged (Figure 5.3.1a). This vector also contains the necessary DNA 
processing sequences for gene expression in T. brucei  (Schimanski et al., 2005).  
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A 1602 bp targeting sequence of the 3‟ end of topoisomerase-IIα featuring a unique StuI 
restriction site, and deleted stop codon (nucleotides: 2763-4365; removing the stop 
codon), was amplified from T. brucei 927 genomic DNA using high fidelity VENT 
polymerase and the TbTopo-IIα PTP tag primer pair (Appendix Table 10.2.2). Two 
additional nucleotides were incorporated into the reverse primers between the 3‟ end of 
the gene and the restriction site, which placed the PTP tag in frame with the gene 
targeting sequence. The fragment was cloned into pC-PTP
NEO
 with ApaI and NotI to 
generate pC-PTP
NEO
-TopoIIα (Figure 5.3.1b). The primers used for amplification were 
also used to confirm the correct protein sequence (Section 3.5.6). The plasmid was 
linearized with StuI, and prepared for transfection as normal. 
3.6.11 Construction of pC-PTPNEO-TcTopoII 
As an alternative to topoisomerase-IIα purification in T. brucei, this vector was 
developed to allow the purification of T. cruzi topoisomerase-II (Genbank: 
XM_805629.1) from T. cruzi. A 978 bp targeting fragment (nucleotides: 3514-4492; 
removing the stop codon) amplified with VENT polymerase from T. cruzi CL Brener 
genomic DNA, was cloned into pC-PTP
NEO
 with ApaI and NotI. Both the DNA 
amplification and sequencing was performed with the TcTopo-II PTP tag primers. The 
resulting pC-PTP
NEO
-TcTopoII (Figure 5.3.1c) was linearized with StuI, and gel purified 
to remove the plasmid backbone, ready for transfection into T. cruzi.   
3.6.12 Construction of pGAP-Luciferase 
This vector was designed to generate high levels of luciferase expression from the 
GAPDH locus in T. cruzi. To generate pGAP-Luciferase, the GAPDH intergenic region 
of the tandem repeat, the upstream neomycin drug resistance gene, and the β/α 
intergenic region of the tubulin array was excised as 1 fragment from pKS-FKN-Neo, 
(Figure 7.1.1a, provided by Dr. Wilkinson, unpublished) with XhoI and EcoRI, and 
cloned into pBlueScript II KS (Stratagene). Firefly luciferase was amplified from 
pGEM-luciferase (Promega) with high fidelity VENT polymerase and Luciferase 
primers (Appendix Table 10.2.3), and cloned downstream of the β/α intergenic region 
with XmaI and BamHI. Then, the 3‟ UTR of GAPDH was amplified from pTEX (Kelly 
et al., 1992) with appropriate primers (Appendix Table 10.2.3) and cloned downstream 
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of the luciferase gene with SacII and SacI. This final plasmid (Figure 7.1.1b) could be 
linearized with a KpnI and SacI double digest, and gel purified to remove the plasmid 
backbone which prevents the formation of episomes within the parasite. The primers 
used for the PCR amplification were also used to confirm the correct sequences of the 
amplified products once they were cloned.  
3.6.13 Construction of pTRIX 
The vector pTRIX was developed as a general high level expression vector designed 
specifically for T. cruzi, targeting the ribosomal array. First, the 3‟ ribosomal spacer 
region was amplified with high fidelity VENT polymerase using the 3‟ rDNA Spacer 
primers (Appendix Table 10.2.3) from T. cruzi CL Brener genomic DNA, and cloned 
into pTEX (Kelly et al., 1992) with KpnI. The inclusion of an additional AscI site at the 
3‟ end of the PCR fragment allowed the confirmation that the fragment was inserted in 
the correct orientation. The 5‟ GAPDH intergenic region and multiple cloning site of 
pTEX, was then replaced with the 5‟ ribosomal region (including a ribosomal promoter) 
and multiple cloning site of pRiboTEX (Martinez-Calvillo et al., 1997), via a SacI and 
XhoI digest and cloning procedure. This generated the plasmid pTRIX (Figure 7.1.3a).   
3.6.14 Construction of pTRIX-Luciferase 
To create the luciferase reporter plasmid the firefly luciferase gene was excised from 
pGEM-Luc (Promega) and cloned into the multiple cloning site of pTRIX with BamHI 
and XhoI. Before transfection, pTRIX-Luciferase (Figure 7.1.3b) was linearized with 
SacI and AscI and gel purified to remove the plasmid backbone to prevent the formation 
of episomes post transfection. 
3.6.15 Construction of pRPaMYC-SQE 
This vector allowed high expression of squalene epoxidase fused with a 3‟ c-myc tag, 
from the ribosomal array of the tagged cell-line 2T1/TAG
PURO
 (Section 3.1.3). To form 
pRPa
MYC
-SQE (Figure 8.1.6), full length squalene epoxidase (minus the stop codon, 
GenBank: XP_828409.1) was amplified from T. brucei 427 genomic DNA using high 
fidelity VENT polymerase and TbSQE-Full primers (Appendix Table 10.2.4). The PCR 
fragment was cloned into pRPa
MYC
-NTR (Wilkinson et al., 2008) with HindIII and XbaI 
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(Figure 8.1.3a), replacing the nitroreductase gene with squalene epoxidase. The 1.7 kb 
squalene epoxidase gene was sequenced using 6 primers for total gene coverage 
(Appendix Table 10.2.4), to confirm the correct translated protein sequence. The 
plasmid was linearized with a NotI and SacII digest, and prepared for transfection into T. 
brucei as standard. 
3.7 Bioinformatics 
3.7.1 Genome analysis  
Assembled genome sequencing data of T. brucei, T. cruzi, and L. major (Berriman et al., 
2005; El-Sayed et al., 2005a; Ivens et al., 2005) was accessed though GeneDB  (Hertz-
Fowler et al., 2004), and analysed using Artemis software (Berriman and Rutherford, 
2003). Artemis was also used to identify and extract DNA sequences of the AT-rich 
repeat regions of T. brucei chromosomes. Repeats of the centromeric AT-rich regions 
were identified with Tandem Repeat Finder (Benson, 1999). Specific genes were 
identified using the BLAST standard algorithm (Altschul et al., 1990) implemented at 
GeneDB or NCBI, against the respective host databases.  
3.7.2 Sequence analysis  
Restriction analysis of DNA fragments, plus translation and reverse complementation of 
DNA sequences was performed with the Colorado State Molecular Toolkit. DNA and 
protein alignments were made with ClustalW (Thompson et al., 1994) using the 
algorithm parameters: Gap Opening Penalty (10) and Gap Extension (0.2). The output 
alignments were scaled and shaded for figure presentation with BioEdit (Ibis 
Therapeutics). 
 
81 
 
3.8  Nucleic Acid Detection 
3.8.1 DNA and RNA blotting 
Agarose gels (both conventional and pulse field) were depurinated for 20 minutes in 
0.25 M HCl, washed in distilled water, and then soaked in denaturation buffer (0.5 M 
NaOH, 1.5 M NaCl) for 1 hour. The gel was then washed in distilled water, and soaked 
in neutralisation buffer (0.5 M Tris-HCl, 1.5 M NaCl, pH 7.2). For RNA gels, these 
steps were omitted and the gel was washed twice in sterile water, then in 10x SSC prior 
to blotting.  
Nucleic acids were transferred to a 0.22 µm MAGNA, nylon membrane (GE Water & 
Process Technologies) by capillary action (Southern, 1975) using a 20x SSC solution (3 
M NaCl, 0.3 M Sodium Citrate, pH 7.0) drawn by layers of paper towels for 16-24 
hours. The gel was placed on a 3 MM filter paper „wick‟ (Whatman), wetted with 20x 
SSC, with the wicks base submerged in a bath of 20x SSC. The nylon membrane was 
cut to gel size and placed on top of the gel, then 3 layers of 3 MM filter paper of gel size 
were placed on top. A pile of paper towels were placed on top of this construct and 
weighted down to compress the sandwich. The gel was lined with Clingfilm to prevent 
short-circuit of the capillary action. Following transfer, the nucleic acid was cross-linked 
to the membrane using a UV cross-linker (Stratagene), using an auto-algorithm, with the 
DNA or RNA side of the membrane facing the UV bulbs. Membranes were stored at 
room temperature in polythene bags. 
3.8.2 Radio-labelling DNA probes 
DNA probes were generated with α-32P CTP (GE Healthcare) using the Rediprime II 
DNA Labelling System (GE Healthcare). Approximately 2 µg DNA, diluted with sterile 
distilled water to a volume of 40 µl, was incubated at 95 C for 5 minutes. The denatured 
DNA was used to re-suspend the components of a Rediprime Premixed Random-Prime 
Reaction mixture to which 30 µCi α-32P CTP was added. The reaction was incubated at 
37 C for 10 minutes to facilitate DNA labelling. Unincorporated radio-label was 
removed with a sephadex G50 column equilibrated in H2O with the labelled, flow-
through DNA collected in a fresh 1.5 ml microcentrifuge tube. 
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3.8.3 Nucleic acid hybridization 
Nylon membranes containing immobilised, single stranded DNA were pre-hybridised at 
65 C for 6 hours with 5x SSC buffer containing 0.5% (w/v) SDS, 1x Denhardt‟s 
solution (200 mg l
-1
 Ficoll® 400, 200 mg l
-1
 Polyvinylpyrrolidone, 200 mg l
-1
 Bovine 
Serum Albumin)  and 0.2 mg ml
-1
 denatured, sheared salmon sperm. The radio-labelled 
DNA probe was denatured (95 C for 5 minutes), added immediately to pre-
hybridisation solution and incubated at 65 C overnight. The following morning, the 
membrane was washed twice in 0.2x SSC, 0.2% SDS at 65 C, 30 minutes per wash, to 
remove non-specifically bound probe. 
Nylon membranes containing immobilised RNA were treated similarly to those 
containing DNA except the pre-hybridization solution consisted of 5x SSC buffer 
containing 0.1% (w/v) SDS, 1x Denhardts solution, 50% (v/v) formamide, and 0.2 mg 
ml
-1
 denatured, sheared salmon sperm. The pre-hybridization and hybridization steps for 
RNA blots were carried out at 42 C. 
Radio-labelled probes were detected by exposure to X-ray film (GE Healthcare) within 
an intensifier cassette at -80 C for the required duration. The X-Ray film was developed 
using a Mini-Medical Series X-Ray Film Processor (AFP Imaging), in accordance with 
the manufacturer‟s instructions.  
3.8.4 Removal of radio-labelled DNA probes from nylon membranes. 
Nylon membranes containing immobilised, single stranded DNA were used several 
times. To strip a probe, the membrane was washed twice in stripping solution (0.2 M 
NaOH, 0.1% (w/v) SDS) at 42 C, 30 minutes per wash. The membrane was then dried 
between 2 sheets of 3MM paper and checked for residual radioactive signal. 
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3.9 Protein Analysis  
3.9.1 Parasite extracts 
Parasites (1 x 10
8
) in the logarithmic phase of growth were pelleted by centrifugation at 
1640 g for 5 minutes, washed in PBS then harvested. The cell pellet was re-suspended in 
1 ml sterile PBS and transferred to a 1.5 ml microcentrifuge tube. The cells were 
pelleted (16,000 g for 1 minute), the supernatant removed and the parasites re-suspended 
in 500 µl sample buffer (40 mM Tris-HCl pH 6.8, 2% (w/v) SDS, 2 mM β-
mercaptoethanol, 4% (v/v) glycerol, 0.01% (w/v) bromophenol blue). Aliquots (15-20 
µl) were taken and denatured (96ºC for 10 minutes) prior to loading onto SDS-PAGE 
analysis. 
3.9.2 Parasite extracts for protein co-immunoprecipitation 
Parasite cultures containing 5 x 10
9
 cells were pelleted at 1640 g for 10 minutes at 4 C. 
Pellets were combined in a series of wash steps in 25 ml and then in 10 ml ice-cold wash 
buffer (20 mM Tris-HCl pH 7.4, 100 mM NaCl, 3 mM MgCl2, 1 mM EDTA). The 
resultant pellet was washed twice in the cell pellet storage buffer (150 mM sucrose, 20 
mM potassium glutamate, 3 mM MgCl2, 20 mM HEPES-KOH pH 7.7, 2mM 
dithiothreitol) containing 10 µg ml
-1
 protease inhibitors (Roche): the first wash step was 
carried out in 10 ml storage buffer, the last wash step in a volume 1.5x that of the pellet 
volume. The washed pellet was then freeze-thawed 3 times in liquid nitrogen then at 
37 C to lyse the cells. Aliquoted samples were then flash frozen in liquid nitrogen and 
stored at -80 C. 
3.9.3 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Pre-cast gels (Biorad) were used for protein electrophoresis with a Mini-Protean III 
system (Biorad). Denatured protein samples were separated on 10% polyacrylamide gels 
(5% gels for experiments involving topoisomerase II) with 1x SDS-PAGE running 
buffer (25 mM Tris-HCl, 200 mM glycine, 0.1% (w/v) SDS) using a constant voltage 
150 volts for 60-90 minutes. Gels were either stained for 2 hours in Coomassie Blue 
solution (0.2% Coomassie brilliant blue, 7.5% acetic acid, and 50% ethanol) followed 
by de-staining in boiling distilled water, or transferred to 0.2 µm nitrocellulose 
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membrane. Samples were run alongside a PageRuler Prestained Protein ladder 
(Fermentas) as a marker.  
3.9.4 Protein blotting and immunodetection 
Protein blotting was carried out using a Trans-Blot Semi-Dry Transfer Cell (BioRad), in 
accordance with the manufacturer‟s instructions. A piece of Protran BA83 nitrocellulose 
membrane (Whatman) and 2 pieces of 3MM paper (Whatman), all cut to the size of the 
SDS-PAGE gel, and the SDS-PAGE gel itself were soaked in transfer buffer (25 mM 
Tris, 192 mM glycine, 0.5% SDS) for 10 minutes. One piece of 3MM paper was laid on 
the anode of the transfer cell on to which was placed the nitrocellulose membrane. The 
SDS-PAGE gel was then sandwiched between the membrane and a second piece of 
3MM paper, with the cathode plate placed on top of the second sheet of 3MM paper, 
completing the transfer cell. A constant voltage of 10-15 volts for 1 hour was then 
applied to the apparatus and protein transfer confirmed by observing the presence of 
prestained markers on the membrane.  
A chemilluminscent system was used in protein detection. Protein containing nylon 
membranes were washed in blocking buffer (10% marvel powdered milk, 1 x PBS, 
0.1% (v/v) Tween 20) overnight at 4ºC, then washed twice in western wash buffer (1x 
PBS, 0.1% (v/v) Tween 20). The membrane was sealed in a polythene bag and 
challenged with primary antibody diluted in blocking buffer for 1 hour at room 
temperature with gentle shaking. Following copious washes in western wash buffer, the 
membrane was then challenged with the secondary horseradish peroxidase conjugate 
antibody, diluted in blocking buffer, for 1 hour at room temperature with gentle shaking. 
After further washes in western wash buffer, chemilluminscent detection was carried out 
using the ECL system (GE Healthcare) and the membrane exposed to X-Ray film (GE 
Healthcare) for different lengths of time. The X-Ray film was developed as described in 
section 3.8.3. 
The primary antibodies used during this project were: the anti-Myc tag clone 4A6 
(Millipore), a mouse monoclonal antibody raised against the 9E10 epitope on the c-Myc 
protein; and the C-tag antibody (ab18591) (AbCam), a rabbit polyclonal primary 
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antibody raised against an epitope (amino acids 206-216) on the human protein C. Both 
antibodies were used at a dilution of 1:1000. 
The secondary antibodies used were a goat anti-mouse conjugated with the horseradish 
peroxidase enzyme (BioRad), diluted 1:2500, and a goat anti-rabbit conjugated with the 
horseradish peroxidase enzyme (BioRad), diluted 1:1500. 
3.10  Parasite Transfection 
3.10.1 T. brucei bloodstream form 
T. brucei BSF parasites in the exponential phase of growth were pelleted by 
centrifugation at 1640 g for 5 minutes at room temperature, washed in 10 ml PBS then 
harvested as described above. The pellet was then re-suspended in cytomix (2 mM 
EGTA pH 7.6, 120 mM KCl, 0.15 mM CaCl2, 10 mM K2HPO4/KH2PO4 pH 7.6, 25 mM 
HEPES pH 7.6, 5 mM MgCl2.6H2O, 0.5 % (w/v) glucose, 100 µg ml
-1
 bovine serum 
albumin, 1 mM hypoxanthine dissolved in 0.1 M NaOH) chilled to 4
o
C at a density of 6 
x 10
7
 cells ml
-1
. A 500 µl aliquot of parasite suspension was transferred to a sterile 2 
mm gap electroporation cuvette (BioRad) then mixed with approximately 10 µg purified 
DNA: the DNA had been pre-treated at 65
o
C for 30 minutes to minimise contamination 
and the volume used by transfection was no greater than 50 µl. Parasites were 
electroporated with a single pulse at 1.4 kV with a 25 µF capacitance using the BioRad 
Gene Pulser II apparatus and the transformation mixture was added to 36 ml pre-
warmed HMI-9 medium. Following incubation at 37
o
C under a 5% CO2 atmosphere for 
6 hours, the appropriate drug selection was carried out and 3 ml aliquots dispensed into 
the wells of a 12-well plate. The drug concentrations used were: G418 at 2 µg ml
-1
; 
phleomycin at 2 µg ml
-1
; hygromycin at 2.5 µg ml
-1
; blasticidin at 10 µg ml
-1
; 
puromycin at 2 µg ml
-1
. Drug-resistant cultures were observed 5 to 7 days post 
transfection.  
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3.10.2 T. cruzi epimastigote form 
T. cruzi epimastigotes in the exponential phase of growth were prepared as described in 
section 3.10.1, except the parasites were suspended at a density of 1 x 10
8
 cells ml
-1
 in 
chilled cytomix. A 500 µl aliquot of parasite suspension was transferred to a sterile 2 
mm gap electroporation cuvette (BioRad) then mixed with approximately 10 µg purified 
DNA. The parasite/DNA mix was electroporated with 2 pulses at 1.6 kV with a 25 uF 
capacitance (BioRad Gene Pulser II) and the cells transferred to 48 ml pre-warmed 
growth medium and incubated at 27 C for 24 hours. The selective drug (G418 at 100 µg 
ml
-1
) was added to the culture and aliquots (2 ml) dispensed into the wells of a 24-well 
plate. Plates were sealed with surgical tape (VWR). Live and dividing parasites could be 
observed 2-4 weeks post transfection. In all T. cruzi transfections, an electroporation 
without DNA was carried out in parallel to confirm the effective positive selection by 
drug pressure. 
3.11  Cell Imaging 
T. brucei bloodstream form in the logarithmic phase of growth were pelleted at 1640 g 
for 5 minutes, washed twice in PBS before re-suspending in 0.5 ml PBS at a density of 1 
x 10
7
 cells ml
-1
. An equal volume of fixative (4% (w/v) paraformaldehyde in PBS) was 
added slowly to the parasites and then incubated for 20 minutes at room temperature; all 
proceeding steps were carried out at this temperature. An aliquot (20 µl) of the parasite 
suspension (~1 x 10
5
 cells) was then air dried on to a single well of a 12-well printed 
microscope slide. The slides were subject to a series of washes, firstly washed twice in 
PBS, 5 minutes per wash, then in 0.2 µM filtered 50 mM NH4Cl, PBS (20 µl per well) 
for 10 minutes and finally in PBS for 5 minutes, before blocking in 50% (v/v) horse 
serum/50% (v/v) wash buffer (PBS, 0.1% (w/v) saponin) for 20 minutes. Following 
further wash steps in PBS (twice) and wash buffer (once), the sample was incubated for 
45 minutes with the primary antibody. The slides were then washed 3 times in wash 
buffer then incubated for 30 minutes with the second antibody. Following further wash 
steps in wash buffer (twice) and PBS (twice), the slide was dried before mounting in a 
1:1 mix of PBS/glycerol containing 200 pM 4',6-diamidino-2-phenylindole stain 
(DAPI). A seal (clear nail varnish) was applied around the edge of the coverslip that was 
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allowed to harden overnight at room temperature in the dark. Slides were stored at 4
o
C 
until use. All blocking steps and antibody incubations were carried out in a humid 
atmosphere (sealed sandwich box containing a wetted sheet of 3MM paper). 
The primary antibodies used were c-Myc sc-40 (Santa Cruz), a mouse monoclonal 
antibody raised against the 9E10 epitope on the c-Myc protein, or a polyclonal antisera 
raised against the topoisomerase-IIα in rabbits (a gift from T. Shapiro, John Hopkins). 
Antibodies were diluted 1:50 for c-Myc (9E10) or 1:500 for anti-topoisomerase-IIα in 
2% (v/v) horse serum, PBS, 0.1% (w/v) saponin. The AlexaFluor 488-conjugated goat 
anti-mouse or Alexa-Fluor 546 goat anti-rabbit (both Molecular Probes) were used as 
secondary antibodies. These were diluted 1:400 in 2% (v/v) horse serum, PBS, 0.1% 
(w/v) saponin. Images were taken on a Zeiss LSM 510 Axioplan microscope.  
3.12  Drug Screening 
3.12.1 T. brucei bloodstream form proliferation assays 
Bloodstream form T. brucei were seeded at 1 x 10
3
 cells ml
-1
 in growth medium 
containing different concentrations of drug: when appropriate, tetracycline (1 µg ml
-1
) 
was added to cultures to induce gene expression. 200 µl aliquots were then dispensed 
into the chambers of a clear 96-well plate. Following incubation at 37
o
C for 3 days in a 
5% CO2 atmosphere, 20 µl alamarBlue® (Invitrogen) was added to each well. Plates 
were incubated for a further 16 hours before measuring fluorescence using a Gemini 
Fluorescent Plate Reader (Molecular Devices) set at 530 nm excitation wavelength, 585 
nm emission wavelength, and cut-off at 550 nm. IC50 values were calculated from linear 
regression based data plots with Excel (Microsoft). 
3.12.2 T. cruzi amastigote proliferation assays 
Vero cells were seeded at 1.5 x 10
4
 ml
-1
 in 100 µl growth medium and allowed to adhere 
to the base of each well of a clear 96-well plate at 37 C for 6 hours in a 5% CO2 
atmosphere. T. cruzi trypomastigotes (10,000 in 100 µl mammalian growth medium) 
derived from previous Vero cell infections and lacking free amastigotes, were added to 
the chambers containing mammalian cells resulting in a parasite:Vero cell ratio of ~7:1. 
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Following infection overnight at 37°C with 5% CO2, the cultures were washed twice in 
mammalian growth medium to remove non-internalized parasites, and the supernatant 
replaced with 200 µl fresh mammalian growth medium containing drug. Drug-treated 
infections were incubated for a further 3 days at 37°C under a 5% CO2 atmosphere. To 
assay infections, the growth medium was removed and the cells washed twice in fresh 
medium to remove extra-cellular parasites. The cells were then lysed using 50 µl cell 
culture lysis buffer (Promega) and 20 µl aliquots transferred to a white 96-well plate. 
Luciferase activity was measured by adding 100 µl enzyme substrate reagent (Promega) 
to the lysed 20 µl aliquots and light emission measured on a β-plate counter (Wallac). 
IC50 values were again calculated from linear regression based data plots. 
3.12.3 Mammalian cells proliferation assays 
Vero cells were seeded at 1.5 x 10
4
 ml
-1
 in 100 µl growth medium and allowed to adhere 
to the base of each well of a clear 96-well plate at 37 C for 6 hours in a 5% CO2 
atmosphere. An equal volume (100 µl) of growth medium containing drug was then 
added to the chambers containing mammalian cells. Following incubation at 37
o
C for 4 
days in a 5% CO2 atmosphere, 20 µl alamarBlue® (Invitrogen) was added to each well. 
Plates were incubated for a further 4 hours before measuring fluorescence using a 
Gemini Fluorescent Plate Reader (Molecular Devices). 
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3.13 Compounds 
Nifurtimox and benznidazole were supplied from stocks held by Prof. Simon Croft, 
London School of Hygiene and Tropical Medicine (Figure 3.13.1). All other compounds 
used for drug screening were synthesized by collaborators. The aziridinyl 
nitrobenzamide compounds were purchased from Sigma (CB1954) or synthesized and 
supplied, and provided to us by Dr. Nuala Helsby, University of Aukland (Table 3.13.1) 
(Helsby et al., 2004a). The nitrobenzyl phosphoramide mustard series were synthesized 
by Prof. Lonqin Hu, Rutgers, University of New Jersey to a purity shown by LC-MS of 
greater than 90% (Table 3.13.2 and Table 3.13.3) (Hu et al., 2003; Jiang et al., 2006; 
Jiang and Hu, 2008). The nitrofuryl compounds were synthesized and provided to us by 
Hugo Cerecetto, Universidad de la República, Montevideo (Table 3.13.4) (Aguirre et 
al., 2004a; Aguirre et al., 2004b; Gerpe et al., 2008). 
 
 
 
Figure 3.13.1. The chemical structures of nifurtimox and benznidazole.  
 
 
Nifurtimox Benznidazole
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Table 3.13.1. Chemical structures of the aziridiny l nitrobenzamides.  
 
 
 
Table 3.13.2. Chemical structures of the cyclic nitrobenzyl  phosphoramides.  
 
Compound Structure
Type Ia:
CB1954 R1=NO2; R2=CONH2; R3=H
NH1 R1=NO2; R2=CONH(CH2)2Nmorpholide; R3=H 
NH2 R1=NO2; R2=CONH(CH2)2CO2Me; R3=H 
Type Ib:
NH3 R1=H; R2=CONH2; R3=H
NH4 R1= SO2Me; R2=CONH2; R3=H
NH5 R1=SO2Me; R2=NHCH2CH(OH)CH2OH; R3=H
Type II
NH6 R1= NO2; R2=H; R3=CONH2
NH7 R1= NO2; R2=H; R3=NHCH2CH(OH)CH2OH
NH8 R1= NO2; R2=H; R3=CONH(CH2)2Nmorpholide
O
2
N
N
R1
R2
R3
Compound Structure
LH3 X=O; Y=NH; (cis)
LH4 X=O; Y=NH; (trans)
LH5 X=NH; Y=O; (cis)
LH6 X=NH; Y=O; (trans)
LH12 X=NH; Y=NH; (cis)
LH13 X=NH;Y=NH; (trans)
Compound Structure
LH8 X=O; Y=NH; (cis)
LH9 X=O; Y=NH; (trans)
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Table 3.13.3. Chemical structures of the acyclic nitrobenzy l phosphoramides.  
 
Compound Structure
LH7 R3=NO2; X=P; Y=NH2; R1=R2=R4=R5=Z=H
LH14 R3=NO2; X=P; Y=NH2; Z=CH3; R1=R2=R4=R5=H
LH15 R5=NO2; X=P; Y=NH2; R1=R2=R3=R4=Z=H
LH16 R4=NO2; X=P; Y=NH2; R1=R2=R3=R5=Z=H
LH17 R3=NO2; R5=OCH3; X=P; Y=NH2; R1=R2=R4=Z=H
LH18 R3=NO2; R4=OCH3; X=P; Y=NH2; R1=R2=R5=Z=H
LH19 R3=NO2; R4=CH3; X=P; Y=NH2; R1=R2=R5=Z=H
LH24 R3=NO2; X=P; Y=NH2; Z=CH3; R1=R2= R4=R5=H
LH27 R3=NO2; X-Y=C; R1=R2= R4=R5=Z=H
LH31 R2=F; R3=NO2; X=P; Y=NH2; R1=R4=R5=Z=H
LH32 R1=F; R3=NO2;X=P; Y=NH2; R2= R4=R5=Z=H
LH33 R1=CF3; R3=NO2; X=P; Y=NH2; R2= R4=R5=Z=H
LH34 R1=Cl; R3=NO2; X=P; Y=NH2; R2= R4=R5=Z=H
LH37 R1=R5=F; X=P;  R3=NO2; Y=NH2; R2= R4=Z=H
LH47 R1=R2= R4=R5=F; R3=NO2; X=P; Y=NH2; Z=H
LH48 R1=R4=R5=F; R3=NO2; X=P; R2=Y=NH2; Z=H
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Table 3.13.4. Chemical structures of the 5’ nitrofuryl compounds.  
 
 
 
 
 
 
 
 
Compound a X R
HC-1 S NH2
HC-2 S NHCH3
HC-3 S NHCH2CH3
HC-4 S NHCH2CHCH2
HC-5 S NHPh
HC-6 O OCHCH2
HC-7 O OCH3
HC-8 O O(CH2)3CH3
HC-9 O O(CH2)5CH3
HC-10 O O(CH2)6CH3
HC-11 O O(CH2)7CH3
HC-12 O OPh
nitrofurazone O NH2
HC-13 O NH(CH2)3CH3
HC-14 O NHCH2CH2OCH3
Compound b X R
HC-2b S NHCH3
HC-4b S NHCH2CHCH2
HC-12b O OPh
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3.14  Spectrometry 
3.14.1 Sample preparation  
Drug metabolites were generated by reducing 100 µM nitrofuryl substrate with 40 µg 
ml
-1
 T. brucei nitroreductase in the presence of 200 µM NADH in 50 mM NaHPO4 at 
37ºC for 10 minutes. Recombinant parasite enzyme was removed from this mixture by 
the addition of Ni-NTA resin (Qiagen), followed by a centrifugation at 16,000 g for 10 
minutes. The supernatant (900 µl) was transferred to a fresh 1.5 ml microcentrifuge tube 
for analysis. Non-reduced nitrofuryl substrate (100 µM) in 50 mM NaHPO4 was 
examined in parallel. 
3.14.2 Liquid Chromatography - Mass Spectrometry (LC-MS) 
LC-MS of selected compounds and metabolites were analysed using an Agilant 1100 
Series LC/MSD. An aliquot (20 µl) was injected into a 5 µm Hypurity Elite 15 x 2.1mm 
C18 column (Thermo Scientific), pre-equilibrated with 10% acetonitrile. Separation was 
carried out using a 10-30% acetonitrile gradient at a flow rate of 0.2 ml min
-1
. 
Metabolites were detected using a diode array with absorption at 250, 300, 340 and 450 
nm. Ions were generated by positive electrospray ionization with a capillary voltage of 4 
kV, a nebulising gas flow of 25 psi, a dry temperature of 325ºC, and dry gas flow at 10 
litres min
-1
. Further settings were auto-optimised based on a target mass to charge ratio 
(m/z) of 200, with a maximum detected m/z value of 350. 
Tandem mass spectrometry was used to identify the presence of a nitrile group on 
selected metabolites. Chromatography conditions remained the same, while ionization 
was performed with negative mode electrospray using the previous ionization 
conditions, with the generated precursor ions fragmented with a collision energy of 1.5 
V. 
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4 Biochemical Mapping of Centromeres 
This chapter sets out to identify the chromosomal regions that represent centromeric 
domains in trypanosomes. The chapter will focus on determining the locations of 
centromeres on T. brucei chromosomes, and will also attempt to identify centromeres on 
L. major chromosomes.  
4.1 Biochemical Mapping of T. brucei Centromeres 
Analysis of the trypanosome genomes reveal they appear to lack many of the core 
components involved in chromosome segregation, including the centromeric variant of 
histone H3. The absence of many proteins considered to be essential for faithful 
chromosome segregation in other eukaryotes poses the question of whether 
trypanosomes simply possess highly divergent homologues, or alternatively, is the 
segregation of chromosomes in trypanosomes mediated via a different mechanism. The 
first stage in addressing this question is to identify the chromosomal regions that 
comprise a centromere and which facilitate the formation of the kinetochore. With a lack 
of a DNA sequence or a constitutive protein based marker, the less direct approach of 
biochemical mapping with topoisomerase-II, a protein active transiently at the 
centromere, was used to map the centromeric regions of the megabase chromosomes of 
T. brucei. This mapping approach (see Section 2.3.1) was first used in a human cell-line, 
where topoisomerase II activity was shown to coincide with centromeric α-satellite 
DNA repeats (Floridia et al., 2000). Further studies in the malaria parasite have 
employed this technique to map the locations of the centromeric regions on P. 
falciparum chromosomes (Kelly et al., 2006).  
4.1.1 Long-range T. brucei centromere mapping 
Purification of whole chromosomes from procyclic stage T. brucei proved 
advantageous, as this lifecycle stage grows denser than the bloodstream forms, allowing 
for an efficient high yield of chromosomal DNA (Section 3.2.3). Initial chromosome 
separations allowed the validation of our laboratory isolate as the correct genome strain 
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T. brucei TREU 927/4, based on reference to the resolution of the mini-, intermediate-, 
and megabase sized chromosomes (Melville et al., 1998). 
Chromosome 1 of T. brucei TREU 927/4 is the smallest of the 11 megabase sized 
chromosomes with homologues estimated at 1.15 Mb and 1.20 Mb, and is therefore the 
easiest to separate by CHEFE. Preliminary experiments demonstrated that etoposide is 
an effective poison of T. brucei topoisomerase-II. In these experiments, T. brucei 
cultures were treated with between 250 µM and 2000 µM etoposide for 1 hour before 
the parasites were embedded in agarose blocks, and then lysed in a mild detergent to 
release the intact chromosomes (Section 3.2.3). Chromosomes from treated parasites 
were then separated by CHEFE alongside chromosomes from untreated cultures under 
conditions designed to resolve chromosome 1 and any derivative breakdown products. 
Probing a Southern blot of the CHEFE gel with a radio-labelled probe specific to 
chromosome 1 detected a discrete band of around 1.2 Mb that corresponded to the 
predicted size of chromosome 1 (Figure 4.1.1). The probe was the α-tubulin gene (Tb1), 
selected due to the multi-copy nature of the gene which is located in a discreet tandem 
array alongside ß-tubulin on chromosome 1. This would therefore generate a strong 
signal from the Southern blots to reveal any cleavage product bands. All probes used 
with Southern blots were designed to be specific for their designated target, and cloned 
from PCR products to minimise background that might be caused by non-specific 
hybridization (Section 3.6.1). In lanes containing DNA from etoposide treated parasites, 
a second band was observed at around 0.8 Mb. This second band was observed for all 
etoposide concentrations. However as drug concentrations increased, the intact 
chromosomal bands diminished, accompanied with an increase in smearing in the lanes. 
The occurrence of this etoposide mediated cleavage product showed that etoposide was 
an effective poison of T. brucei topoisomerase-II, and prevents the re-ligation step 
following DNA scission (Section 2.3.1). It also demonstrated that the activity of 
topoisomerase-II is concentrated to a specific region of the chromosome. Using 
etoposide at 500 µM for 1 hour was considered the optimum treatment conditions for 
generating cleavage products to map the centromeric regions of chromosomes. A 
previous attempt using 100 µM etoposide for 30 minutes, 1 hour, and 2 hours generated 
no observable DNA cleavage products with procyclic T. brucei (data not shown).    
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Figure 4.1.1.  Topoisomerase-II mediated DNA cleavage in T. brucei.  
Chromosomes of T. brucei  are separated by CHEFE using an auto algorithm that 
opt imises separat ion up to  1.6 Mb (CHEF Mapper,  Biorad; sect ion 3.4.2).  An ethidium 
bromide stained gel (A)  shows the mini-chromosomes at  the bottom (~ 100 kb),  with the 
intermediate chromosomes above (~ 400 kb),  and the major chromosome 1 further up. 
Many o f the larger chromosomes get  trapped in the gel compression zone under the 
separat ion condit ions used. For  size est imat ions S. cerevisiae  chromosomal ladder 
markers (Bio-Rad) were run (M) next  to  un-treated parasites (N),  with 250 µM (lane 1),  
500 µM (lane 2),  1000 µM (lane 3), and 2000 µM (lane 4) etoposide t reatment  for 1 hour. 
A Southern blot  (B)  probed with Tb1 shows chromosome 1 and the etoposide mediated 
cleavage products.  At  higher etoposide concentrat ions the lane smear ing intensifies and 
the chromosome 1 band fades.  Given the relat ive posit ion of the Tb1 probe (at  ~ 570 kb), 
and the size o f the cleavage product  (approximately 800 kb),  on a 1.2 Mb chromosome, it  
is not  possible to  determine at  which end of the 1.2 Mb chromosome the centromere is  
located from this single experiment .  
 
This experiment showed that DNA cleavage products generated by topoisomerase-II 
poisoning were stable and specific enough to be detected through Southern blotting of 
CHEFE gels, and identified the optimum conditions. The next step was to more 
accurately locate the site of topoisomerase-II activity. Multiple sets of chromosomal 
DNA isolated from etoposide treated procyclics were run in parallel with non-treated 
samples on CHEFE gels. This allowed simultaneous probing of split Southern blots with 
different probes (see Appendix Table 10.2.1 for probe details). For the next experiment, 
another probe (Tb4) located at the opposite end of the chromosome to probe Tb1, was 
used. This demonstrated that T. brucei chromosome 1, with homologues around 1.2 Mb, 
was effectively split in two, with the 0.8 Mb fragment identified by probe Tb1 
corroborated with fragments between 0.3 and 0.4 Mb identified by Tb4 (Figure 4.1.2). 
Chromosome 1: 1.15/1.20 Mb homologues
Tb1
Chromosome 1 (1.2 Mb)
Cleavage products 
(0.8 Mb)
Tb1Probe:
Wells
N 1 2 3 4M
(A) (B)
N 1 2 3 4
Mini-chromosomes
Chromosome 1
Compression zone
Intermediate chromosomes
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The smear observed with probe Tb4 is probably due to the difference in homologue 
sizes, coupled with topoisomerase-II activity focussed over a small chromosomal region 
rather than a single specific locus.  
With reference to the genome database (www.genedb.org), the area of topoisomerase-II 
activity appeared to be located around a divergent polycistron strand-switch region 
containing a ribosomal RNA array, two INGI retrotransposons and a degenerate INGI-
like retrotransposon element (DIRE). Within this region was also a degenerate AT-rich 
(66%) repeat sequence spanning 5.5 kb (Figure 4.1.2). In chromosome 1, this type of 
repeat sequence was specific to this region only. An additional experiment using two 
new probes located closer to this region (Tb2 and Tb3) further demonstrated 
topoisomerase-II activity focused within a 100 kb region containing these features 
(Figure 1.1.2). The additional two probes were designed on the basis of their proximity 
to the repeat region, while providing a unique and specific DNA hybridization site.     
The proposed centromeric region of T. brucei chromosome 1 coincided with previous 
experimental results with T. cruzi. Chromosome 3 of T. cruzi is syntenic with that of T. 
brucei chromosome 1. In T. cruzi, a 65 kb region of chromosome 3 was determined to 
be essential for mitotic stability through a series of chromosome truncations generated 
by telomere-associated chromosome fragmentation experiments (Obado et al., 2005). 
Reminiscent of the centromeric region of T. brucei chromosome 1, this region also 
contained degenerate retro-elements, and uniquely to T. cruzi, a 16 kb GC-rich non 
repeat based sequence. The observation that topoisomerase-II based etoposide mediated 
cleavages sites were also located at this locus reinforced the notion that this region of T. 
cruzi chromosome 3 represents a centromeric domain (Obado et al., 2007). Therefore, a 
domain proposed as a centromere in T. cruzi chromosome 3, based on two independent 
experimental approaches, is syntenic with a T. brucei chromosome 1 domain proposed 
as a centromere on the basis of the biochemical mapping data presented here.  
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Figure 4.1.2.  The centromeric region of T. brucei chromosome 1.  
A graphical display using  Artemis software shows the %GC level of chromosome 1 
between the labelled posit ions on a 110 kb region (A). At each nucleot ide posit ion, the 
%GC composit ion is determined by the average composit ion of the surrounding 120 bp .  
The blue arrows show the loca t ion of the proximal DNA probes to  the proposed 
centromeric locale,  while the red arrow highlights a unique repeat region on chromosome 
1 that  is  part icular ly AT r ich. Southern blots of CHEFE separated chromosomes (0.2-3.5 
Mb, sect ion 3.4.2) demonstrate localized topoisomerase-II act ivity (B).  A schematic 
shows the locat ion of the Southern blot  probes labelled Tb1 –  Tb4 on chromosome 1, and 
the locat ion of the mapped centromere „C‟.  Non -treated etoposide parasites (lane N) and 
parasites treated with etoposide (lane T) are run side by side for comparison. Predicted 
sizes of bands are shown as est imated from S. cerevisiae  chromosomal ladder markers.  
The centromeric region is determined to be between probe Tb2 and Tb 3, and within the 
region containing the AT-rich domain.  
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Analysis of the GeneDB database for chromosome 2 showed a similar AT-rich repeat 
region located at a single domain of the chromosome. It was hypothesized that this 
domain may be the location of the topoisomerase II cleavage foci on chromosome 2, and 
therefore specific probes were generated to this area, both proximal to the repeat region 
(Section 3.6.1). Concentrated DNA cleavage was observed in this region after etoposide 
treatment (Figure 4.1.3). Probes Tb5 and Tb6 both identified two cleavage product 
bands, possibly derived from the two chromosomal homologues of 1.25 Mb and 1.30 
Mb. Probe Tb5 identified bands at 280 kb and 450 kb, whilst probe Tb6 identified bands 
of 900 kb and 1000 kb. When combined, these estimates fit closely with the predicted 
size of the intact chromosome.  
Analysis of the putative centromeric region on chromosome 2 identified though 
etoposide mediated DNA cleavage displays similar features to that of chromosome 1. 
Accompanying the AT-rich (66%) repeat region are two INGI retrotransposons and two 
ribosomal RNA arrays, all sandwiched between a divergent polycistron strand-switch. 
Comparison of the 8 kb AT-rich region of chromosome 2 to its 5.5 kb chromosome 1 
counterpart showed that while both regions are AT-rich and comprised of repeats, the 
actual sequences are not closely related.  
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Figure 4.1.3.  The centromeric region of T. brucei chromosome 2.  
A graphical display using Artemis software shows the %GC level of chromosome 2 
between the labelled posit ions on a surrounding 222 kb region (A).  At  each nucleot ide 
posit ion, the %GC composit ion is plotted  (see Figure 4.1.2 for details).   Blue arrows 
show the locat ion of the two proximal centromeric DNA probes,  the red arrow highlights 
a unique repeat  region on chromosome 2 that  is part icular ly AT rich. Southern blots of 
CHEFE separated chromosomes (B) with non-treated etoposide parasites (lane N) and 
parasites t reated with etoposide ( lane T). Specific cleavage is rest ricted to the region 
between probe Tb5 and Tb6. 
 
Given that topoisomerase-II DNA cleavage appeared to be associated with a distinctive 
region of AT-rich repeats on both chromosomes, and that a domain of this nature could 
be readily identified on each of the 8 megabase sized chromosomes completely 
assembled by the genome project, further mapping experiments were performed. 
Putative centromeric domains of chromosomes 3 and 4 were mapped to these proposed 
domains by Dr Obado (Obado et al., 2007), with the data for chromosome 5 generated 
as part of this thesis. Chromosome 5 of T. brucei has 2 homologues of around 1.7 Mb. 
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Two probes were designed (Tb7 and Tb8), 1 either side of the single AT-rich repeat 
domain (Section 3.6.1). The Tb7 probe identified an intense band at 200 kb in lanes 
containing chromosomal DNA from etoposide treated parasites (Figure 4.1.4). Mapping 
with the Tb8 probe proved less clear. Although this probe did detect a strong band at 1.5 
Mb, it also detected a smear including many smaller sized products. This could be as a 
result of non-centromere specific topoisomerase-II activity along the chromosome, 
which would become more apparent the larger the size of the centromere derived 
cleavage fragment generated. 
The AT-rich (61%) repeat domain of chromosome 5 corresponded with the site of major 
etoposide mediated topoisomerase-II activity, as inferred from the data derived with 
probe Tb7 from the short arm of the chromosome. The GeneDB database shows the 
repeat region as 2.5 kb, adjacent to a single DIRE retro-element, and between divergent 
strand-switch polycistrons. Comparison of the repeat array with the sequences from 
chromosome 1 and 2 shows some similarity (Figure 4.1.5). Both the repeats of 
chromosome 2 and 5 appear to be consistent in sequence composition, albeit the 
chromosome 5 repeat is much longer. The repeats of chromosome 1 are highly 
degenerate however, and so a consensus sequence unit was used when generating the 
alignment.   
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Figure 4.1.4.  The centromeric region of T. brucei chromosome 5.  
Artemis shows the %GC level of chromosome 5 between the labelled posit ions on a 
surrounding 110 kb region (A) . A blue arrow shows the proximal centromeric DNA 
probe, and the red arrow highlights the characterist ic AT rich unique repeat  region on 
chromosome 5.  A Southern blot  of CHEFE separated chromosomes (B)  from non-treated 
etoposide parasites (lane N) and parasites treat ed with etoposide (lane T) .  This shows 
intensive cleavage to be just  beyond probe Tb7. 
 
In each of the three examples above, topoisomerase-II activity is shown to be 
concentrated to specific loci along a given chromosome, as demonstrated though the 
mapping of etoposide mediated cleavage products. In each case, major topoisomerase-II 
activity is observed at domains unique on each chromosome that are comprised of an 
AT-rich repeat region accompanied by retro elements. For chromosome 1, this domain 
corresponds to the syntenic region of T. cruzi chromosome 3, which has been proposed 
as a centromeric domain, based on both topoisomerase-II based biochemical mapping 
and mitotic stability experiments. Although the centromere on chromosome 1 of T. cruzi 
has also been studied using biochemical mapping and mitotic stability experiments, with 
both converging on a domain comprising of a GC-rich region of DNA flanked by 
retrotransposons (Obado et al., 2007), this region cannot currently be related back to T. 
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brucei. This is because the syntenic region in T. brucei occurs in an unassembled contig 
of chromosome 11. 
 
 
Figure 4.1.5.  Alignment of AT-rich centromeric repeat sequences.  
Consensus repeat  units within the AT -rich region for each chromosome were ident ified 
using Tandem Repeat Finder  (Benson, 1999) on sequences derived from the genome 
database (Sect ion 3.7.1).  These were aligned with ClustalW (Thompson et  al. ,  1994). 
Chromosomes 2 and 5 contained regions of consistent repeat  sequence units of defined 
sequence and length.  However,  the repeat sequences  of chromosome 1 were much more 
divergent  throughout  the AT-rich repeat  region, so therefore the most  abundant  consensus 
sequence repeat  ident ified by Tandem Repeat  Finder is presented for chromosome 1.   
Some sequence similar it y can be observed  in an alignment  of these three sequences.   
 
Following successful biochemical mapping of the eight fully assembled chromosomes 
of T. brucei to the corresponding eight unique AT-rich repeat regions (Obado et al., 
2007), a general analysis of these regions can be made. All of the ribosomal RNA arrays 
of the T. brucei megabase chromosomes are found within these regions (chromosomes 
1, 2, 3, and 7), and DNA retro-elements are prevalent in these areas. Also, although 
some similarity in sequence was observed between the repeats of chromosomes 1, 2, and 
5, as described here, a high degree of similarity can be found between the repeats of 
chromosomes 4, 5, 8, and the unassembled contigs of chromosomes 9, 10, 11. In 
addition the repeat sequence of chromosome 2 is very similar to the repeat of 
chromosome 7 (Figure 4.4.1). Whether any of these features represent a functional 
component of the centromere, or are merely acquired due to a relaxed regulation of 
DNA content at the centromere remains to be determined.   
                    10        20        30        40        50        60        70        80 
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
Chr1       --------------------------------------------------------------------------------  
Chr2       --------------------------------------------------------------------------------  
Chr5       ATGCAACATGTAAGGTGTTTTTGGTGTAAAACACGCATTCTTGCACAACCTGCACAATGTTGCATGTTTGTTCACAAATT  
Consensus                                                                                    
 
                    90       100       110       120       130       140             
           ....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Chr1       ------------------------CAATAATGCACACATATGCACAATTATGCAATA-----------  
Chr2       -----------------------------ATGTCATTACGTGTTTTAT-GTGCAAAAGC---------  
Chr5       GTGCATTATTGCGTATTTTCACGTCAAATACGCATTCATGCGTATGATTGTGCAAAAACAGTGTTGCA  
Consensus                               * *     *   *    **  ***** *             
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4.1.2 Fine mapping T. brucei chromosome 1 
Since AT-rich repeat regions were common features of the domains that are major sites 
of topoisomerase-II DNA cleavage activity, these repeat domains were analysed in 
further detail to determine whether specific elements were the central focus of the 
activity. Although topoisomerase-II is active, to an extent, along the whole 
chromosome, there potentially could be unique structure or sequence features that mark 
out the transiently active zones in the centromeric domains. Each chromosome was 
analysed via in silico restriction mapping to identify potential endonuclease restriction 
fragments that would span the proposed centromeric domain, while containing a region 
that would allow specific hybridization of a radio-labelled probe to a single fragment.  
Chromosome 1 represented an ideal candidate for this strategy, using the enzyme NotI to 
generate the required restriction fragments.  
To analyze the genome restriction fragments for etoposide mediated DNA cleavage on 
T. brucei chromosome 1, whole chromosomes from etoposide treated parasites were 
first embedded in agarose blocks as previously described (Section 3.2.3). These blocks 
were then washed repeatedly in a buffer containing a protease inhibitor, to remove the 
residual proteinase K remaining from the chromosome extraction process. This was 
required to prevent the downstream degradation of the restriction endonuclease used to 
generate the DNA fragments. The restriction digests were performed overnight on whole 
gel blocks using the enzyme NotI (Section 3.3.2). The next day the digested 
chromosome gel blocks were cooled to aid their loading into a CHEFE gel. The CHEFE 
separation conditions that allowed effective resolution of the full length restriction 
fragments of NotI digests on chromosome 1 were identified empirically using lambda 
digest and S. cerevisiae markers.  
Unexpectedly, Southern blots of the resulting gel containing the separated DNA 
fragments showed two bands of 150 kb and 190 kb, when probed with Tb2. The NotI 
fragment size was predicted by GeneDB to be around 120 kb for this chromosome 1 
probe (Figure 4.1.6). The genome sequencing project opted to sequence and assemble 
the smaller of the two homologues (Hall et al., 2003), therefore there is at least a 30 kb 
discrepancy between what we observe experimentally, and the genome database. 
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Significantly, this difference makes it difficult to map topoisomerase-II mediated DNA 
cleavage patterns directly back to specific loci on the chromosome. The difference 
suggests that this region of the chromosome may not be fully sequenced and/or 
assembled, most likely due to difficulties associated with the nature of AT-rich repeat 
regions. This observation could have important consequences in itself, as missing parts 
of the repeat region makes rigorous comparisons between repeats of limited value at this 
stage, and may mask any important downstream conclusions such as trying to relate any 
DNA sequence to a putative role within the centromere.  
 
 
Figure 4.1.6.  Fine-mapping topoisomerase-II mediated cleavage.  
Southern blot  of in-situ  NotI digested DNA embedded in agarose blocks,  for both non-
treated etoposide parasites (lane N) and parasites treated with 500 µM etoposide for 1 
hour (lane T).  The schematic shows the organizat ion of the chromosome 1 centromer ic 
region with direct ional gene arrays (shaded grey),  ret rotransposons (blue),  a rRNA array 
(green) and the AT-rich repeat  region (black/white striped box).  Probe Tb2 is located 
within the mapped centromeric NotI “120 kb” rest rict ion  fragment  and was used in an 
attempt  to  accurately map cleavage  products.  Tb4 is located away from the centromere 
and is shown as a control.  
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Despite the size variation, it is interesting that at the higher resolution achieved by fine-
mapping, distinct topoisomerase-II cleavage products appear as bands within a smear 
(Figure 4.1.6). This suggests that topoisomerase-II can act on the DNA at discreet and 
prescribed sites, spread over a defined region. This potentially means there is some 
feature that very specifically guides topoisomerase-II localization and activity, which 
may be DNA or other epigenetic factors.  
4.1.3 Mapping T. brucei mini-chromosomes 
T. brucei have around 100 linear mini-chromosomes  at around 100 kb in size (Section 
1.5.1) (Van der Ploeg et al., 1984). These mini-chromosomes have been shown to be 
faithfully segregated during mitosis (Alsford et al., 2001; Zomerdijk et al., 1992). To 
investigate whether the mini-chromosomes possessed a centromere feature analogous to 
the megabase chromosomes, the etoposide mediated topoisomerase-II DNA cleavage 
technique was applied to these chromosomes. The principle was that any DNA or 
epigenetic marker of a megabase chromosomal centromere which guides the 
accumulation of topoisomerase-II could also apply similarly to potential centromeres on 
the abundant mini-chromosomes.  
Procyclic T. brucei cultures were treated with etoposide (Section 3.1.3) and their 
chromosomes were embedded in agaraose blocks as before (Section 3.2.3). The 
chromosomal separation conditions by CHEFE were designed specifically for resolution 
of the much smaller mini-chromosomes, while preventing any lower molecular weight 
fragments from running beyond the end of the gel (Section 3.4.2). A single unit of the 
177 bp inverted repeat region that constitutes over 80% of a mini-chromosome (Sloof et 
al., 1983) was cloned and used as a probe to detect the mini-chromosomes on a Southern 
blot of the CHEFE gel (TbMini, Section 3.6.1).  
A Southern blot of the resulting CHEFE gel probed with TbMini, revealed that under 
these separation conditions many of the mini-chromosomes concentrate as a major band, 
although the probe also detected the intermediate chromosomes to a lesser extent. A 
comparison between the control gel lane containing chromosomes from an untreated T. 
brucei culture, with the experiment lane of chromosomes from etoposide treated 
parasites, displays no evidence of topoisomerase-II mediated DNA cleavage products 
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derived from the mini-chromosomes of etoposide treated parasites (Figure 4.1.7). To 
confirm the effectiveness of the etoposide treatment, this same Southern blot membrane 
was stripped of the TbMini probe (Section 3.8.4), and re-probed with Tb1 of the 
megabase chromosome 1. As expected, this displayed the same sized etoposide 
mediated cleavage product observed in a previous experiment (Section 4.1.1).  
The lack of observable etoposide mediated DNA cleavage products demonstrates a lack 
of topoisomerase-II accumulation and activity on the mini-chromosomes. This in turn 
suggests that the characteristic centromeric domains of the megabase chromosomes that 
recruit topoisomerase-II are missing on the mini-chromosomes. Therefore it seems 
unlikely that the mechanism for segregating the mini-chromosomes is completely 
identical to that of the megabase sized chromosomes, at least in terms of centromere 
composition, and may even be centromere-independent.  
A centromere-independent mechanism would be in agreement with a previous study. 
This showed that during mitosis an insufficient number of microtubules were observed 
to segregate the full complement of T. brucei chromosomes through the classical 
mechanism. Instead the authors propose that multiple mini-chromosomes are „stacked‟ 
laterally on opposing microtubules potentially though chromatin interactions (Gull et al., 
1998). This mechanism would not require the assembling of a kinetochore structure and 
would therefore not require a centromere.   
It cannot be excluded however that tiny DNA cleavage fragments were lost, and any 
cleavage products detected with the TbMini probe were un-resolved from the whole 
mini-chromosomes, as a consequence of topoisomerase-II activity localized towards the 
telomeres of these chromosomes. In this instance, centromeres of the mini-chromosomes 
would be located at sub-telomeric loci and would be un-detectable with this 
experimental system.   
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Figure 4.1.7.  Topoisomerase-II activity at the mini -chromosomes. 
A Southern blot  of CHEFE separated T. brucei  chromosomes extracted from non-treated 
etoposide parasites (lane N) and parasites treated with 500 µM etoposide for 1 hour (lane 
T).  The chromosomal separat ion was performed using  condit ions opt imised for resolut ion 
of the mini-chromosomes (Sect ion 3.4.2).  The mini-chromosomes were probed with a 
cloned single unit  of a repeat  sequence common to all mini chromosomes (TbMini,  
marked brown; Sect ion 3.6.1).  This repeat is  also found to a lesser extent  on the slower 
migrat ing intermediate sized chromosomes, and is visible on the blot .  Analysis of the 
Southern blot  shows no apparent  etoposide mediated topoisomerase-II act ivity on the 
mini-chromosomes, which would result  in the generat ion of lower molecular weight 
cleavage products.  To demonstrate the effect ive inhibit ion of topoisomerase-II by 
etoposide,  this membrane was st ripped of the TbMini probe (Sect ion 3.8.4),  and re-
probed with Tb1. This revealed the corresponding chromosome 1 cleava ge product  of the 
expected size (see Figure 4.1.2).      
4.2 Biochemical Mapping of L. major Centromeres 
4.2.1 L. major chromosome 32 centromere mapping 
Given the success of topoisomerase-II based biochemical mapping of centromeres in T. 
brucei, similar experiments were attempted in L. major Friedlin. Earlier research 
appeared to validate the strategy of applying etoposide to Leishmania to generate 
topoisomerase-II mediated DNA cleavage products. For example, experiments using L. 
donovani promastigotes treated with 100 µM etoposide resulted in the linearization of 
kDNA (Mittra et al., 2000), demonstrating that etoposide can successfully enter this 
parasite. Also, topoisomerase-II has been identified in L. donovani, where the 
recombinant enzyme was shown to decatenate kDNA in vitro (Sengupta et al., 2003). 
N    T N    T
1.2 Mb
0.82 Mb
0.10 Mb
TbMini Tb1
Mini-Chromosomes: ~ 100 Kb
TbMini
Probe:
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Importantly, further experiments with this same topoisomerase-II showed etoposide was 
an effective inhibitor of topoisomerase-II ATPase activity within an in vitro assay, using 
both a recombinant truncated enzyme (Sengupta et al., 2005a), and full length 
topoisomerase-II (Sengupta et al., 2005b). This indicated that etoposide would mediate 
the formation of irreversible chromosomal DNA lesions within this parasite.  
The preliminary experiments performed here focused on obtaining the optimum 
treatment conditions to detect etoposide mediated topoisomerase-II DNA cleavage 
products. L. major has 36 chromosomes ranging from 0.28 to 2.8 Mb (Section 1.5.3) 
(Ivens et al., 2005). Probes were cloned specific to chromosome 12 (syntenic with T. 
brucei chromosome 1 and T. cruzi chromosome 3) and chromosome 32 (syntenic with 
T. brucei chromosome 11 and T. cruzi chromosome 1). These 2 chromosomes were 
selected due to the available results of both biochemical mapping experiments in T. 
brucei and T. cruzi, alongside the mitotic stability data from T. cruzi (Obado et al., 2007; 
Obado et al., 2005). Treatments of parasites ranging from 100 µM etoposide for 30 
minutes, to 1 mM etoposide for 1 hour resulted in no cleavage product bands (Figure 
4.2.1b) with the chromosome 32 probe (Section 3.6.1). Indeed even low levels of 
smearing in treated lanes characteristic of previous experiments with high etoposide 
concentrations appeared absent. Similar results when probing for chromosome 12 were 
observed (data not shown).  
Further experiments using amsacrine, another anti-cancer agent well characterised as a 
topoisomerase-II inhibitor (Zwelling et al., 1985), and chlorpromazine, implicated in 
inhibiting E. coli topoisomerase-I activity (Mizushima et al., 1992) were employed. 
Whereas etoposide inhibits topoisomerase-II facilitated DNA re-ligation, by directly 
binding to the active site of the enzyme (Chen et al., 1984), amsacrine intercalates 
within the DNA (Nelson et al., 1984) and appears to prevent the active site of 
topoisomerase-II from effectively interacting with the cleaved DNA by impeding the 
catalytic tyrosine residue from performing the re-ligation step (Rogojina and Nitiss, 
2008). This alternative type of inhibition also results in the formation of topoisomerase-
II mediated double stranded DNA breaks. Chlorpromazine is a less studied DNA 
intercalating compound, and is structurally related to amsacrine. It has been shown to 
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display greater cytotoxicity against L. donovani than either etoposide or amsacrine 
(Werbovetz et al., 1992), suggesting it may prove to be a more potent topoisomerase-II 
inhibitor within Leishmania.  
Neither amsacrine nor chlorpromazine had any detectable effect in poisoning 
topoisomerase-II and generating DNA lesions in L. major using the established 
experimental system, even at concentrations of 500 µM for 4 hours (Figure 4.2.1c). This 
compares to previous experiments performed in the laboratory using these 2 drugs with 
T. cruzi, where intense, but non-specific lesions induced by drug treatment appeared to 
be easily generated.  
  
 
Figure 4.2.1.  Attempts to generate  topoisomerase-II mediated DNA cleavage in L. 
major. 
A Southern blot  of CHEFE separated chromosomes fro m etoposide treated parasites (A) 
showed no cleavage products (B)  from the standard 100 µM etoposide t reatment  for 30 
minutes (lane 1) compared with untreated parasites (lane N). Increasing the etoposide 
treatment  to  1 mM for 1 hour also genera ted no cleavage products (lane 2).  Etoposide 
analogues that  had previously resulted in indiscr iminate chromosome cleavage in T. cruzi  
were used to treat  L. major  (C).  Amsacr ine at  concentrat ions 100 µM for 1 hour (lane 3), 
500 µM for 1 hour (lane 4),  and 500 µM for 4 hours (lane 5),  as well as chlor promazine 
at  100 µM for 1 hour  (lane 6),  500 µM for 1 hour (lane 7),  and 500 µM for 4 hours (lane 
8) showed no evidence of either localized or general chromosome cleavage.   
 
 
Lmf1
Chromosome 32: 1.6 Mb homologues
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Taken together, the results of the preliminary drug treatments in L. major suggest that 
the L. major topoisomerase-II enzyme is refractory to poisoning by etoposide, amsacrine 
and chlorpromazine. This appears to contradict the earlier work which showed etoposide 
successfully inhibited L. donovani topoisomerase-II activity in vitro (Sengupta et al., 
2005b). However, BLAST analysis of the L. donovani topoisomerase-II used by this 
group (GenBank ID: AF150876) against the annotated L. major genome database 
suggests they examined the mitochondrial topoisomerase-II isoform (95% amino acid 
identity; L. major GeneDB ID: LmjF.15.1290), and not the nuclear isoform (28% amino 
acid identity; L. major GeneDB ID: LmjF.28.2280). Although a detailed biochemical 
analysis has been performed with the L. donovani topoisomerase-II, no localization data 
has yet been presented in the literature to confirm the physiological activity of their 
topoisomerase-II isoform. If etoposide is only inhibiting the mitochondrial isoform, it 
would explain the resulting linearized DNA within the mitochondrion of etoposide 
treated L. donovani promastigotes (Mittra et al., 2000), and also the lack of nuclear 
DNA cleavage observed here in L. major. That nuclear L. major topoisomerase-II  
appears refractory to etoposide, may also occur in L. donovani, where IC50 values for 
etoposide and amsacrine could not be established at drug concentrations up to 100 µM 
(Werbovetz et al., 1992). If these compounds were successfully inhibiting nuclear 
topoisomerase-II, it could be expected that the resulting double stranded breaks in the 
genome would be fatal to the parasite. Although chlorpromazine is toxic to L. donovani, 
and has been shown to actively generate double stranded DNA breaks in mouse cells 
(Darkin et al., 1984), this compound has not been subjected to such a detailed analysis 
as etoposide and amsacrine, and may be generating cytotoxicity via alternative 
mechanisms.  
Alternatively it could also be possible that the segregation of L. major occurs by a 
centromere-independent mechanism. Bioinformatic analysis of L. major chromosomes 
12 and 32 with Artemis (Section 3.7.1) revealed no features that resembled either the 
AT-rich domain characteristic of a T. brucei centromere, or a GC-rich region observed 
in the T. cruzi centromeres. While these do not necessarily define a centromere in 
themselves, it is interesting that these very different DNA features are nonetheless 
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present in T. brucei and T. cruzi, while L. major appears to lack any noticeable features 
with respect to %GC skew.  
Previous studies in L. major on chromosome 1, have shown that the only strand-switch 
region between the two polycistrons present on that chromosome, is not required for 
mitotic stability (Dubessay et al., 2002a). This contrasts with our findings on the strand-
switch localized centromeric regions that are required for mitotic stability in T. cruzi 
(Obado et al., 2007; Obado et al., 2005). A further study by this group with a 
chromosome 1 derived, smaller artificial chromosome, supported this finding, and 
suggested that sub-telomeric regions possessing a relatively higher AT content may be 
involved in mitotic stability (Dubessay et al., 2002b), This was disputed by another 
group, who failed to identify these small sub-telomeric regions or similar domains, in a 
mitotic stability library screen of genome fragments incorporated into an artificial 
chromosome (Casagrande et al., 2005). Other attempts to identify characteristic 
centromeric domains in L. donovani have also proved elusive. Mitotic stability analysis 
through chromosome fragmentation yielded minimal sized chromosomes capable of 
faithful segregation, however analysis of either truncated native chromosomes (Tamar 
and Papadopoulou, 2001), or a truncated artificial chromosome (Dubessay et al., 2001), 
have so far failed to identify a definitive centromeric domain in L. donovani.  
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4.3 Chapter Summary  
Biochemical mapping experiments using etoposide mediated topoisomerase-II DNA 
cleavage II have demonstrated:  
 DNA cleavage foci are observed at unique AT-rich repeat domains in the 3 
T. brucei chromosomes examined here (chromosomes 1, 2 and 5).  
 The sites of etoposide-mediated DNA cleavage in T. brucei chromosome 1 
and the biochemically mapped cleavage region of T. cruzi chromosome 3 are 
syntenic. This region of T. cruzi chromosome 3 also corresponds to a region 
required for mitotic stability (Obado et al., 2007). 
 Topoisomerase-II based fine mapping using a restriction fragment 
encompassing the T. brucei chromosome 1 AT-rich domain, showed a 
discrete pattern of DNA cleavage bands. Also, the restriction fragments 
derived from this region are larger than predicted from the database.  
 No etoposide-mediated DNA cleavage of the T. brucei mini-chromosomes 
was observed, consistent with the hypothesis that these may segregate 
through an alternative mechanism (Gull et al., 1998). 
 Experiments in L. major yielded no detectable drug mediated DNA cleavage 
of any kind, suggesting either etoposide cannot interact with L. major 
topoisomerase-II, or that the nature of chromosome segregation, including 
the role of topoisomerase-II, is not conserved between trypanosomatids.  
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4.4 Discussion 
In this chapter, three centromeric domains of T. brucei chromosomes have been 
biochemically mapped using etoposide mediated topoisomerase II cleavage experiments 
to AT-rich repeat regions. The AT-rich nature of the T. brucei centromeres is similar to 
those centromeres described for S. cerevisiae, S. pombe, Drosophila, P. falciparum 
(relative to the genome average) and human centromeres. An increase in AT-richness at 
the centromere appears fairly common in the various organisms studied to date, but by 
no means is it the rule. Plant centromeres such as those of Arabidopsis and rice contain 
no alteration in AT/GC content (Section 2.2.1), and T. cruzi display a GC-rich domain 
as opposed to an AT-rich region (Obado et al., 2007). Recently, the biochemical 
technique employed here was used to map the centromeric domains of Toxoplasma 
gondii, which revealed this organism also lacked any nucleotide bias in their centromere 
composition (Brooks et al., 2011). Therefore, although a nucleotide bias could 
potentially alter the DNA secondary structure at the centromere and contribute to a 
physical designation of a centromeric domain, it may alternatively be that these domains 
are simply susceptible to shifts in codon bias as they are non-gene coding regions. 
Susceptibility to a drift in nucleotide bias in this region due to an absence of selective 
pressure on genome maintenance may also explain the accumulation of retro-elements 
observed in T. brucei (Section 4.1.1), as well as in plants and metazoans (Section 2.2.1). 
Consistent with the observations made in many of the model systems, the centromeric 
repeats in T. brucei vary in sequence across chromosomes, and therefore no single DNA 
sequence appears to define a centromere in this organism (Figure 4.4.1). It seems likely 
that centromeres in T. brucei are instead defined epigenetically by chromatin structure, 
despite the absence of the characteristic CENP-A histone variant (Section 2.2.2). This 
puzzle raises the question of what then is the defining marker, and is this marker for 
kinetochore assembly the same as that which guides topoisomerase-II accumulation? It 
is conceivable that the designation of a centromere could occur through the post-
transcription modifications of canonical histones within the centromere, in a similar 
fashion to that of transcriptional start site markers (Siegel et al., 2009).  
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Another hypothesis would be that a novel DNA binding protein defines a centromere, 
and its location is maintained through epigenetic inheritance. Either result would support 
the founding hypothesis that the mechanism of chromosome segregation varies between 
T. brucei and the mammalian host.    
 
 
Figure 4.4.1.  Complete alignment of AT-rich centromeric DNA repeat sequences.  
The software Tandem Repeat  Finder (Benson, 1999)  was used to  ident ify consensus 
repeat units within the AT-rich region for each chromosome. These were aligned with 
ClustalW (Thompson et  al. ,  1994).  In generat ing this alignment ,  2 units of the array were 
used for chromosomes 1,  2,  6 and 7.  These units were much smaller (~30 bp),  relat ive to 
the unit  sizes of the other chromosomes (~150 bp).  A high degree of similar ity can be 
observed between the repeat units of chromosomes 4,  5,  and 8 -11, as well as clear 
similar ity between chromosomes 2 and 7 (Obado et al. , 2007).     
 
The caveat remains that due to the repetitive nature and length of centromeric domains it 
is difficult to accurately sequence across the whole region and correctly assemble the 
resulting contigs, so it would be possible to miss a small S. cerevisiae-like „point‟ 
centromere hidden amongst the repeats. This difficulty in assembly is highlighted by a 
restriction digest based fine-mapping experiment of T. brucei chromosome 1 (Section 
10        20        30        40        50        60        70        80               
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Chr1     ---------------------------------------------------------------------ATGCGCAATAA
Chr6      ---------------------------------------------------------------------ATGTGCAATAA
Chr10     ATGCAATATGTAAGGTGTTTT-GGTGTAAAACACGCATTCTTGCATAACATGCACAATGTGGCATGTTTGTGTGCAA-AT
Chr11     ATGCAATATGTAAGGTGTTTT-GGTGTAAAACACGCATTCTTGCATAACATGCACAATGTGGCATGTTTGTGTGCAA-AT
Chr4      ATGCAATATGTAAGGTGTTTT-GGTGCAAAACACGCATTCTTGCATAACATGCACAATGTGGCATGTTTGTGTGCAA-AT
Chr9      ATGCAATATGTAAGGTGTTTT-GGTGCAAAACACGCATTCTTGCATAACATGCACAATGTGGCATGTTTGTGTGCAA-AT
Chr5       ATGCAACATGTAAGGTGTTTTTGGTGTAAAACACGCATTCTTGCACAACCTGCACAATGTTGCATGTTTGTTCACAA-AT
Chr8       ATGCAACATGTAACGTGTTTT-GGCGTAAAACACGCATTCTTGCACAACCTGCACAACGTTGCATGTTTGTGCACAA-AA
Chr2       --------------------------------------------------------------------------------
Chr7       --------------------------------------------------------------------------------
Chr3       ---------------------------------------------------------TTTCATGGTTATCGCCCCTACGG
Consensus
90       100       110       120       130       140       150       
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Chr1       TACGCAATAATACGCAATAATGCG-CAATAATGCACACATATGCACAA-TTATGCAATA-----------
Chr6       TGTGCAATTATATGCAATAATGTG-CAAT--TGCAATAATGTGCA-AT-TTGTGCAATT-----------
Chr10      TGTGCACTATTGCGTATTTTCACGTCAAATACGCGTTCATGCGTATGA-TTGCGCAAAAACAGTGTTGCA
Chr11      TGTGCACTATTGCGTATTTTCACGTCAAATACGCGTTCATGCGTATGA-TTGCGCAAAAACAGTGTTGCA
Chr4       TGTGCACTATTGCGTATTTTCACGTCAAATACGCGTTTATGCGTATGA-TTGCGCAAAAACAGTGTTGCA
Chr9       TGTGCACTATTGCGTATTTTCACGTCAAATACGCGTTCATGCGTATGA-TTGCGCAAAAACAGTGTTGCA
Chr5       TGTGCATTATTGCGTATTTTCACGTCAAATACGCATTCATGCGTATGA-TTGTGCAAAAACAGTGTTGCA
Chr8       TGTGCACTATTGCGTATTTTCACGTAAAATACGCGTTCATACGTGTGT-TTGTGCAAAAACAGTGTTGCA
Chr2       -ATGTCATTACGTGTTTTATGTGCAAAAGCATGTCATTACGTGTTTTA-TGT-GCAAAAGC---------
Chr7       -GTGTTATTAAGTGTTTTATGTGAAAAAGCGTGTTATTAAGTGTTTTA-TTTTGAAAAAGC---------
Chr3       CGCATAATGGCGTGTTAT-CGCACAAAACCCTGTTACAGTGTGATTGGGTAACGCCCTTCCACTGATCAC
Consensus * * * ** * * * *
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4.1.2), which showed that the domain corresponding to a centromere is much larger than 
reported in the genome project. A difference between fragment sizes for the 
chromosome homologues of around 40 kb would also explain the difference in 
homologue sizes, as opposed to the previous proposal that size variations between sub-
telomeric regions are the cause of these size variations (Callejas et al., 2006). A further 
experiment with chromosome 4 of T. brucei also identified larger than expected 
restriction digest fragments with a 10 kb difference between homologues (Obado et al., 
2007). This secondary finding supports the original observation as genuine, rather than it 
being an experimental artefact as the result of an altered restriction site through a 
nucleotide polymorphism. It will be interesting to see if the nine yet to be analysed 
centromeres also contain longer than currently reported repeat regions, and whether the 
composition of these full length sequences are consistent in repeat formations, or if new 
embedded sequences are identified.      
Once the mini-chromosomes have been duplicated, they seem to be faithfully 
segregated. While this process has been shown to be microtubule dependent (Ersfeld 
and Gull, 1997), the actual mechanism is still unknown. The biochemical evidence 
reported here supports the role for a non-classical kinetochore based mechanism, since 
there is no specific site attracting topoisomerase-II activity on the mini-chromosomes 
(Section 4.1.3), which is in agreement with the „lateral stacking model‟ of mini-
chromosomes on microtubules (Gull et al., 1998). During early anaphase, standard 
model kinetochores associate with the polar end of the microtubules, yet the lateral 
stacking model proposes that mini-chromosomes associate along the length of the 
microtubule polymer as it contracts during chromosome segregation. However, this 
leaves open the question of how do mini-chromosomes associate along the length of a 
tubulin polymer? This proposal is not as radical as it may first seem, as part of the 
general „search and capture‟ mechanism of microtubules connecting to the assembled 
kinetochore begins with a lateral association of chromosomes to the microtubule 
polymer, followed by a migration towards the polar end (Tanaka et al., 2005). To 
achieve a kinetochore-microtubule attachment either an adapter complex must connect 
the DNA to tubulin, potentially through the existing chromatin, or alternatively DNA 
and microtubules could be tied together by a cohesin-like ring complex. A similarly 
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structured complex has been observed before in S. cerevisiae, when a 10 protein DASH 
complex formed an oligomer ring around microtubules in vitro (Miranda et al., 2005), 
which may potentially create a chromosomal tether in vivo (Buttrick and Millar, 2011). 
It is possible a similar structure may facilitate the lateral microtubule based segregation 
of the T. brucei mini-chromosomes.     
While the biochemical technique of mapping the T. brucei megabase chromosomes 
proved successful, as well as the parallel mapping of T. cruzi chromosomes (Obado et 
al., 2007), this technique failed to identify any centromeres on L. major chromosomes. 
As discussed previously (Section 4.2.1), this could be due to the technical limitation of 
etoposide not being effective against L. major topoisomerase-II. Alternatively it may be 
that topoisomerase-II activity is not required at mitosis for L. major, perhaps due to the 
smaller nature or their chromosomes, or maybe chromosomes in this organism are 
segregated differently. If it is the latter, this raises the possibility that the mechanism 
used to segregate L. major chromosomes could be similar to the T. brucei mini-
chromosomes, through a lateral stacking of chromosomes along microtubules. 
Investigating whether chromosome segregation in L. major is based on the classical 
microtubule spindle mechanism involving kinetochores assembled on centromeres 
remains a challenge.   
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5 Characterization of Topoisomerase-II 
T. cruzi and L. major both possess one nuclear isoform of topoisomerase-II, however it 
has been shown that T. brucei has two isoforms of this enzyme (Kulikowicz and 
Shapiro, 2006) designated topoisomerase-IIα and topoisomerase-IIß. This chapter 
explores the roles of the two T. brucei topoisomerase-II isoforms at the centromere in 
bloodstream form T. brucei, and addresses the unknown mechanism in which 
centromere specific targeting is achieved. 
5.1 The T. brucei Topoisomerase-II Nuclear Isoforms 
The GeneDB database erroneously records only one entry for a nuclear topoisomerase-II 
(Tb11.01.3390) in T. brucei, which is a fusion between the N-terminus of the α-isoform 
and the C-terminus of the ß-isoform. Previously it has been demonstrated by RNAi 
experiments that in the insect procyclic stage, only the α-isoform is essential for growth 
(Kulikowicz and Shapiro, 2006). In addition, western blotting of cell extracts with a ß-
isoform specific antibody showed that it appeared not to be expressed in the procyclic 
form. Also, the same authors found that recombinant topoisomerase-IIß appeared 
inactive by in vitro decatenation assays. The discovery that nuclear topoisomerase-II has 
two isoforms in T. brucei, raises the questions: which isoforms are essential, and 
responsible for the centromere specific DNA cleavage, in the clinically relevant 
bloodstream stage? 
5.1.1 RNAi knockdown of topoisomerase-II in bloodstream form T. brucei 
Topoisomerase-II contains four designated domains as shown in Figure 5.1.1. The 
ATPase, linker, and catalytic domains are highly conserved between trypanosomatids, 
however this conservation appears absent in regard to the variable domains (Appendix 
Figure 10.1.1). By taking advantage of the underlying variation in DNA sequence of the 
C-terminal variable domain of topoisomerase-II it is possible to distinguish between the 
α- and ß- isoforms, and indeed between these, and the T. cruzi and L. major 
homologues. This difference in the C-terminal variable domain can be exploited to clone 
specific sequences to generate RNAi mediated knockdown of either topoisomerase-II 
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isoform, or to produce isoform and species specific DNA probes for Southern and 
northern blotting. 
Firstly to determine if either topoisomerase-II isoforms are essential for growth in the 
bloodstream form stage, RNAi mediated knockdown of both genes was performed 
independently. To generate effective RNAi mediated knockdown of T. brucei 
topoisomerase-IIβ, the T. brucei 427 strain featuring the hygromycin-tagged ribosomal 
spacer locus (2T1/TAG
PURO
 cell-line) was used in conjunction with the tetracycline 
regulated RNAi stem-loop plasmid pRPa
iSL
 (Alsford and Horn, 2008). A 600 bp DNA 
fragment specific to the variable domain of topoisomerase-IIß was amplified and cloned 
head-to-head into the stem-loop plasmid (Section 3.6.2) to generate pRPa
iSL
-TopoIIβ 
(Figure 5.1.2). This plasmid was linearized with AscI, purified, and used to transform 
the T. brucei 2T1/TAG
PURO
 cell-line.  
   
 
Figure 5.1.1.  Illustration of the different topoisomerase-II domains . 
A typical topoisomerase-II enzyme contains four dist inct  domains.  The ATPase domain is 
connected by a small linker domain to the catalyt ic DNA cleavage and re-ligat ion 
domain. The C-terminal var iable domain‟s funct ion is  unknown. The sizes of each 
domain are based on T. brucei  topoisomerase-IIα (Kulikowicz and Shapiro,  2006) .  
Although around 85-90% amino acid sequence ident ity is observed between the first  three 
domains of T. brucei  topoisomerase-IIα and topoisomerase-IIβ, the ident it y between 
var iable domains is reduced to only 23%. This ident ity between respect ive domains is  
maintained in further comparisons with  the T. cruzi and L. major  topoisomerase-II.  
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Figure 5.1.2.  An RNAi construct for topoisomerase-IIβ.  
Two ident ical 600 bp DNA fragments of the unique 3‟ region of T. brucei  topoisomerase-
IIβ were cloned head to head to form a stem-loop RNAi fragment ,  separated by a lacZ 
stuffer into pRPa
iSL
 to  facilitate tetracycline induced RNAi, dr iven by a rRNA pro moter 
(Sect ion 3.6.2).  The result ing pRPa
iSL
-TopoIIβ plasmid ( linear ized by AscI digest) 
integrates into the tagged locus of the 2T1/TAG
PURO
 cell- line using the target ing 5‟ 
region of the hygromycin resistance gene to  generate a complete resistance gene 
integrated into the chromosome (Alsford and Horn, 2008) .  
 
A drug-resistant topoisomerase-IIß RNAi clone selected on hygromycin was chosen for 
analysis, in parallel with a cell-line generated by Dr. Obado designed to knockdown the 
topoisomerase-IIα isoform (Obado et al., 2011). The effect of RNAi mediated 
knockdown of the 2 topoisomerase-II isoforms on parasite proliferation was studied 
first.  
The two RNAi cell-lines representing the two topoisomerase-II isoforms were split into 
two cultures each. For a given cell-line, one of these cultures was supplemented with 1 
g ml
-1
 tetracycline to induce RNAi knockdown, while the other culture remained in 
standard growth medium as a negative control. Parasites of both cell-lines were seeded 
at 1 x 10
5
 ml
-1
 and grown for 4 days in parallel and free of selective drug pressure. They 
were counted every 24 hours with a haemocytometer and then diluted back to 1 x 10
5
 
ml
-1
 at each daily time point. No change in growth rate of the topoisomerase-IIß RNAi 
cell-line was observed when RNAi was induced over a 4 day period, relative to the non-
induced lineage. This contrasted with the topoisomerase-IIα experiment, where growth 
rate ceased within 24 hours of RNAi induction, followed by cell death (Figure 5.1.3a). 
Over 7 days, no phenotypic effect was observed as a result of topoisomerase-IIβ 
knockdown. After 5 days, outgrowth was observed in the cultures where topoisomerase-
Topo-II lacZHyg 5’ Tet Op Topo-II
Ampicillin
Asc IAsc I
rDNA
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IIα had been depleted, presumably as a consequence of the selection of revertants (data 
not shown). This phenomenon is common in RNAi experiments, especially when 
essential genes are targeted in the bloodstream form (Chen et al., 2003).  
 
 
Figure 5.1.3.  Topoisomerase-IIα,  but not topoisomerase-IIβ  is essential for growth of 
bloodstream form T. brucei.  
(A) Cumulat ive growth plots of two T. brucei  bloodstream form cell lines modified to 
facilitate specific  inducible RNAi mediated knockdown of topoisomerase -II  (Obado et 
al. ,  2011) and topoisomerase-II  by targeting their respect ive var iable domains (Sect ion 
3.6.2).  Cells were counted every 24 hours by haemocytometer then diluted back to  1 x 
10
5
 ml
-1
 with expression of the hairpin looped transcript  init iated  using 1 g ml
-1
 
tetracycline  (Sect ion 3.1.3).  Only the topoisomerase-II  isoform was found to be 
essent ial for growth of bloodstream forms, with cell death occurring after 24 hours  
(topoisomerase-II : blue line untreated, brown line tetracycline t reated).  Down-
regulat ion of topoisomerase-IIβ appeared to  have no effect  on parasite growth 
(topoisomerase-IIβ:  green line untreated, red line tetracycline t reated).  (B) Northern blots 
of RNA isolated 28 hours after RNAi induct ion were probed with iso form-specific 
fragments derived from the variable regions (Sect ion 3.6.2),  and with  tubulin as a 
loading control,  to  demonstrate appropriate RNAi knockdown respect ive to  non -induced 
cell lines.   
 
To demonstrate effective RNAi knockdown, RNA was isolated from both RNAi 
induced and un-induced cell-lines of the α- and ß- isoforms, separated by 
electrophoresis, and blotted. These northern blots were probed with the fragments 
specific to each isoform, which were isolated from the RNAi constructs (Section 3.6.2). 
The blots showed that both the α- and ß- isoform mRNA transcript levels were 
effectively reduced (Figure 5.1.3b). Both blots were probed with ß-tubulin to show 
equal loading of the gel. These results show that topoisomerase-IIα is essential for 
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growth in bloodstream from parasites, in addition to the procyclic stage (Kulikowicz and 
Shapiro, 2006).       
Next, the two RNAi cell-lines were investigated using the etoposide mediated cleavage 
technique. This has the advantage that topoisomerase-II activity can be assessed under 
physiological conditions to provide an insight into the roles of the two isoforms at the 
centromere. Given that the tagged locus cell-line is of the T. brucei 427 strain, whose 
karyotype is different to that of the T. brucei 927 strain used for genome sequencing 
(Melville et al., 2000), cleavage products obtained after etoposide mediated cleavage 
will not necessarily be identical in size to previous centromere mapping experiments.   
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Figure 5.1.4.  Topoisomerase-IIα,  but not topoisomerase-IIβ  generates chromosomal 
cleavage fragments.   
Etoposide mediated DNA cleavage experiments were performed on both the 
topoisomerase-IIα and topoisomerase-IIβ RNAi cell- lines,  with a non-etoposide t reated 
wild-type T. brucei 427 (lane N) as a control.  Lanes 1 and 2 contain chromosomes 
extracted from etoposide treated cultures of the topoisomerase -IIα RNAi cell- line,  while 
lanes 3 and 4 contain chromosomes extracted from etoposide t reated cultures of the 
topoisomerase-IIβ RNAi cell- line (Sect ion 3.1.3).  Lanes 2 and 4 are from the stated 
cultures further supplemented with 1µg ml
-1
 tetracycline for 28 hrs  to  init iate the gene 
specific  RNAi,  before chromosome extract ion (Sect ion 3.2.3).  The ethidium bromide 
stained gel (A) shows most  of the chromosomes of this st rain migrate in the non-resolved 
region of the gel under these separat ion condit ions (0.2 -  2.0 Mb), within the gel 
compression zone. Sizes are interpolated from S. cerevisiae  chromosomal markers 
(Sect ion 3.4.2).   The light  coloured smear ing observed in lanes 1,  3,  and 4 are 
characterist ic of lanes containing  chromosomes derived from etoposide treated cultures. 
The Southern blot  of the gel (B) demonstrates this more clear ly,  as the consequence of 
etoposide mediated cleavage results in a cleavage product  of 0.65 Mb when probed with 
the Tb7 probe of chromosome 5 .  In this st rain chromosome 5 is predicted to  be 2.0 Mb in 
size (Melville et  al. ,  2000).  When topoisomerase-IIα transcript  levels are reduced  under 
tetracycline t reatment ,  this cleavage product is no longer produced (lane 2 compared with 
lane 1).  Conversely when topoisomerase-IIβ transcript  levels are reduced, the cleavage 
product remains ( lane 4 compared with lane 3). The 1.2 Mb band observed in the 4 lanes 
of the genet ically modified  cell- lines,  and absent  in the wild-type control lane,  results 
from contaminat ing plasmid DNA hybr idising to the tagged rDNA locus of chromosome 
2a (Alsford and Horn, 2008).  
 
Chromosomes from wild-type T. brucei 427 were embedded in agarose blocks, as well 
as chromosomes from the topoisomerase-IIα and topoisomerase-IIß RNAi cell-lines 
treated with 100 µM etoposide for 30 minutes. Another set of chromosome embedded 
blocks were prepared from both of these cell-lines following treatment with 1 g ml
-1
 
tetracycline induction for 28 hours, and then 100 µM etoposide for 30 minutes, just 
before chromosome extraction. These chromosomes were fractionated in parallel by 
CHEFE, blotted, and hybridised with the previously used Tb7 probe. Etoposide 
treatment of the un-induced topoisomerase-IIα RNAi cell-line generated a cleavage 
product of 0.65 Mb, however no cleavage was observed when topoisomerase-IIα had 
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been knocked down (Figure 5.1.4). In contrast, when the topoisomerase-IIß was 
depleted, the cleavage product remained. This shows that it is specifically the 
topoisomerase-IIα isoform that is responsible for cleavage at the centromere. In 
addition, given that knockdown of topoisomerase-IIα, but not topoisomerase-IIβ 
coincides with a loss of smearing in the ethidium bromide stained gel, it seems likely 
that only topoisomerase-IIα is active along the full length of chromosomes in this life-
cycle stage. With the near identity of the protein sequence of the catalytic domain in the 
two isoforms (Appendix Figure 10.1.1), it is unlikely that etoposide inhibits only the α-
isoform.  
5.1.2 Localizing T. brucei topoisomerase-IIα 
With the observation that only topoisomerase-IIα appears active at T. brucei 
centromeres the next experiment was to clearly demonstrate nuclear localization. This 
may appear superfluous, since if an enzyme is shown to be active on chromosomes 
within live cells, it is implicit it would be targeted to the nucleus. However, 
demonstrating this fact and establishing the system is an important first step into 
dissecting the mechanism by which topoisomerase-IIα is targeted to the nucleus, and 
more interestingly, focused towards the centromere in a cell-cycle specific manner. 
A strategy was devised to knockout one topoisomerase-IIα allele, while in-situ tagging 
the remaining allele at the C-terminal end with a c-myc tag facilitating 
immunofluorescence based localization (see Methods for experimental details). As the 
two topoisomerase isoforms are found in tandem, despite the database erroneously 
showing a single fused gene, the first hurdle was to sequence the 3‟ un-translated region 
of topoisomerase-IIα to allow the cloning of flanking regions for incorporation into gene 
deletion constructs. Using two primers, one specific to the 3‟-end of the topoisomerase-
IIα gene, the other primer to the conserved 5‟-end of topoisomerase-IIß, the intergenic 
region was amplified using high fidelity DNA polymerase (Section 3.6.3). However, 
this revealed that the sequence of the 3‟ un-translated region of topoisomerase-IIα is 
identical to the 3‟ un-translated region of topoisomerase-IIß, possibly as a consequence 
of gene duplication. Therefore a gene disruption, rather than a gene replacement 
approach was taken, where the majority of the catalytic region was removed and 
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replaced with a drug selectable marker (see below for details). This allowed the use of 
the 3‟ end of topoisomerase-IIα to facilitate specific targeted disruption to the intended 
isoform.     
A gene disruption plasmid containing flanking regions of topoisomerase-IIα was 
developed based on the blasticidin resistance cassette p
BLA
 (Rudenko et al., 1994). A 
800 bp fragment of the 5‟ end of topoisomerase-IIα, and a 1 kb fragment of the 3‟ end of 
topoisomerase-IIα were amplified and cloned into pBLA (Section 3.6.5) to make  
pKO
BLA
-TopoIIα (Figure 5.1.6). The gene tagging vector pNATx12M (Alsford and Horn, 
2008) was modified to incorporate a 1.7 kb targeting sequence derived from the 3‟ end 
of the gene to form pNAT
x12M-HYG
-TopoIIα (Section 3.6.4 and Figure 5.1.5). A targeting 
fragment of this size should only allow in situ tagging of the allele that remains 
undisrupted. 
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Figure 5.1.5.  T. brucei topoisomerase-IIα localization constructs.  
Two constructs were generated to localize topoisomerase-IIα. (A) The plasmid  
pNATx
T AG
,  designed for tagging an in-situ gene locus with a C-terminal tag consist ing of 
12 consecut ive c-myc epitopes (Alsford and Horn, 2008),  was adapted for use here by 
replacing the exist ing drug selectable marker.  Next  a 1.6 kb specific 3‟ region of 
topoisomerase-IIα was cloned into this modified plasmid (Sect ion 3.6.4),  to generate 
pNAT
x12M-HYG
-TopoIIα . The plasmid could be linear ized with a unique AgeI rest rict ion 
site.  (B) The second plasmid was designed to disrupt  the second topois omerase-IIα  allele 
by t runcat ing the gene, and removing the act ive site.  An 800 bp region of the 5‟ end of 
topoisomerase-IIα  and a 1 kb region of the 3‟  end of topoisomerase-IIα  was amplified and 
cloned into p
BLA
 to form pKO
BLA
-TopoIIα (Sect ion 3.6.5).  This plasmid was linearized 
with NotI and KpnI restrict ion digests.    
 
To generate the required cell-line for localization experiments, first the linearized gene 
disruption construct pKO
BLA
-TopoIIα was electroporated into wild-type T. brucei 427. 
Blasticidin based drug selection using culture plates allowed the generation of clones 
(Section 3.10.1).  One such clone was then immediately transfected with the linearized 
topoisomerase-IIα c-myc tagging construct pNATx12M-HYG-TopoIIα, with parasites 
selected on hygromycin while maintained on blasticidin drug pressure. A resulting dual-
drug resistant clone was selected for analysis. Genomic DNA was extracted from this 
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clone, along with DNA from the single gene disruption cell-line and wild-type T. brucei 
427 (Section 3.2.2). Restriction analysis of the topoisomerase-II region of the assembled 
genome (Berriman et al., 2005) showed an XhoI restriction site that would generate 
different size bands on a Southern blot for a wild-type, disrupted and tagged allele. The 
gene disruption of the first allele and the tagging of the remaining allele both proved 
successful (Figure 5.1.6), with a 4 kb increase in fragment size as a result of gene 
disruption, and a 6 kb increase as a result of inserting the myc-tag topoisomerase-IIα 
plasmid, as predicted by in silico restriction mapping.   
 
  
Figure 5.1.6.  In-situ integration of tagged topoisomerase -IIα. 
Correct integrat ion of localizat ion plasmids was confirmed by a Southern blot  probed by 
the specific 3‟ topoisomerase -IIα  fragment  (ident ified by red bar).  Panel (A)  shows the 
XhoI restrict ion sites affected, with the gene disrupt ion of one allele removing the site 
within topoisomerase-IIα,  and the locus tagging extending the region to  the downstream 
XhoI site of topoisomerase-IIβ.  This predicted increase in both allele fragment  sizes are 
observed in the Southern blot (B).     
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Localization of topoisomerase-IIα was performed by confocal immunofluorescence of 
bloodstream form parasites (Section 3.11).  A mouse monoclonal antibody specific to 
the c-myc tag was incubated in conjunction with a rabbit polyclonal antibody raised 
against topoisomerase-IIα (a gift from the Shapiro laboratory) within permeablized cells 
fixed in paraformaldehyde. The concentrations of each antibody were determined 
empirically (Section 3.11). Secondary goat antibodies were conjugated with a green 
AlexaFluor (targeting the c-myc primary antibody), and a red AlexaFluor (targeting the 
topoisomerase-IIα primary antibody). Cells were mounted in PBS/glycerol containing 
DAPI to label the DNA. The images taken with a confocal microscope demonstrate that 
both the c-myc tag and topoisomerase-IIα specific antibodies detect topoisomerase-IIα 
only within the nucleus (Figure 5.1.7a). Analysis of cells in various stages of the cell-
cycle showed topoisomerase-IIα localized solely to the nucleus.  An example of a cell 
undergoing mitosis, where the kinetoplast (which replicates first, Section 2.1.1) has 
already doubled can be seen in Figure 5.1.7b. The distribution of topoisomerase-IIα 
within the nucleus appeared general, although given the small size of the trypanosome 
nuclei (around 5 µm), observing any punctuate patterns on individual chromosomes 
within the nucleus would be limited by the effective resolution of light microscopy.  
These results established that c-myc in-situ tagging of the only intact topoisomerase-IIα 
allele gave a strong immunofluorescence signal with very little background. 
Importantly, they also demonstrate that localization and activity of topoisomerase-IIα is 
unperturbed by the presence of the C-terminal tag. This observation will facilitate 
further downstream experiments studying topoisomerase-IIα centromeric signal 
targeting with C-terminally tagged constructs (Obado et al., 2011).   
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Figure 5.1.7.  The nuclear localization of topoisomerase -IIα. 
DAPI (light  blue) stains both the nucleus (N) and kinetoplast  (K).  Ant ibody labelled 
fluorescence to  the c-myc tag (green) and nat ive ant ibody labelling of topoisomerase -IIα 
(red) confirm localizat ion (Sect ion 3.11) of topoisomerase-IIα  to  the nucleus (A) .  Since 
only the full length tagged allele is present  this shows the tag does not  perturb 
localizat ion. Also pictured is a dividing cell (B)  containing two kinetoplasts with 
topoisomerase-IIα remaining dist ributed around the nuclear region.   
5.2 Functional Complementation of T. brucei Topoisomerase-IIα 
While the N-terminal catalytic domain of topoisomerase-IIα appears highly conserved 
between trypanosomatids, there is great variation between the C-terminal sequences, a 
feature exploited previously to generate selective RNAi mediated knockdown. This 
feature could also prove advantageous in a search to identify essential regulatory regions 
of topoisomerase-II. By replacing the native topoisomerase-IIα in T. brucei with its L. 
major counterpart, and assessing if parasites are still viable, insight may be gained into 
the importance of the native C-terminal domain. Given that centromere identification in 
L. major by biochemical mapping proved elusive, replacing T. brucei topoisomerase-IIα 
with the L. major enzyme could also shed light on whether L. major topoisomerase-II is 
simply refractory to etoposide.  
5.2.1 Complementing T. brucei with the L. major topoisomerase-II 
To assess whether L. major topoisomerase-II can substitute for T. brucei topoisomerase-
IIα, a complementation assay was performed featuring full length L. major 
topoisomerase-II expressed in the T. brucei topoisomerase-IIα RNAi cell-line. First, the 
DAPI Anti-Myc Anti-TopoII
Phase Merged
DAPI Anti-Myc Anti-TopoII
Phase Merged
(A) (B)
K
K
N
N NK
K
130 
 
full length L. major topoisomerase-II was amplified from L. major Friedlin strain and 
cloned into the plasmid pTub-EX
BLA
 (Obado et al., 2011) to form the final plasmid 
(Section 3.6.7). The resulting pTub-Ex
BLA
-LmfTopoII was linearized with BamHI and 
KpnI, and transfected into the topoisomerase-IIα RNAi cell-line, with clones generated 
under blasticidin drug selection (Section 3.10.1). The parasites were also maintained on 
hygromycin and phleomycin to select for retention of the RNAi machinery.     
 
 
 
Figure 5.2.1.  The L. major topoisomerase-II expression plasmid.  
Full length L. major  topoisomerase-II (LmfTopoII) was amplified and cloned into pTub-
Ex
BLA
 for const itut ive expression from the tubulin array of  T. brucei  (Sect ion 3.6.7). The 
result ing plasmid pTub-Ex
BLA
-LmfTopoII  was linear ized with BamHI and KpnI restrict ion 
digests.   
 
 
First, a growth assay was performed to assess whether L. major topoisomerase-II could 
complement the growth arrest phenotype of RNAi mediated knockdown of the T. brucei 
topoisomerase-IIα. The parent topoisomerase-IIα RNAi cell-line and the complemented 
cell-line were grown in parallel, with both tetracycline induction and non-induction. As 
observed previously, the non-complemented cell-line displayed growth arrest after 24 
hours, whereas the cell-line complemented with L. major topoisomerase-II showed no 
evidence of a slowdown in growth, relative to the un-induced parasites (Figure 5.2.2a). 
This phenotype was observed for the 7 day duration of the assay. To establish that 
effective transcript knockdown had occurred, samples of RNA were purified for 
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northern blot analysis using specific probes generated from the 3‟ end of the gene 
(Section 3.6.2 and Section 3.6.7). Knockdown of T. brucei topoisomerase-IIα was 
observed in both the parental and complemented RNAi cell-lines under tetracycline 
induction, while the L. major topoisomerase-II was shown to be constitutively expressed 
in the complemented cell-line (Figure 5.2.2b).     
 
 
Figure 5.2.2. L. major topoisomerase-II complements RNAi mediated depletion of 
topoisomerase-IIα  in bloodstream form T. brucei.    
Cumulat ive growth plots  of the T. brucei  topoisomerase-IIα  RNAi and complemented 
cell- lines (A).  Cells were counted every 24 hours by haemocytometer then diluted back to 
1 x 10
5
 ml
-1
.  The topoisomerase-IIα  RNAi cell- line untreated (red line) ,  and tetracycline 
treated (blue line) displays the inducible lethal phenotype as before (Figure 5.1.3). 
Comparing the topoisomerase-IIα RNAi cell- line const itut ively expressing L. major 
topoisomerase-IIα  untreated (green line) with a tetracycline t reated culture (orange line)  
to deplete nat ive topoisomerase-IIα  shows the growth inhibit ion phenotype of T. brucei 
topoisomerase-IIα  RNAi is complemented by the expression of the L. major  
topoisomerase-II  (Sect ion 3.1.3). Northern blots of RNA extracted 28 hours after  RNAi 
induct ion were probed with isoform-specific fragment s (Sect ion 3.6.2 and Sect ion 3.6.7) 
from the var iable regions (B).  This showed successful knockdown of T. brucei 
topoisomerase-IIα  under tetracycline induct ion, and const itut ive expression of L. major  
topoisomerase-II (LmfTopoII) in the complemented cell line.    
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Next, the biochemical activity of L. major topoisomerase-II at the centromere was 
examined using the etoposide mediated topoisomerase-II DNA cleavage assay. Cultures 
of both the original topoisomerase-IIα RNAi cell-line (Obado et al., 2011) and the 
topoisomerase-IIα RNAi cell-line constitutively expressing L. major topoisomerase-II, 
were induced for RNAi with tetracycline for 28 hours, and treated with etoposide for 30 
minutes before being embedded in agarose blocks. Non-induced parasites were also 
treated with etoposide. As expected, both the non-induced cell-lines displayed etoposide 
mediated cleavage products, as a result of the activity of the native topoisomerase-IIα 
activity. As previously observed, the parent RNAi cell-line ceased to generate cleavage 
products when RNAi was induced, a phenotype concomitant with cell death. 
Interestingly the cell-line complemented with L. major topoisomerase-II also ceased to 
generate cleavage products (Figure 5.2.3), despite demonstrating that it could rescue the 
growth arrest phenotype. This could be a consequence of the L. major topoisomerase-II 
lacking the required recognition features of the T. brucei centromere to be successfully 
recruited, while still effectively complementing the general role of a nuclear 
topoisomerase-II enzyme. Alternatively etoposide may simply not inhibit the L. major 
orthologue. Indeed, analysis of the ethidium bromide stained gel supports the latter, 
given the lack of smearing in the lane corresponding to the complemented culture 
treated with etoposide. A smeared lane of a CHEFE gel appears characteristic of 
inhibited topoisomerase-II activity, and its absence here suggests that this etoposide 
mediated enzyme inhibition is not occurring in T. brucei parasites expressing only the 
Leishmania enzyme. 
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Figure 5.2.3.  L. major topoisomerase-II does not generate etoposide mediated DNA 
cleavage products.  
Etoposide mediated DNA cleavage experiments were performed on the topoisomerase -IIα 
RNAi cell- line (Obado et  al. ,  2011) and the topoisomerase-IIα RNAi cell- line 
const itut ively expressing L. major  topoisomerase-II. A non-etoposide treated wild-type T. 
brucei  427 (lane N) is shown as a control.  Lanes 1 and 2 contain chromosomes extracted 
from etoposide t reated cultures  of the topoisomerase-IIα RNAi cell- line,  while lanes 3 
and 4 contain chromosomes extracted from etoposide treated cultures of the  
complemented cell- line (Sect ion 3.2.3).  Lanes 2 and 4 are from the stated cultur es further 
supplemented with 1  µg ml
-1
 tetracycline for 28 hrs to  init iate the gene specific RNAi 
(Sect ion 3.1.3).  The ethidium bromide stained gel (A) shows most of the megabase sized 
chromosomes within the compression zone of the CHEFE gel,  with S. cerevisiae 
chromosomes used as size markers (Sect ion 3.4.2).   The Southern blot of the gel (B) 
shows etoposide mediated cleavage products of topoisomerase -IIα  in lanes 1 and 3 (0.65 
Mb) when probed for chromosome 5 using the Tb7 probe. In parasites depleted of 
topoisomerase-IIα,  there is an absence of cleavage products (lane 2).  With the added 
const itut ive expression of L. major  topoisomerase-II this absence o f cleavage products 
remains ( lane 4).  A lack of cleavage product  is again accompanied by a lack of smearing 
in the corresponding lane of the ethidium bromide stained gel (see also Figure 5.1.4).  
Plasmid contaminat ion appears faint ly in  the RNAi cell- lines due to  the presence of the 
tagged locus on chromosome 2a (Alsford and Horn, 2008) .  
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As an alternative approach to the above question, we sought to express the L major 
topoisomerase-II in a null mutant background utilizing the single allele gene disruption 
cell-line already generated (Section 5.1.2, Figure 5.1.6) with the pKO
BLA
-TopoIIα 
plasmid, which contained a blastacidin selection marker. To generate the second 
knockout vector for the remaining allele the two gene disruption targeting fragments 
were cloned from the blasticidin based vector (Figure 5.1.5b) to a hygromycin resistance 
cassette (Section 3.6.6) to form pKO
HYG
-TopoIIα (Figure 5.2.4a). Then the L. major 
topoisomerase-II was transferred from pTub-EX
BLA
-LmfTopoII to pTub-EX
PURO
 
(Section 3.6.8) forming pTub-EX
PURO
-LmfTopoII (Figure 5.2.4b). This prevented the 
complementation plasmid sharing the same drug selectable marker as the first gene 
disruption plasmid. In addition the T. cruzi topoisomerase-II orthologue was also 
transferred from the existing pTub-EX
BLA
-TcTopoII (Obado et al., 2011), to create  
pTub-EX
PURO
-TcTopoII (Section 3.6.9 and Figure 5.2.4c) for further analysis. 
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Figure 5.2.4. Plasmids for generating T. brucei topoisomerase -IIα null mutants with 
heterologous topoisomerase-II complementation.   
The target ing fragments of the gene disrupt ion vector pKO
BLA
-TopoIIα  (Figure 5.1.5) 
were cloned into a hygromycin resistance cassette (Sect ion 3.6.6) to  produce the second 
gene disrupt ion plasmid pKO
H Y G
-TopoIIα, required for the disrupt ion of the remaining T. 
brucei  topoisomerase-IIα allele  (see Figure 5.1.6).  The L. major  topoisomerase-II gene 
was cloned from pTub-Ex
BLA
-LmfTopoII (Figure 5.2.1) into pTub-Ex
PURO
-LmfTopoII 
(Sect ion 3.6.8) to prevent  a conflict  of drug markers.  Also the T. cruzi  topoisomerase-II 
was transferred from pTub-Ex
BLA
-TcTopoII (Obado et  al. ,  2011)  to  pTub-Ex
PURO
-
TcTopoII (Sect ion 3.6.9).  The latter  two plasmids were used independent ly in attempts to 
generate T. brucei  topoisomerase-IIα null mutants complemented with the const itutively 
expressed topoisomerase-II orthologue. The restrict ion sites used for the linear izat ion of 
these plasmids are indicated.   
 
 
 
TopoIIα 5’ Flank TopoIIα 3’ FlankHygromycin
Ampicillin
(A)
NotI KpnI
LmfTopoII
Ampicillin
Puromycin
BamHI KpnI
TcTopoII
Ampicillin
Puromycin
NotI XhoI
(B)
(C)
Intergenic region 
tubulin
Intergenic region 
tubulin
Intergenic region 
tubulin
Intergenic region 
tubulin
Intergenic region 
actin
Intergenic region 
tubulin
Intergenic region 
tubulin
Intergenic region 
actin
136 
 
With the first round of gene disruption previously genetically validated (Figure 5.1.6b), 
the next stage was to transform this cell-line with the L. major and T. cruzi pTub-
EX
PURO
 based topoisomerase-II complementation vectors. After linearization of the 
complementation vectors using BamHI and KpnI (for L. major) or NotI and XhoI (for T. 
cruzi), the constructs were then independently used to transform the single knockout 
cell-line. Transformants were selected on puromycin drug pressure, while being 
maintained on blasticidin. The second T. brucei topoisomerase-IIα gene disruption 
vector (Figure 5.2.4a) was linearized with NotI and KpnI before being immediately used 
to transfect one clone from each of the generated complementation cell-lines. Selection 
was performed with hygromycin, while parasites were maintained on both blasticidin 
and puromycin. Southern blots hybridised with T. cruzi and L. major specific probes 
(Section 3.6.7 and Section 3.6.9) demonstrated correct integration of the respective 
complementing genes in the tubulin array (Figure 5.2.5a and Figure 5.2.5b) 
Analysis of nine clones complemented with the T. cruzi gene and six clones 
complemented with the L. major gene derived from two independent transfection 
experiments showed no loss of the remaining T. brucei topoisomerase-IIα allele, by 
either Southern blot of the target loci (Figure 5.2.5d) or northern blot analysis of the 
native transcript (Figure 5.2.5e), for any clones. The northern blot shows the clearest 
indication of the full length topoisomerase-IIα transcript remaining in triple drug 
resistant clones complemented with either topoisomerase-II orthologue. This is because 
the topoisomerase-IIα mRNA band is still present, and remains the same size as the 
wild-type transcript in the complemented null mutant cell-lines. 
The resulting Southern blot of DNA from three triple drug resistant clones expressing 
the T. cruzi gene appears peculiar. The restriction fragment pattern does not match the 
single gene disruption pattern, suggesting there has been some form of second 
integration event, a notion supported by the fact that the clones are resistant to the three 
selection drugs. However this new pattern does not match the predicted sizes, in 
particular the appearance of a HindIII fragment at 3.5 kb, observed in three all cases. 
This is accompanied by an NruI DNA digest showing all three clones producing 
restriction fragment bands larger than the predicted 8.2 kb fragment size. 
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Given the unexplainable Southern blot restriction patterns, combined with the 
topoisomerase-IIα transcripts remaining in a northern blot across a total of 14 clones, it 
can be concluded that topoisomerase-IIα null mutants cannot be readily generated in 
either a L. major or T. cruzi topoisomerase-II complemented background with this 
strategy.   
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Figure 5.2.5 (overleaf) .  T. brucei topoisomerase-IIα  null mutants complemented with 
T. cruzi or L. major topoisomerase-II orthologues could not be created.  
T. cruzi  topoisomerase-II or L. major  topoisomerase-II were inserted into the tubulin 
array of the T. brucei  427 cell- line in which one copy of the topoisomerase-IIα gene had 
already been disrupted (sKO, see Figure 5.1.6).  These two lines were then transfected 
with a second gene disrupt ion fragment  to target the remaining T. brucei topoisomerase-
IIα allele.  Southern blots of DNA extracted from triple drug resistant,  potent ial null 
mutants complemented with either the T. cruzi  or L. major  topoisomerase-II were probed 
with gene specific probes (Sect ion 3.6.7 and Sect ion 3.6.9) to confirm the integrat ion of 
the complement ing topoisomerase-II orthologues into the tubulin array. This confirmed 
the presence of both the T. cruzi (A) and L. major (B)  genes. To examine whether T. 
brucei topoisomerase-IIα  null mutants had been generated in the T. cruzi  complemented 
background a fresh Southern blot was probed with a fragment  specific for the 3‟ end of 
topoisomerase-IIα (Sect ion 3.6.2). (C) An in silico map out lines the predicted restrict ion 
fragment  sizes from the 2 original wild-type T.  brucei topoisomerase-IIα  alleles,  the first  
allele disrupted with the blast icidin resistance cassette,  and the second allele generated 
with the hygromycin resistance cassette. The downstream topoisomerase-IIβ and the 
upstream histone acetylt ransferase  2 (HAT2) genes are also shown. The results of the 
Southern blot  (D) show the wild-type (WT) and first  round gene disrupt ion (sKO) 
fragment  sizes match the in silico  predicted pattern.  However after the second round of 
gene disrupt ion, the three clones analysed here show three new bands at  3.5 kb with a 
HindIII rest rict ion digest ,  and in the case of clones 1 and 3,  no loss of the nat ive 6 kb 
rest rict ion fragment.  Even though clone 2 shows two bands at  the predicted sizes,  the 
origin of the addit ional 3.5 kb band remains unclear.  An NruI DNA digest  shows a 
similar pattern with clones 1 and 3 maintaining the wild -type 6 kb band, while all three 
clones show bands larger than the predicted 8.2 kb fragment  size.  For a rapid screening 
approach of further potent ial null mutant  clones,  a northern blot  analysis was performed  
(E).  This assessed the expression of T. brucei  topoisomerase-IIα  in parasite clones 
resistant  to  3 drug selectable markers,  and const itut ively expressing either T. cruzi (C4-
9) or L. major  (L1-6) topoisomerase-II.  The results indicated the nat ive gene cont inued  to 
be expressed in a further 12 independent  clones.  
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5.3 Affinity Purification of Topoisomerase II Complexes 
Affinity purification of topoisomerase-II from trypanosomes could allow the 
identification of regulator enzymes or any post-translational modifications of 
topoisomerase-II, which determine the regulatory mechanisms of topoisomerase-II 
activity and its accumulation at the centromere.  Therefore a plasmid facilitating tandem 
affinity purification of proteins was obtained (a gift from the Günzl laboratory). There is 
both an N-terminal tag and C-terminal version of the PTP-tag plasmid available, termed 
pN-PTP
NEO
 and pC-PTP
NEO
 (Schimanski et al., 2005).   
5.3.1 Co-immunoprecipitation of topoisomerase-II 
To tag the C-terminus of T. brucei topoisomerase-IIα and T. cruzi topoisomerase-II, 3‟ 
targeting fragments (with the stop codon deleted) of each gene were cloned into pC-
PTP
NEO
 to generate the plasmids pC-PTP
NEO
-TopoIIα and pC-PTPNEO-TcTopoII 
(Sections 3.6.10 and 3.6.11 respectively). The resulting plasmids were then sequenced to 
confirm the correct translated protein sequence, and that the tag was in frame with the 
gene. Both of the final plasmids (Figure 5.3.1) could be linearized by a unique StuI 
restriction site and inserted into the native gene locus by double homologous 
recombination for stable integration.   
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Figure 5.3.1.  Affinity purification constructs for topoisomerase -II. 
The PTP tag (A)  consists of a Prot  A epitope separated by a TEV protease site and two 
parallel ProtC epitopes,  which facilitates tandem affinity purificat ion of the tagged 
protein from the nat ive allele (Schimanski et  al. ,  2005) .  A 3‟ target ing fragment  from T. 
brucei  topoisomerase-IIα  and T. cruzi  topoisomerase-II were cloned individually into pC-
PTP-NEO (sect ions 3.6.10 and 3.6.11).  The result ing plasmids pC-PTP
NEO
-TopoIIα (B) 
and pC-PTP
NEO
-TcTopoII  (C) were linear ized by a unique StuI rest rict ion site within the 
target ing fragment ,  and transfected into T. brucei  927 procyclic forms and T. cruzi CL 
Brener epimast igotes respect ively.  
  
Since T. cruzi epimastigotes grow to far higher densities than that of even the procyclic 
stage of T. brucei, the system was developed first in T. cruzi. This would facilitate the 
production of higher yields of tagged protein. Therefore linearized pC-PTP
NEO
-
TcTopoII was transfected into epimastigote T. cruzi CL Brener wild-type strain, and 
selected on G418 drug pressure. Multiple clones were generated. Genomic DNA was 
purified from 1 clone and subjected to restriction digest and Southern blot analysis to 
confirm the topoisomerase-II locus had been successfully targeted. Although T. cruzi 
CL Brener has been successfully sequenced (El-Sayed et al., 2005a), it has yet to be 
fully assembled. This often makes the generation of in silico restriction maps difficult. 
Figure 5.3.2a shows the predicted restriction map generated by independent EcoRI and 
NcoI digests of the allele possessing the largest shotgun sequence fragment (GeneDB 
Accession: Tc00.1047053508699.10). Results from the Southern blot demonstrate 
correct integration of the tag (Figure 5.3.2). The restriction digest of wild-type genomic 
DNA with EcoRI revealed the predicted 7.2 kb band, but also an additional band at 8.8 
kb. This presumably is simply the consequence of allelic variation, which is extensive in 
the CL Brener genome (El-Sayed et al., 2005a). This band remains in the PTP-tagged 
cell-line, and therefore represents the untagged allele. The 7.2 kb band is replaced by 
Intergenic region     
3’ RNA polymerase I 
(large sub-unit) 
Neomycin3’ TbTopoIIα PTP
STOPStuI
Intergenic region     
3’ RNA polymerase I 
(large sub-unit) 
Neomycin3’ TcTopoII PTP
STOP
TEVProt A Prot C Prot CPTP Tag:
Ampicillin Ampicillin
(B) (C)
(A)
StuI
Intergenic region 
tubulin
Intergenic region 
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two bands at 3.7 kb and 9.4 kb. This is because insertion of the full pC-PTP
NEO
-
TcTopoII plasmid introduces a new EcoRI site (3.7 kb) and also extends the distance to 
the downstream native EcoRI site (9.4 kb). The former is detected by the probe to the 
newly introduced 3‟ gene fragment tagged with the PTP epitopes. The latter is the 
replaced native 3‟ gene fragment looped downstream by the recombination event. The 
NcoI digest is simpler to interpret, with both wild-type alleles generating a fragment at 
3.5 kb. The tagged allele of the selected cell-line again produces two bands due to an 
NcoI site within pC-PTP
NEO
-TcTopoII producing a 3.9 kb band and a 5.5 kb band. 
 
  
Figure 5.3.2.  Integrating PTP tagged topoisomerase -II in T. cruzi. 
An in silico  predicted map shows restrict ion site fragment  sizes  for two enzymes at the 
topoisomerase II locus of T. cruzi (A).  The Southern blot  and accompanying table (B) 
demonstrates correct  integrat ion of the plasmid. The rest rict ion fragment  sizes from the 
wild-type (WT) is shown in the top row of the table,  with the observed fragment  sizes 
from the Southern blot  described below. One modified allele generates two bands due to 
the mechanism o f plasmid integrat ion, whereby the probe dete cts both the in situ  tagged 
allele and remaining nat ive 3‟ end of topoisomerase -IIα now located further downstream 
(not  shown on map).  The EcoRI Southern blot  results in two separate wild-type bands 
from a polymorphism between homologues.  The remaining nat ive allele is shown in 
parenthesis.       
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Whole cell lysate preparations were made from a total of 5 x 10
9
 epimastigotes (Section 
3.9.2), of either exponential growth phase wild-type T. cruzi cultures, or transformed T. 
cruzi cultures possessing the epitope tagged topoisomerase-II. A further culture which 
possessed the tagged topoisomerase-II was grown to stationary phase, before cell lysates 
were prepared. A 10 µl aliquot of each lysate sample was separated by SDS-PAGE on 
two 5% gels in parallel. The first gel was coomassie stained to demonstrate equal 
loading, the second was subjected to western blotting, and probed with a ProtC antibody 
(Figure 5.3.3). This revealed that topoisomerase-II tagged with PTP was cleanly 
recognised by the ProtC antibody and full length topoisomerase-II was successfully 
expressed, within the lysate. This preliminary result also suggests that topoisomerase-II 
may be present at higher concentrations in actively dividing cells, although further 
experiments would be required to confirm this. 
This tagged system was designed and developed to analyse the nature of any post-
translational modifications to topoisomerase-II, and identify any other proteins bound to 
topoisomerase-II in a complex, and is the subject of downstream work.   
 
 
Figure 5.3.3.  T. cruzi express PTP tagged topoisomerase -II. 
Protein lysates from T. cruzi  epimast igotes were run on a 5% denaturing gel w ith PTP 
tagged topoisomerase II lines grown in exponent ial phase (exp) and to  stat ionary phase 
(sta),  and compared with the wild type. A coomassie stain (A)  shows protein loading, 
with the western blot  (B)  probed with a ProtC ant ibody to the tag  (Sect ions 3.9.3 and 
3.9.4),  showing T. cruzi  topoisomerase II tagged protein expression.   
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5.4 Chapter Summary 
The study of the nuclear topoisomerase-II isoforms in the T. brucei bloodstream form 
parasites is summarized below:  
 RNAi experiments demonstrate that only the topoisomerase-IIα isoform is 
essential for parasite growth of bloodstream form parasites. The topoisomerase-
IIβ isoform appears non-essential. This echoes what was observed previously in 
the procyclic parasite form (Kulikowicz and Shapiro, 2006).  
 The RNAi studies further show that only the topoisomerase-IIα isoform 
generates centromere specific etoposide mediated DNA cleavage. 
 Immunofluorescence localization demonstrates that topoisomerase-IIα resides 
within the nucleus. Also the in situ addition of a C-terminal c-myc epitope tag to 
topoisomerase-IIα does not perturb enzyme function. 
 The heterologous expression of L. major topoisomerase-II rescues the cell death 
phenotype generated by the RNAi mediated depletion of topoisomerase-IIα.  
 The expression of L. major topoisomerase-II does not however restore 
centromere specific etoposide mediated DNA cleavage. This suggests L. major 
topoisomerase-II may be refractory to etoposide poisoning. 
 Since centromeric cleavage was not generated by heterologous L. major 
topoisomerase-II expression with etoposide treatment, no examination of the C-
terminal function in respect to centromere targeting was possible.  
 Generating topoisomerase-IIα null mutants with a gene disruption strategy, in a 
background of either L. major or T. cruzi topoisomerase-II constitutive 
expression, proved elusive. 
 A T. cruzi cell-line was developed allowing the tandem affinity purification of 
native topoisomerase-II. In future this could facilitate the study of 
topoisomerase-II in terms of examining post-translational modification or 
associated bound proteins. The system would also be readily applicable to 
procylic form T. brucei. 
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5.5 Discussion 
Since topoisomerase-II has been shown to accumulate at T. brucei centromeres, and yet 
no single primary DNA sequence appeared to define this region (Section 4.4) the 
question arises as to what guides this enzyme specifically towards the centromere? 
Unlike L. major and T. cruzi, there are two nuclear isoforms of topoisomerase-II in T. 
brucei (Kulikowicz and Shapiro, 2006). The first step in analyzing the targeting 
mechanism of T. brucei topoisomerase-II to the centromere was to establish which 
isoforms would be active at the centromere. Using isoform-specific RNAi mediated 
knockdown, it was shown that only the topoisomerase-IIα isoform was active at the 
centromere (Section 5.1.1). In fact the topoisomerase-IIβ isoform appeared dispensable, 
which is perhaps unsurprising as it appeared catalytically inactive during an in vitro 
DNA de-catenation assay (Kulikowicz and Shapiro, 2006). The reason for its inactivity 
in vitro is not clear, as the catalytic N-terminal shares a very high level of sequence 
homology to the topoisomerase-IIα isoform (Figure 10.1.1). It therefore seems that 
topoisomerase-IIβ could be a pseudogene, albeit with the catalytic and ATPase domains 
remaining highly conserved. Pseudogenes are fairly abundant in the T. brucei genome 
with approximately 10% of open reading frames designated as pseudogenes (Berriman 
et al., 2005). Recently it has been proposed that RNAi fragments derived from 
duplicated pseudogenes may have a regulatory role on their functional gene 
counterparts, however so far this has only been demonstrated for 9 proteins of unknown 
function (Wen et al., 2011). Notably, topoisomerase-IIβ is absent in T. cruzi and L. 
major, neither of which possess the RNAi machinery (Section 1.5.5). It may be that 
topoisomerase-IIβ plays some regulatory role on the –α isoform, which may warrant 
further investigation.  
Given that in other model organisms, the C-terminal of topoisomerase-II is not required 
for in vitro activity, yet this domain contains in vivo cell-cycle dependent 
phosphorylation sites (Section 2.3), it is conceivable that the C-terminal of 
topoisomerase-IIα is involved in the cellular regulation of its activity and localization. 
An interesting experiment had shown that constitutive expression of the T. cruzi 
topoisomerase-II in an T. brucei topoisomerase-IIα RNAi mediated knockdown 
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background could rescue the growth inhibition phenotype and restore the withdrawal of 
centromeric activity (Obado et al., 2011). If the hypothesis of C-terminal based 
regulation is true, then despite a divergent C-terminus between topoisomerase-IIα and 
the T. cruzi orthologue, there must be shared features conferring the regulatory control 
and guidance towards a centromere. Here, using a similar approach to extend this 
hypothesis, it was shown that the constitutive expression of L. major topoisomerase-II 
could rescue the growth inhibition phenotype, but not restore the etoposide mediated 
centromeric cleavage activity (Section 5.2.1). This result strongly suggests that the L. 
major enzyme also shares at least some of these regulatory features, and that the reason 
behind the ineffective L. major centromere mapping experiments is that etoposide does 
not inhibit the nuclear L. major topoisomerase-II. An assessment of in vitro DNA 
cleavage activity with recombinant nuclear L. major topoisomerase-II and etoposide 
would aid confirmation. Although it appears likely that a technical limitation led to the 
failure to map centromeres of L. major chromosomes, the underlying question as to 
whether this organism segregates its chromosomes by a centromere dependent 
mechanism remains to be resolved. Since topoisomerase-II has received interest as a 
drug target in trypanosomatids (Das et al., 2004), noting differences in drug 
susceptibility between the L. major nuclear and kinetoplast isoforms could prove 
important in developing the appropriate drug screening strategies.  
Experiments described in this chapter have shown that within the constitutive 
complementation background of either the L. major or T. cruzi topoisomerase-II, null 
mutants of T. brucei topoisomerase-IIα could not be generated (Section 5.2.1). Although 
failure to disrupt the remaining allele does not provide irrefutable proof that the native 
T. brucei topoisomerase-IIα is essential, it is noteworthy that the first allele proved 
routine to disrupt. Why it should be the case that the second allele could not be disrupted 
is unclear, given the success of its orthologues complementing the topoisomerase-IIα 
RNAi growth inhibition phenotype. Perhaps there is a requirement for a low level of 
native enzyme for a particular function that would remain from RNAi mediated 
knockdown. On the other hand it may be a technical problem due to the nature of the 
tandem repeat locus. In this region there is a high level of similarity in DNA sequences 
between the two isoforms, as well as between their surrounding un-translated regions. 
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While the single allele sequenced here contains notable similarities in the intergenic 
sequences for the two isoforms, any significant sequence differences across the two 
alleles would prevent the correct insertion of a second gene disruption plasmid, which 
was designed on the basis of the first allele. This may lead to unpredictable insertions 
using either topoisomerase-IIβ or downstream sequences as the template, and could 
explain the obscure Southern blot based restriction maps (Figure 5.2.5). 
Comprehensively sequencing the intergenic sequences of both alleles would help in 
answering these issues, especially given the current sequencing artefacts that still reside 
in the genome database.  
Due to the inability of L. major topoisomerase-II to generate etoposide mediated DNA 
cleavage when expressed in T. brucei, it could not be exploited to dissect the centromere 
targeting mechanism. This is primarily because any experiment of this kind would be 
based on the unsupported assumption that the L. major enzyme locates to the centromere 
similarly to its T. brucei and T. cruzi counterparts. In addition, any experiments 
involving alterations to the enzyme‟s C-terminal that could affect its centromeric 
targeting behaviour would also be difficult to assess. Therefore it would not be possible 
to draw parallels between C-terminal protein sequence features of the native T. brucei 
topoisomerase-IIα to the L. major orthologue, or to the T. cruzi enzyme from other 
experiments. Consequently, a new experimental system was pursued where endogenous 
T. brucei topoisomerase-IIα was PTP tagged to facilitate native enzyme purification. As 
T. cruzi epimastigotes grow to higher cell densities in culture, this system was 
developed for the T. cruzi enzyme as well (Section 5.3.1). In future work this system 
could allow the study of any cell-cycle dependent phosphorylation of the enzyme, and 
also reveal whether other proteins relevant to mitosis are associated with topoisomerase-
II.  
The c-myc epitope tag system was originally designed as a positive control to assess the 
nuclear localization of the native topoisomerase-II for use in any future truncated or 
mutated enzyme experiments (Section 5.1.2). It has since been used to purify T. brucei 
topoisomerase-IIα. The purified protein was then analyzed for any associated SUMO 
conjugation using an antibody against the SUMO protein, which revealed that the 
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SUMO modifier could not be detected in the sample (Obado et al., 2011). In 
experiments with other organisms, SUMO modified topoisomerase-II can often be 
observed on a western blot as higher molecular weight bands above the native enzyme. 
In preliminary experiments with the PTP tagged T. cruzi enzyme, no such additional 
bands could be observed (Section 5.3.1). Together, these results tentatively suggest that 
unlike in some other systems (Section 2.3), SUMO does not play a role in targeting the 
enzyme towards the centromere. 
Overall, the mechanism of centromere targeting of topoisomerase-II remains elusive. 
While it has now been shown that that T. brucei topoisomerase-IIα and T. cruzi 
topoisomerase-II enzymes are capable of locating T. brucei centromeres, the system that 
facilitates the specific target guidance remains unknown. The system is most likely 
sensitive to chromatin structure rather than pure DNA sequence, due to the differences 
observed between centromere sequences across chromosomes. Further analysis of the 
cell-cycle phosphorylation of topoisomerase-II, as well as any bound accessory proteins 
would help us to understand this process for topoisomerase-II. Many pieces of the 
centromere/kinetochore complex are yet to be identified. Although it was hoped that 
understanding topoisomerase-II in more detail would aid in the identification of other 
centromeric targeted proteins, other future experimental approaches will probably be 
required to begin to unravel the puzzle of chromosome segregation in trypanosomatids. 
 
149 
 
 
 
 
 
 
 
 
 
SECTION II: 
Nitroreductase mediated drug metabolism 
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6 Introduction to Nitroreductase Based Drug Metabolism 
Nitroaromatic compounds represent a large group of molecules characterised by a nitro 
group linked to a heterocyclic (e.g. furan, thiophene, imidazole, triazole etc) or cyclic 
(eg benzyl) ring (Raether and Hanel, 2003). They rarely occur in nature, with most 
generated synthetically during the production of plastics, dyes, solvents, pesticides, 
explosives and pharmaceuticals (Rieger et al., 2002; Roldan et al., 2008). Their 
medicinal uses were first recognised in the early 20
th
 century with the 5‟ nitrofuryl, 
nitrofurazone emerging as a topical treatment for burns and wounds (Raether and Hanel, 
2003). They have been used extensively to treat a variety of microbial urinary or 
gastrointestinal tract (GI) infections, but concern over their reported mutagenic 
properties has resulted in a decline in their use, particularly in Europe and the United 
States (McCalla, 1983). However, this scepticism about using nitro-based compounds is 
being questioned, as recent studies suggest that these compounds are not as toxic as 
initially thought (Trunz et al., 2011; Yamada et al., 1997). Such observations have led to 
renewed interest in this group of agents as potential anti-cancer therapies (Dachs et al., 
2005; Denny, 2003) and anti-microbial agents (Stover et al., 2000; Wilkinson and Kelly, 
2009). 
This chapter will first discuss the initial key step involved in the mode of action of many 
nitroaromatics. It will then focus on the 5‟ nitrofuryl compounds using nitrofurazone, 
the best studied agent in terms of its activity, selectivity and host toxicity, as a lead 
example and explore how this can inform our knowledge relating to the trypanocidal 
activity of nifurtimox. Finally it will describe how the current knowledge of pro-drug 
activation has been exploited to develop anti-cancer therapies such as the azirindyl 
nitrobenzyl CB1954, and the nitrobenzyl mustards, which may be suitable as future 
trypanocidal agents. 
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6.1 Nitroreductase Mediated Drug Activation 
Based on the nature of the ring structure and the position/number of nitro groups on the 
ring, nitroaromatics can be divided into several classes, with each sub-group having 
distinct chemical properties. One feature shared by the diverse medicinal compounds is 
that they function as pro-drugs and must be „activated‟ before they mediate their 
cytotoxic effects. A key reaction to this activation process is catalyzed by a group of 
oxidoreductases called nitroreductases. Based on their sensitivity to oxygen, this group 
of enzymes can be separated into two distinct classes, the type I and type II 
nitroreductases, with members of each class often unrelated in their primary sequence 
and physiological substrate (Peterson et al., 1979; Roldan et al., 2008). 
Type I nitroreductases are a group of flavin mononucleotide (FMN)-containing enzymes 
found in prokaryotes and absent from most eukaryotes, with a sub-set of protozoan 
parasites, including Trypanosoma and Leishmania, being major exceptions (Nixon et al., 
2002; Wilkinson et al., 2008). They catalyse the reduction of the conserved nitro group 
present on the target substrate, through a nitroso intermediate, to a hydroxylamine 
derivative via a series of 2-electron transfers, utilizing NADPH and/or NADH as 
electron donors (Race et al., 2005). The hydroxylamine can then undergo further 
processing to generate a series of additional cytotoxic metabolites (Denny, 2003; Gavin 
et al., 1966; Streeter and Hoener, 1988). As this reaction does not involve oxygen and 
does not result in the production of reactive oxygen species, this activity is said to be 
“oxygen insensitive”. Generally, bacteria have multiple type I nitroreductases. For 
example, E. coli expresses two major type I nitroreductases, designated as nfsA and 
nfsB, with 2 further minor activities also reported: azoR and nemA (Prosser et al., 2010; 
Zenno et al., 1996a; Zenno et al., 1996b). As with other type I nitroreductases, these E. 
coli enzymes can metabolize a wide variety of nitroaromatic compounds (Roldan et al., 
2008), ranging from medicinally used pro-drugs such as nitrofurazone, to environmental 
pollutants including 2, 4, 6-trinitrotoluene (TNT). Intriguingly, the precise physiological 
role for any of these enzymes remains unknown. 
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A wide array of FMN or flavin adenine dinucleotide (FAD)-containing enzymes display 
a type II oxygen-sensitive nitroreductase activity. These mediate a 1-electron reduction 
of the conserved nitro group to produce an unstable nitro anion radical (Docampo and 
Stoppani, 1979; Mason and Holtzman, 1975; Peterson et al., 1979). In the presence of 
oxygen, this radical can undergo futile cycling, resulting in the production of superoxide 
anions and the regeneration of the parent nitro-compound. When oxygen is limited, the 
nitroso form can be produced by a further single electron reduction step, or by the 
interaction of two nitro anions, with the latter reaction also resulting in regeneration of 
the parent nitro-compound (Mason and Holtzman, 1975). The nitroso form is highly 
reactive and can promote cellular damage directly or through the formation of a 
hydroxylamine derivative (Leitsch et al., 2007). Examples of type II nitroreductases 
include the cytochrome P450 reductase and xanthine oxidoreductase. Most organisms 
express several cytochrome P450 reductases, with each enzyme containing FMN and 
FAD as co-factors, while using NADPH as a source of reducing equivalents (Iyanagi 
and Mason, 1973). They function to transfer a single electron to various physiological 
substrates including cytochrome P450, heme oxygenase, cytochrome b5 and squalene 
epoxidase (Murataliev et al., 2004). In mammals, the FAD-dependent xanthine 
oxidoreductases are iron-sulphur cluster enzymes that function to convert hypoxanthine 
to uric acid via a xanthine intermediate (Green, 1934). This activity was thought to be 
due to the concerted action of two distinct enzymes, xanthine oxidase and xanthine 
reductase, but it has been shown that a single enzyme can perform both reactions (Corte 
and Stirpe, 1972). Initially, this finding was believed to be an experimental artefact, 
however evidence is emerging that this behaviour may also occur in vivo (Nishino et al., 
2008). 
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6.2 Anti-Microbial Activity of 5’ Nitrofuran Compounds 
6.2.1 Nitrofurazone 
The 5‟ nitrofuryl class of compounds were one of the first nitroheterocyclics to be 
recognized as potential chemotherapies, and are characterized by a nitro group linked to 
a furan ring in the 5‟ position (Figure 6.2.1). Screening programmes targeting different 
bacterial species using furyl derivatives revealed that the nitro group was key to 
cytotoxic activities (Dodd, 1944). From in vitro and mouse in vivo studies, nitrofurazone 
(5-nitro-2-furaldehyde semicarbazone, also called furacin) emerged as the lead structure, 
showing anti-microbial activity against bacteria species such as Staphylococcus aureus 
and Salmonella spp. (Dodd, 1946). These experiments were extended to other 
organisms, revealing that nitrofurazone was very effective against the trypanosomatid 
horse parasite Trypanosoma equiperdum (Dodd, 1946) and human parasite T. b. 
gambiense (Evens et al., 1957; Packchanian, 1955). However, due to adverse side-
effects including severe joint pain and peripheral neuritis, the use of nitrofurazone 
became limited to a topical treatment of bacterial infections (Grunberg and Titsworth, 
1973).  
 
 
Figure 6.2.1.  Chemical structures of nitrofurazone and nifurtimox.  
 
 
 
 
NifurtimoxNitrofurazone
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Early experiments exploring nitrofurazone‟s mode of action showed that bacterial 
strains lacking an unknown reductase activity displayed resistance to this nitrofuryl, 
relative to sensitive strains containing this activity (Asnis, 1957). This lead to the 
proposal that nitrofurazone functioned as a pro-drug and required „activation‟ before it 
could mediate its bactericidal activity (Asnis, 1957). Further studies using E. coli strains 
selected on progressively higher concentrations of nitrofurazone revealed that resistance 
could be acquired in a stepwise fashion (McCalla et al., 1970). Firstly, a low (3-fold) 
level of resistance could be generated that coincided with the partial loss of the unknown 
reductase activity. Following prolonged drug exposure, strains exhibiting a higher (10-
fold) level of resistance could be selected, with these cells now having a very low 
reductase capacity. Genetic analysis identified that this phenotype stemmed from the 
acquisition of mutations in 2 oxygen-insensitive (type I) nitroreductases called nfsA and 
nfsB (McCalla et al., 1978), resulting in the loss of enzymatic function. It was shown 
that the initial low level of nitrofurazone resistance was due to mutations in nfsA, while 
higher levels of resistance were caused by subsequent alterations in nfsB. These data 
provided the first direct link between nitroheterocyclic drug activity and bacterial 
oxygen-insensitive nitroreductases. 
In addition to phenotypic selection, studies aimed at elucidating nitrofurazone‟s 
mechanism of action using biochemical approaches were also conducted. These studies 
centred on identifying the nature and toxicity of metabolites generated from pro-drug 
activation. Using the bacterial species Aerobacter aerogenes grown under hypoxic 
conditions, analysis of the nitrofurazone reduction products revealed that its nitro group 
underwent reduction to generate an aminofuran derivative (Beckett and Robinson, 
1959). Prolonged storage of this product resulted in cleavage of the furan ring leading to 
an open chain nitrile structure (Beckett and Robinson, 1959). Studies on a nitrofurazone 
variant using E. coli indicated that in an aerobic environment the open chain nitrile form 
was the major end-product, without first going through an aminofuran intermediate 
(Figure 6.2.2) (Gavin et al., 1966). Following observations that production of the 
aminofuran under hypoxia was accompanied by production of free radical anion 
intermediates, it was proposed that formation of the aminofuran was due to the activity 
of a type II oxygen-sensitive nitroreductase, while the open-chain nitrile was generated 
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by an oxygen-insensitive type I nitroreductase (Peterson et al., 1979). The formation of 
an open chain nitrile by an oxygen-insensitive nitroreductase was later confirmed using 
a purified enzyme from Enterobacter cloacae (Bryant and DeLuca, 1991). This situation 
highlights that nitrofurazone can act as a substrate for more than one nitroreductase, 
creating the potential for a variety of reduction metabolites and a range of cytotoxic 
effects. Understanding these processes could prove vital in unravelling the mechanisms 
of parasite killing and host toxicity of nitrofurazone, nifurtimox, and for nitroaromatic 
compounds in general   
Intriguingly, the open-chain nitrile product derived from nitrofurazone was shown to 
lack toxicity. This led to the hypothesis that intermediates generated by reduction of the 
nitrofuryl by a type I oxygen-insensitive nitroreductase were responsible for its 
antimicrobial properties (McCalla, 1983). A similar idea had already been proposed 
regarding the activity of mammalian oxygen-sensitive nitroreductases. Here, it was 
proposed that reduction of the nitro-group generated nitroso and hydroxylamine 
intermediates (Figure 6.2.2) that could then form adducts with proteins and DNA, 
leading to cytotoxicity (Swaminathan et al., 1982). This concept was supported by the 
observation that the addition of the thiol glutathione to mixtures containing intact E. coli 
and nitrofurazone resulted in a decrease in the level of the open chain nitrile product 
(McCalla, 1983). These findings all highlight that although prokaryotic and eukaryotic 
organisms activate nitroaromatic drugs by different mechanisms catalysed by type I or 
type II nitroreductases, the downstream cytotoxicity may be mediated in a common 
fashion (Figure 6.2.2). In most eukaryotic cells where oxygen is present, nitrofurazone 
reduction by type II nitroreductases leads to the establishment of a futile cycle resulting 
in formation of superoxide anions and nitro anion radicals (Figure 6.2.2) (Mason and 
Holtzman, 1975). Based on in vitro biochemical studies, cytochrome P450 reductase can 
catalyse this type of reaction (Orna and Mason, 1989). In an aerobic environment, this 
futile cycle may be the predominant metabolite pathway however the detection of open-
chain nitrile end-metabolites in vertebrate tissue samples suggests the nitroso pathway 
also occurs to some degree (Tatsumi et al., 1984; Wang et al., 2010). In contrast, 
bacteria can readily form these reductive end products regardless of oxygen availability 
due to their expression of type I nitroreductases.  
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As several of the nitrofurazone derived reduction metabolites could potentially interact 
with DNA, worries over its genotoxic and carcinogenic properties have emerged. This 
issue has been complicated by different approaches in different model systems 
providing conflicting results. When nitrofurazone was analysed using the Ames test it 
was initially shown to be a strong mutagen (Gajewska et al., 1990; McCalla and 
Voutsinos, 1974). However, it soon became apparent that the „classical‟ S. typhimurium 
strains used in these screens (designated TA98 and TA100) contained active type I 
nitroreductases. When the reversion assay tests were repeated using Salmonella strains 
lacking these activities, a significant reduction in the mutagenic effect was observed 
(Yamada et al., 1997). Experiments on mammalian toxicity using mice treated with 
nitrofurazone resulted in the identification of single stranded breaks in DNA that 
correlated with the reduction of nitrofurazone (Olive, 1978), whereas in vivo cytogenetic 
testing in rats and Drosophila failed to identify any DNA damaging activities (WHO, 
1990). From these studies it was concluded at the time that there is inadequate evidence 
for the carcinogenicity of nitrofurazone in humans (WHO, 1990). Since stable 
nitrofurazone derived reduction intermediates have not been successfully isolated, it is 
difficult to allocate cytotoxicity to a particular intermediate. Yet, it appears clear that it 
is the reaction intermediates for both the type I oxygen-insensitive and type II oxygen-
insensitive nitroreductases that cause cytotoxicity, not the final products. 
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Figure 6.2.2.  Summary scheme of type I & II nitroreductase mediated nitrofuran 
metabolites . 
Nitrofurans are metabolized by bacterial type I oxygen- insensit ive nit roreductase via a 2-
electron reduct ion to  a non-toxic open chain nit rile  end-product,  implying cytotoxicity is 
derived from the proposed react ion intermediates (McCalla,  1983).  Nit rofuryl adducts are 
found bound to DNA and protein (Hiraku et  al. ,  2004; Samsonova et  al. ,  2008) , 
suggest ing this is the mechanism o f cytotoxic act ion. The ubiquitous type II oxygen-
sensit ive nit roreductases generates a nit rofuryl anion through a 1 -electron reduction, 
which does not  appear to easily react  with proteins (Polnaszek et  al. ,  1984).  Therefore 
the nit roso and hydroxylamine intermediates formed by both pathways appear the likely 
protagonists in cell death.  
 
6.2.2 Nifurtimox 
The finding that trypanosomal infections could potentially be treated with nitrofurazone 
sparked a series of screening programmes to explore the parasite killing activities of 
other nitrofurans, with nifurtimox (Figure 6.2.1) showing particular promise against T. 
cruzi infections (Bock et al., 1969). Initial findings demonstrated that the addition of 
nifurtimox to T. cruzi mitochondrial fractions or rat liver microsomes stimulated 
production of superoxide anions (Docampo et al., 1981b; Docampo and Stoppani, 1979; 
Maya et al., 2003; Viode et al., 1999). This resulted in the widely accepted view that 
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nifurtimox induced oxidative stress within trypanosomes, and suggested that a type II 
nitroreductase mechanism was key to its trypanocidal activity. Several parasite enzymes 
such as trypanothione reductase, lipoamide dehydrogenase and cytochrome P450 
reductase were shown to mediate this reaction in vitro, appearing to confirm these early 
findings (Blumenstiel et al., 1999; Henderson et al., 1988; Viode et al., 1999). This idea 
gained strength as reports had also shown that trypanosomes had a limited enzymatic 
capacity to metabolize reactive oxygen species (Boveris et al., 1980). Additional indirect 
evidence for this case arose following functional studies on a trypanosomal superoxide 
dismutase isoform, where parasites lacking this activity were more susceptible to 
nifurtimox than control lines (Prathalingham et al., 2007).  
Another trypanosomal enzyme that has been implicated in the metabolism of nifurtimox 
is prostaglandin F2α synthase (also called the “old yellow enzyme”). In vitro studies 
using the T. cruzi enzyme revealed that it could catalyse the 2-electron reduction of the 
nitrofuran but only under anaerobic conditions. Immuno-precipitation of this activity in 
T. cruzi lysates drastically lowered the total extracts capacity to reduce nifurtimox, 
suggesting that this enzyme may have an important role in nifurtimox metabolism 
(Kubata et al., 2002).  
Circumstantial evidence has shown that nifurtimox resistance between strains correlates 
with an increase in free glutathione levels (Moncada et al., 1989), and that T. cruzi life-
cycle stages with the highest thiol levels display an increased resistance to nifurtimox 
(Maya et al., 1997). Additionally, treating T. cruzi with nifurtimox reduces the levels of 
detectable free glutathione and trypanothione (Repetto et al., 1996), an effect that 
appears to be independent of any superoxide production (Boiani et al., 2010). As in the 
case of nitrofurazone, the nitroso and/or hydroxylamine intermediates generated 
following nifurtimox reduction by a type I nitroreductase could result in the formation 
of thiol conjugates. Therefore, one possible mechanism that leads to nifurtimox 
resistance could stem from the parasite increasing its thiol synthesis capacity.  
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Any significant nifurtimox-glutathione conjugates formed in T. cruzi may be explained 
by the discovery that trypanosomatids contain a bacterial like type I oxygen-sensitive 
nitroreductase (Wilkinson et al., 2008). In the classical behaviour of a pro-drug 
activator, parasites with altered levels of the trypanosomal type I nitroreductase have 
been shown to posses differing susceptibility to nifurtimox such that null mutant/ 
heterozygous cells display resistance to the nitrofuran, while over-expression confers 
hypersensitivity. Additionally, T. cruzi parasites selected for resistance to nifurtimox 
undergo the loss of a chromosome containing the type I nitroreductase (Wilkinson et al., 
2008). Also performing a nifurtimox drug resistance based selection with a T. brucei 
RNAi library singly identified the type I nitroreductase enzyme in a loss of function 
screen (Baker et al., 2010). Together, these data provide a clear link that this enzyme 
plays a key role in activating this drug within the parasite. The T. cruzi cell-lines 
selected for resistance to nifurtimox are also cross-resistant to other nitroheterocyclic 
compounds such as benznidazole and nitrofurazone (Wilkinson et al., 2008). This 
observation is re-affirmed by nifurtimox drug selection studies on T. brucei, where again 
the resulting cell-lines were found to display cross-resistance to nitrofurazone, the 
nitroheterocyclic drug candidate fexinidazole, and the anti-cancer nitroaromatic agent 
CB1954 (Sokolova et al., 2010). Although not established in these studies, the 
phenotype is reminiscent of observations made using the T. cruzi selected lines and T. 
brucei/ T. cruzi recombinant lines having lowered levels of the type I nitroreductase. 
Worryingly, this has significant repercussions for trypanosomal drug development, as 
investing in nitroheterocyclic monotherapies may have long term associated problems 
with clinical resistance.  
As with nitrofurazone, nifurtimox has been shown to be mutagenic in E. coli assays 
(Ohnishi et al., 1980) and the Ames test using the „classical‟ S. typhimurium strains 
TA98 and TA100 (Nagel and Nepomnaschy, 1983). Interestingly, the DNA 
mutagenicity observed in the Ames test was abolished when using bacterial mutants 
deficient in the oxygen-sensitive nitroreductase complement (Ferreira et al., 1988), 
suggesting this type I nitroreductase activity is the predominant activator of nifurtimox. 
Also, E. coli mutants deficient in their superoxide dismutase gene reportoire had no 
alteration on mutagenicity (Prieto-Alamo et al., 1993), implying that any superoxide 
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anions formed from a type II nitroreductase activity had no detectable role in causing 
DNA damage. The issue regarding the genotoxic properties of nifurtimox in eukaryotic 
systems is confusing. In Drosophila, nifurtimox appears to be mutagenic (Moraga and 
Graf, 1989), in contrast to what was reported when using nitrofurazone (this difference 
probably reflects the different approaches used), while a study in rats assessing 
nifurtimox‟s potential for inducing carcinogenicity found no evidence of cancer causing 
lesions over a 40 week period (Iatropoulos et al., 2006), despite its known genotoxicity 
in other systems (Buschini et al., 2009). Nevertheless, the carcinogenicity of this drug 
continues to remain controversial. 
6.3 Nitroaromatic Pro-drugs as Anti-Cancer Agents    
The nitroaromatic pro-drug CB1954 (5-aziridinyl-2, 4-dinitrobenzamide, also known as 
tretazicar) was first developed as an anti-cancer therapy in the 1970‟s and displayed 
promising pre-clinical results in a rat model (Cobb, 1970). Unfortunately, this success 
did not translate to human clinical trials, mainly as DT-diaphorase (also known as 
NADPH quinone oxidoreductase 1, or NQO1), the enzyme responsible for pro-drug 
activation, was far less active in human cells than its rodent orthologue (Boland et al., 
1991; Knox et al., 1988). This lead to the concept of using E. coli type I nitroreductase 
nfsB, which had previously been shown to activate numerous nitroaromatic-based pro-
drugs, to substitute as a mammalian CB1954 activator (Drabek et al., 1997). In a two-
step process, known as gene-directed enzyme pro-drug therapy (GDEPT), firstly a gene 
encoding for a type I nitroreductase such as E. coli nfsB is targeted to, and expressed 
within the tumour cell. This is followed by administration of the CB1954 pro-drug 
which is then activated to cytotoxic moieties by the bacterial enzyme (McNeish et al., 
1998). Although GDEPT requires the contentious implementation of trans-gene therapy, 
in which so far one trial participant has died (Lehrman, 1999) and two developed 
leukaemia (Kohn et al., 2003), clinical trials with nitroreductase and CB1954 are 
currently underway (Patel et al., 2009). 
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Figure 6.3.1.  Chemical structures of 3 anti -cancer compounds used with GDEPT.   
 
CB1954 possesses two nitro groups in the 2- and 4- positions on a benzyl ring, with an 
aziridinyl substituent found at the 5-position (Figure 6.3.1). Analysis of its mode of 
action indicates that following activation of either nitro groups by the type I 
nitroreductase, an equimolar mixture of 2- and 4- hydroxylamine metabolites are formed 
(Helsby et al., 2004b; Knox et al., 1991; Venitt and Crofton-Sleigh, 1987). Both of these 
intermediaries can then be processed further to form the corresponding 2- and 4- amine 
molecules, while the 4- hydroxylamine is also able to react with DNA. The interaction 
of the 4- hydroxylamine with DNA is not direct, but first requires it to react with a 
thioester such as acetyl coenzyme A to form the necessary reactive group (Figure 6.3.2) 
(Knox et al., 1991). All of these metabolites have cytotoxic activities in mammalian 
systems (Helsby et al., 2004b; Tang et al., 2005). Recently CB1954 has been shown to 
display good in vitro activity against bloodstream form T. brucei (Sokolova et al., 2010), 
raising the possibility that this clinical candidate represents a promising lead in 
developing new anti-trypanocidal agents.  
CB1954 4-Nitrobenzyl Phosphoramide
Mustard
Nitrobenzamide
Mustard
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Figure 6.3.2.  Summary scheme of nitroreductase mediated reduction of CB1954.  
Either nit ro group of the benzyl r ing may be reduced by nit roreductase.  Reduct ion of the 
2- nit ro group first  forms the 2-hydroxylamine, which can then be reduced further to form 
the 2-amine der ivat ive.  A similar pathway is observed for the 4 - nit ro group, however the 
4-hydroxylamine is also able to  react  with thioesters such as acetyl coenzyme A. It  has 
been shown that  all o f these metabolites have cytotoxic propert ies (Helsby et  al. ,  2004b; 
Tang et al. , 2005). Figure adapted from Wilkinson et  al. , 2011.    
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In an attempt to increase the potency of CB1954 against mammalian tumour cells, the 
aziridinyl group was replaced with a mustard group. This nitrobenzamide mustard 
(Figure 6.3.1) has an increased affinity for the nitroreductase enzyme, while its 
reactivity becomes limited to only reduction of the nitro group in the 2- position 
(Anlezark et al., 1995). Consequently, the benzene ring acts as an „electronic switch‟, 
with the specific activation of the 2- position nitro group leading to the rearrangement of 
electrons throughout the molecule (Siim et al., 1997). This electronic rearrangement 
results in the opposite mustard group becoming highly reactive, now being able to 
directly react with DNA, without requiring an intermediate reaction step involving a 
stable hydroxylamine metabolite and thioester molecule (Helsby et al., 2003). It also 
improves the potency of the compound against human cell-lines featuring nfsB, relative 
to the original CB1954 (Helsby et al., 2004b).  
Based on the studies with CB1954, another series of novel compounds for GDEPT were 
developed which combined a nitro-aromatic ring linked to a variety of phosphoramide 
mustards (Hu et al., 2003). These nitrobenzyl phosphoramides (Figure 6.3.1) expand 
upon the anti-cancer drug cyclophosphamide, which is used in co-therapies with drugs 
such as etoposide (El-Helw and Hancock, 2007). The cyclophosphamide itself acts as a 
pro-drug, and first requires activation via an interaction with cytochrome P450, which 
opens up the basic ring structure and forms a toxic linear alkylating mustard group 
(Borch and Millard, 1987). For the nitrobenzyl phosphoramides, activation of the nitro 
group on the benzene ring by nitroreductase triggers an electronic switch which replaces 
the need for cytochrome P450. Depending on the nature of the phosphoramide opposite 
the nitro group, the activation of this molecule can have one of two effects.  If the 
nitrobenzyl component contains an associated cyclic phosphoramide, then 
nitroreductase mediated activation results in exposure of the mustard group, which is 
intended to cause direct cellular toxicity (Figure 6.3.3). However if a linear 
phosphoramide mustard is present opposite the electronic switch, then this group is 
designed to release from the nitrobenzyl, forming a separate linear alkylating mustard 
that generates cytotoxicity (Jiang et al., 2006). In assays with mammalian cells 
expressing nitroreductase, these compounds have been shown to generate strong growth 
inhibition, plus good selectivity towards these transgenic cells relative to their 
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unmodified parent lines (Jiang et al., 2006). It will be interesting to see if these 
compounds are active against trypanosomes, given the presence of a native 
nitroreductase. 
 
 
Figure 6.3.3.  Summary scheme of nitroreductase mediated reduction of nitrobenzyl 
phosphoramides.  
For both cyclical and linear n it robenzyl phosphoramides,  reduct ion of the nit ro group on 
the benzyl r ing by nit roreductase leads to  the format ion of the hydroxylamine der ivat ive.  
This leads to  a rearrangement  of electrons across the benzene r ing. For cyclica l 
nit robenzyl phosphoramides,  this movement  of electrons results in exposure of the toxic 
mustard moiety,  while for the linear n it robenzyl phosphoramides the toxic mustard is  
released from the parent  compound (Jiang et al. ,  2006).  Figure adapted from Wilkinson et 
al. , 2011.  
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6.4 Research Objectives 
The aim of investigating novel type I nitroreductase activated nitroaromatic pro-drugs in 
trypanosomes can be defined by the following core objectives: 
 Develop a high-throughput drug screening system for the medically relevant 
amastigote stage of T. cruzi to facilitate assaying nitroaromatic compounds. 
 Screen novel nitroaromatic compounds for trypanocidal activity against T. cruzi 
using the high-throughput system. 
 Utilize the T .brucei cell-lines with altered levels of nitroreductase expression to 
define the mechanism of action of nitroaromatic drugs in trypanosomes.  
166 
 
7 Nitroaromatic Compounds against T. cruzi 
Nitroheterocyclic based pro-drugs such as nifurtimox and benznidazole have been used 
for more than forty years to treat trypanosomal infections (Wilkinson and Kelly, 2009). 
Recently, it has been demonstrated that such compounds undergo activation in a 
reaction catalysed by a type I nitroreductase (Wilkinson et al., 2008). This chapter 
describes the construction and validation of a luciferase-based T. cruzi reporter system, 
which is then used to evaluate the effectiveness of 39 nitroaromatic compounds from 
three distinct classes towards the medically relevant, intracellular amastigote form of the 
parasite. 
7.1 The Luciferase Cell Reporter System 
There is an urgent need for new drugs targeting the protozoan parasite T. cruzi. 
However, most research aimed at identifying trypanocidal compounds against this 
pathogen has focused on the insect epimastigote or the non-dividing, infectious 
trypomastigote stages instead of the medically important amastigote form. The main 
issues associated with analysing the epimastigote and trypomastigote lifecycle stages is 
that they do not accurately reflect the amastigote inside a mammalian cell where the 
abundance of protein drug targets, activators, and drug import/export complexes may 
vary considerably, as suggested by preliminary observations of the life-cycles differing 
relative proteomic profiles (Atwood et al., 2005). Therefore, promising trypanocidal 
compounds may be mistakenly overlooked while agents that show promise against the 
epimastigote or trypomastigote forms may not be effective against T. cruzi amastigotes. 
The primarily reasons for focusing on T. cruzi epimastigote or trypomastigote forms for 
drug screening are that large quantities of these life-cycle stages can be cultured or 
obtained with relative ease, while high-throughput evaluation of parasite numbers can be 
carried out using colorimetric approaches with dyes such as MTT and AlamarBlue 
(Muelas-Serrano et al., 2000; Rolon et al., 2006).  In contrast, maintaining T. cruzi 
amastigotes within a mammalian cell and evaluating parasite infectivity load is both 
time consuming and labour intensive. The construction of transgenic parasites 
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expressing β-galactosidase (Buckner et al., 1996) has greatly aided drug screening 
within the medically relevant lifecycle stages (Bettiol et al., 2009; Bressi et al., 2001; 
Buckner et al., 2003), but a major drawback with this strategy is that it does not work 
when testing coloured compounds (Buckner et al., 1996). Given that many of the 
nitroheterocyclic compounds in our library are coloured, it was decided that an 
alternative screening approach using a bioluminescence reporter should be developed. 
Luciferase-based cell reporter systems have been implemented for a range of organisms 
and applied in drug screening against various pathogens such as Mycobacterium 
tuberculosis (Jacobs et al., 1993), Leishmania species (Lang et al., 2005; Osorio et al., 
2011; Roy et al., 2000), T. brucei (Claes et al., 2009) and P. falciparum (Lucumi et al., 
2010). Here, a trypanosomal integrative expression vector facilitating the constitutive 
expression of a bioluminescence reporter gene is developed and used to evaluate 
whether three series of nitroaromatics have potential in treating T. cruzi intracellular 
form parasites.  
7.1.1 Luciferase expression from the GAPDH locus 
To develop a luciferase-based system that could be used in drug screens against T. cruzi 
amastigotes, a DNA vector was required that facilitated the constitutive expression of 
the bioluminescence reporter gene. Several episomal constructs such as pTEX (Kelly et 
al., 1992) and pRIBOTEX (Martinez-Calvillo et al., 1997) have been developed that 
meet this need. However, as culturing of T. cruzi amastigote within mammalian cells 
occurs in the absence of drug pressure, and recombinant parasites may readily lose 
plasmids in the absence of such selection, a more stable integrated expression system 
was required. Based on a previous finding that the 3‟ un-translated region (UTR) of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) increased mRNA stability of 
episomal luciferase expression in T. cruzi (Nozaki and Cross, 1995), a DNA vector was 
designed that would integrate into the GAPDH loci of the parasite‟s genome. In T. cruzi, 
there are 4 GAPDH genes per diploid genome and these are arranged in tandem with 
two genes per array (Kendall et al., 1990). Using the T. cruzi GAPDH intergenic and 3‟ 
UTR sequences, an expression plasmid was developed to integrate into, and replace, the 
downstream copy of the GAPDH gene. To generate this plasmid, first the GAPDH 
intergenic region of the tandem repeat, the upstream neomycin drug resistance gene, and 
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the β/α intergenic region of the tubulin array was excised as 1 fragment from pKS-FKN-
Neo, (Figure 7.1.1a) and cloned into pBlueScript II (Section 3.6.12). Next, the firefly 
luciferase gene and the 3‟ UTR of GAPDH were cloned adjacent to this fragment within 
pBlueScript II, to form the final plasmid, pGAP-Luciferase (Figure 7.1.1b). This was 
linearized with a KpnI and SacI double digest, and the 4.6 kb DNA fragment containing 
neomycin/luciferase cassette was gel purified. 
 
Figure 7.1.1.  Map of pGAP-Luciferase, a GAPDH targeted expression const ruct.  
(A) Restrict ion map of pKS-FKN-Neo (provided by Dr.  Wilkinson, unpublished).  This 
construct  contains a neomycin resistance gene flanked at  it s 5‟ end by the T. cruzi  
GAPDH intergenic region and at  it s 3‟ end by the T. brucei β/α  tubulin intergenic repeat. 
The ent ire cassette is  bordered by mult iple cloning sites.  (B) To form the 
bio luminescence expression vector,  a DNA fragment  containing the luciferase gene and 
T. cruzi  GAPDH 3‟ untranslated region (UTR) was inserted into the downstream mult iple 
cloning sites of pKS-FKN-Neo to generate the plasmid pGAP-Luciferase.  The two 
intergenic sequences and the 3‟UTR provide the genet ic elements required for processing 
the neomycin and luciferase mRNAs. Restrict ion digest ion o f pGAP-Luciferase with KpnI 
and  SacI releases the neomycin/ luciferase expression cassette  from the plasmid backbone 
(Sect ion 3.6.12).  Following introduct ion into T. cruzi,  this cassette is designed to 
integrate into the GAPDH array, delet ing the downstream GAPDH gene. 
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The purified DNA fragment was then introduced into wild-type T. cruzi X10/6 and a T. 
cruzi X10/6 NTR
+/-
 heterozygous cell-line by electroporation, followed by drug 
selection using G418 (Section 3.10.2). The T. cruzi X10/6 NTR
+/-
 heterozygous 
parasites were also grown in the presence of blasticidin to maintain selection of the 
nitroreductase gene deletion (Wilkinson et al 2008). From each transformation, drug 
resistant clones were selected. To rapidly assess whether the parasites were expressing 
luciferase, an aliquot of cells (20,000) was taken and their bioluminescence activity 
determined (Figure 7.1.2). The untransformed wild-type T. cruzi X10/6 control was 
analysed in parallel. For transgenic lines, designated as T. cruzi X10/6
Gap-Luc
 and 
X10/6
Gap-Luc
 NTR
+/-
, a luminescence reading of more than 100,000- fold greater than the 
untransformed control was detected, indicating that the recombinant parasites had a high 
level of luciferase expression. 
 
Figure 7.1.2. Luciferase expression by T. cruzi epimastigotes using a construct targeted 
to the GAPDH loci.  
The luciferase act ivity,  as measured in light  units,  of extracts derived from 20,00 0 
recombinant  T. cruzi epimast igotes (X10/6
Ga p-Lu c
 and X10/6
Ga p-Lu c
 NTR
+/-
) was 
determined and compared to that  of the parental line (X10/6). Both luciferase expressing 
lines displayed a 100,000 fold increase in luminescence (measured in light  units) relat ive 
to the wild-type, confirming expression of the luciferase gene.   
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The main reason for developing the luciferase reporter system was to facilitate a 
procedure for determining the intracellular amastigote loads within mammalian cells. 
Therefore, before analysing the bioluminescence activity of recombinant parasites any 
further, the infectivity of these lines was investigated. Cultures of wild-type T. cruzi 
X10/6 (control), X10/6
Gap-Luc
 and X10/6
Gap-Luc
 NTR
+/-
 in the stationary phase of growth 
were used to infect African green monkey kidney (Vero) cells. For wild-type T. cruzi 
X10/6 controls, amastigotes were detected microscopically 2-4 weeks post-infection, 
with bloodstream trypomastigotes subsequently observed in the growth medium 
following mammalian cell lysis. For both luciferase expressing lines, amastigotes and 
bloodstream trypomastigotes were never seen, even 2-3 months post-infection. This 
strongly suggests that during in vitro infections, the luciferase expressing parasites were 
attenuated and were no longer infective. Interestingly, this non-infectious phenotype has 
been observed previously using a pTEX episomal plasmid that had inadvertently 
integrated adjacent to the GAPDH loci (Zacks, 2007). Combined, this data indicates that 
GAPDH activity is critical during the differentiation of epimastigotes to metacyclic 
trypomastigotes, or the establishment of the amastigote within the mammalian cell. This 
observation was not examined any further. 
7.1.2 Construction of a ribosomal array-based luciferase expression system 
As luciferase expression at the GAPDH locus resulted in the inability of T. cruzi to 
infect mammalian cells in vitro, an alternative strategy to integrate the bioluminescence 
reporter gene into another site of the parasite genome was required. In T. brucei, several 
DNA constructs have previously been targeted to ribosomal regions for functional 
genomics studies (Alsford and Horn, 2008; Obado et al., 2011). As there are numerous 
ribosomal gene arrays in trypanosomal genomes (Section 1.5.2) (Berriman et al., 2005; 
El-Sayed et al., 2005a), integration of constructs to these regions should not affect the 
overall expression levels of the encoded ribosomal proteins. Also, other protein coding 
regions of the genome would be unaffected, thus reducing any possible off-target effects 
such as loss of infectivity. The new cloning strategy involved using two episomal 
expression vectors pTEX (Kelly et al., 1992) and pRIBOTEX (Martinez-Calvillo et al., 
1997) as the source of a neomycin expression cassette and ribosomal promoter, 
respectively. 
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The authors of pRIBOTEX have themselves shown that pRIBOTEX is already capable 
of genomic integration, although they only speculated as to the locus, suggesting 
GAPDH as the most likely. It has since been shown that pRIBOTEX integrates into the 
ribosomal array, although surprisingly not via targeting of the ribosomal spacer (Lorenzi 
et al., 2003), but by some currently unknown mechanism specifically involving the 
ribosomal promoter itself. The advantage of using pRIBOTEX as a template though, is 
that the ribosomal spacer contains a characterized ribosomal promoter (Martinez-
Calvillo and Hernandez, 1994) to drive gene expression, and an apparent trans-splicing 
site (Martinez-Calvillo et al., 1997) to allow the required mRNA processing of the 
downstream expressed gene (Section 1.5.4). Since the actual mechanism of integration 
of pRIBOTEX is unknown, and gene expression in the amastigote stage would not be 
under drug pressure for extended periods of time, a new plasmid was designed to 
integrate through double homologous recombination, using twin rRNA flanking regions 
to ensure a stable integration.  
To generate the integrative plasmid, a 3‟ ribosomal spacer region was amplified from T. 
cruzi CL Brener genomic DNA and cloned into a unique KpnI site of pTEX located 
downstream of the neomycin expression cassette. This cassette contains the neomycin 
phosphotransferase gene flanked by intergenic (upstream) and 3‟ UTR (downstream) 
GAPDH sequences that provide the required trans-splicing/poly-A addition sites needed 
for processing the drug resistance mRNA. Next, the 5‟ ribosomal region of pRIBOTEX 
was inserted into pTEX, replacing a 5‟ UTR sequence of GAPDH.  The cloning was 
done such that a multiple cloning site (MCS) was maintained between the 5‟ ribosomal 
region and neomycin expression cassette (Section 3.6.13). This resulted in the plasmid 
pTRIX (Figure 7.1.3a). Restriction digestion of pTRIX with SacI and AscI releases a 4.2 
kb DNA fragment consisting of the neomycin expression cassette bordered by the 5‟ and 
3‟ T. cruzi ribosomal spacer sequences. These flanking regions provide DNA sequences 
required for integration through double homologous recombination of this fragment into 
the T. cruzi ribosomal spacer loci. Additionally, several key features required for protein 
expression have been engineered into this vector, including: a multiple cloning site into 
which the gene of interest can be inserted, a characterized promoter in the 5‟ ribosomal 
region  upstream of the multiple cloning site, and a trans-splicing and a poly-A addition 
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site (Martinez-Calvillo et al., 1997), found in the 5‟ ribosomal region and intergenic 
GAPDH sequence respectively. These provide the elements needed for processing the 
mRNA generated from a gene cloned into the multiple cloning site of the plasmid. 
 
 
Figure 7.1.3.  Map of pTRIX, a ribosomal promoter based expression construct.  
(A) The episomal expression plasmid pTEX (Kelly et  al. ,  1992)  was modified by 
insert ing DNA sequences corresponding to  the T. cruzi  r ibosomal spacer region either 
side of a neomycin expression cassette, generat ing the construct  pTRIX. To facilitate 
high levels of gene expression, pTRIX contains a r ibosomal promoter derived from 
pRIBO-TEX in the 5‟ r ibosomal spacer sequence  (Mart inez-Calvillo  et  al. ,  1997). 
Immediately downstream is a  mult iple cloning site where the gene under study can be 
cloned. (B) The firefly luciferase gene was inserted into the mult iple cloning site of 
pTRIX to form pTRIX-luciferase.  Restrict ion digest ion of pTRIX -luciferase with SacI 
and AscI  releases the neomycin/ luciferase expression cassette  from the plasmid backbone. 
Following introduct ion into T. cruzi,  this casset te is designed to integrate into the 
ribosomal array.   
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Following construction of the expression plasmid (Figure 7.1.3a), the firefly luciferase 
gene was cloned into the multiple cloning site of pTRIX (Section 3.6.14) to form 
pTRIX-luciferase (Figure 7.1.3b). Digestion of this plasmid with SacI and AscI liberated 
a 5.8 kb DNA fragment that was subsequently gel purified. The purified, linear DNA 
fragment was electroporated into wild-type T. cruzi (CL Brener and X10/6) and the 
X10/6 NTR
+/-
 heterozygous cell-line. Selection was carried out using G418, with the 
heterozygous line maintained in the presence of blasticidin (Section 3.10.2). Drug 
resistant epimastigote clones were observed approximately 4 weeks post-
electroporation. As previously described for the GADPH-based expression system, 
parasite extracts derived from 20,000 trypanosomes were assayed for luciferase activity. 
The luminescence readings were compared against untransformed wild-type T. cruzi 
(CL-Brener and X10/6) that were analysed in parallel. In total, 10 drug resistant T. cruzi 
cultures were examined including four clones from electroporations involving CL 
Brener and 3 each from the X10/6 and X10/6 NTR
+/-
 lines. These cell-lines were 
designated as CL Brener
Ribo-Luc
, X10/6
Ribo-Luc
 and X10/6
Ribo-Luc 
NTR
+/-
. In all cases, the 
drug resistant clones displayed a higher luciferase activity than untransformed controls, 
exhibiting up to 10,000-fold increase in luminescence relative to the wild-type 
background (Figure 7.1.4). 
Further comparisons revealed that luminescence data obtained from CL Brener
Ribo-Luc
 
clones was, on average, 10-fold higher than that of the X10/6 luciferase expressing lines. 
This result was consistent across all clones. One possible reason for this difference may 
be due to the origin of the ribosomal promoter, a sequence originally derived from the T. 
cruzi La Cruz cell-line. It is plausible that this ribosomal promoter may be able to 
initiate transcription more readily in CL Brener than in X10/6, resulting in a higher level 
of gene expression. Polymorphisms in T. cruzi ribosomal promoter sequences have been 
reported (Nunes et al., 1997), and shown to affect levels of gene expression (Floeter-
Winter et al., 1997). Analysis of the luciferase activity levels from T. cruzi X10/6
Gap-Luc
 
and X10/6
Ribo-Luc
 cells revealed that luminescence was approximately 10-fold higher in 
extracts derived from cells where the reporter was expressed at the GAPDH loci than 
from the ribosomal spacer region. Again, this difference may reflect transcription 
efficiencies, with the La Cruz ribosomal promoter not being as effective at initiating 
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transcription in T. cruzi X10/6 as compared to the endogenous RNA polymerase II 
machinery. However, it must be noted that this observation is based on a single 
luminescence value for the T. cruzi X10/6
Gap-Luc
 cell-line. Additionally, although 
Southern hybridizations have not been carried out to map the sites of integration, it 
appears that using a 5‟ ribosomal targeting sequence from one T. cruzi strain (La Cruz), 
in combination with a 3‟ ribosomal targeting sequence from another strain (CL Brener), 
does not impede recombination of the expression vector into the T. cruzi CL Brener or 
X10/6 genomes. 
 
 
 
Figure 7.1.4.  Luciferase expression by T. cruzi epimastigotes using a construct targeted 
to the ribosomal array.  
(A) The luciferase act ivity of 4 recombinant  T. cruzi  CL-Brener
Ribo-Lu c
 epimast igote 
clones (1-4) were determined and compared to  the parental line ( WT). (B) A similar 
analysis was carried out on 3 recombinant  T. cruzi X10/6
Ribo-Lu c
 (1-3) and 3 X10/6
Ribo-Lu c
 
NTR
+ / -
 (1-3) epimast igote clones.  In both panels,  20,000 cells were used in each analysis.  
The luciferase act ivity,  as measured in light  units,  was 1000 fold higher in recombinant  
T. cruzi  X10/6 lines than wild-type background levels but  was lower than that  detected in 
recombinant CL-Brener extracts.  
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Since the T. cruzi CL Brener strains demonstrated the highest luciferase activity per 
sampled aliquot, consistently across clones, the T. cruzi CL Brener
Ribo-Luc
 cell-line was 
selected to develop the first luciferase based drug screening system. Although high 
expression levels were observed in the epimastigote form of the parasite, it was 
unknown at this stage what the expression levels would be like when analyzing the 
amastigote stage in much fewer parasite numbers, and if luciferase activity would be 
high enough to detect in an infective replication stage based drug assay.   
Initially, assays were performed to determine whether integration of the DNA construct 
into the T. cruzi genome and/or expression of the luminescence affected parasite growth 
(Figure 7.1.5). In these experiments, two CL Brener
Ribo-Luc
 clones and a wild-type CL 
Brener cell-line, all grown without drug, were analysed in parallel. Starting from a 
density of 5 x 10
5
 parasites ml
-1
, the cumulative cell growth was determined over a 9 
day period, with all cultures maintained in the exponential phase of growth. This was 
achieved by diluting cultures when they reached the late logarithmic phase of growth (1 
x 10
7
 parasites ml
-1
; 96 hrs into the experiment). Over the 9 day time course, both CL 
Brener
Ribo-Luc
 lines behaved similarly to the wild-type, with all 3 cell-lines demonstrating 
an approximate doubling time of 21 hours. This indicates that integration of pTRIX-
luciferase into the CL Brener genome, and the resulting luciferase expression has no 
effect on epimastigote growth rates, demonstrating that pTRIX can be used as a general 
purpose integrative plasmid containing any required gene, without the plasmid 
components affecting parasite growth.   
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Figure 7.1.5.  Growth of luciferase expressing T. cruzi CL Brener epimastigotes.    
The cumulat ive cell dens ity of wild-type T. cruzi  CL Brener epimast igotes (blue) and 2 
CL Brener
Ribo-Lu c 
clones (clone 1: red, clone 2: green) was fo llowed for 9 days.  At  day 0, 
all lines were seeded at  5 x 10
5
 cells ml
-1
.  Parasite loads were determined every 2 days, 
and diluted back to 5 x 10
5
 cells ml
-1
 when appropriate,  to prevent  the cultures from 
reaching the st at ionary phase of growth. Over the period examined here,  all T. cruzi 
epimast igote lines grew at equivalent  rates.  
 
7.1.3 Characterizing T. cruzi CL BrenerRibo-Luc in mammalian lifecycle stages 
After establishing that growth of T. cruzi epimastigotes is not affected by luciferase 
expression, the ability of CL Brener
Ribo-Luc
 clones to infect mammalian cells was 
investigated. In these experiments, stationary growth phase epimastigote cultures of 
wild-type T. cruzi CL Brener and 2 CL Brener
Ribo-Luc
 clones (those analyzed in Figure 
7.1.5) were used to infect Vero cells. Under these stationary phase conditions, T. cruzi 
epimastigotes appear to undergo metacyclogenesis (Kollien and Schaub, 2000). 
Approximately 2-4 weeks post-infection, intracellular amastigotes were detected 
microscopically for all parasite lines, demonstrating that the recombinant T. cruzi CL 
Brener clones containing pTRIX-luciferase remained infectious. Maintenance of this 
infected Vero culture for approximately two months resulted in the near destruction of 
the mammalian cell monolayer and, based on morphology, high numbers of free 
amastigotes in the medium. Supernatants containing free amastigotes from the CL 
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Brener
Ribo-Luc
 infections were collected and the parasites were washed in fresh culture 
medium. After evaluating the cell density using a haemocytometer, a series dilution was 
made and the relationship between luminescence activity and amastigote load 
determined (Figure 7.1.6). A direct linear correlation between cell number and luciferase 
levels was observed for both CL Brener
Ribo-Luc
 clones, with as few as 10 amastigotes 
giving a luminescence reading above the negligible background signal. Together, this 
data indicates that for this in vitro model, the luciferase expressing parasites are 
infectious to mammalian cells, the amastigote parasites are able to express genes using 
the pTRIX system, and that luciferase expression by the mammalian form parasites is 
stable for up to 2 months. 
   
 
Figure 7.1.6.  Correlation between T. cruzi amastigote load and luciferase activity.  
The luciferase act ivity,  as measured in light  units,  of 10 to  10,000 recombina nt  T. cruzi  
CL Brener
Ribo-Lu c
 amast igotes,  obtained from the supernatants of old Vero cell cultures 
infected with luciferase expressing parasites,  was determined for two independent  clones 
(clone 1: red squares,  clone 2: green triangles).  The “free” amast igote load was 
determined and a serial dilut ion performed before cell lysis.  
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To assess the ability of T. cruzi CL Brener
Ribo-Luc
 amastigotes to differentiate into 
bloodstream form trypomastigotes and also indirectly measure amastigote growth, a 
defined number (7 x 10
4
) of wild-type and transgenic trypomastigotes were used to 
infect Vero cells. The trypomastigotes were harvested from the supernatant of a 
previous Vero cell infection and multiple infections (in quadruplicate) were carried out 
for T. cruzi CL Brener
 
and T. cruzi CL Brener
Ribo-Luc
 lines. After an overnight 
incubation, non-internalised trypanosomes were removed through copious washing and 
the cultures were incubated for a further 10 days. The number of bloodstream form 
trypomastigotes present in the medium was then determined using a haemocytometer 
(Figure 7.1.7). The numbers of trypomastigotes observed in the luciferase expressing 
clone was similar to that of the wild-type, suggesting that the incorporated luciferase 
gene had no detectable affect on parasite infectivity or their intracellular growth rate.  
 
Figure 7.1.7.  Luciferase expression by T. cruzi amastigotes does not affect growth rate.  
To assess the growth rate of T. cruzi  amast igotes,  Vero cells were infected with 7 x 10
4
 
metacyclic t rypomast igote parasites (CL-Brener or CL Brener
Ribo-Lu c
 clone 1) overnight. 
The following morning, cultures were extensively washed to remove non -internalised 
cells and then incubated at 37
o
C under a 5% CO2  atmosphere for 10 days.  Equal aliquots 
of the medium were collected and the number of released bloodstream form 
trypomast igotes determined  by haemocytometer.  This count  acts as an indirect  measure of 
the amast igote growth rate and the ability of this parasite stage to  different iate into 
bloodstream form trypomast igotes.  No observable difference in the number of released 
bloodstream form trypomast igotes was observed between  the two cell- lines.  The results 
are the mean of 4 parallel infect ions ± standard deviat ions.       
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All the above data shows that the expression of the reporter does not influence:  
1. Growth of epimastigotes parasites.  
2. The ability of epimastigotes cells to differentiate into infective metacyclic 
trypomastigotes. 
3. Invasion of mammalian cells by metacyclic trypomastigotes.  
4. Growth of intracellular amastigote parasites.  
5. Differentiation of amastigote cells into infective bloodstream trypomastigotes. 
6. The ability of bloodstream trypomastigotes to infect mammalian cells.  
Therefore, it is implicit that luciferase has no effect on trypanosome growth, 
differentiation, and infectivity. 
 
7.1.4 Development of the T. cruzi CL BrenerRibo-Luc drug assay 
After showing that luciferase expression has no apparent adverse affects on parasite 
growth, differentiation, and infectivity, experiments were conducted to evaluate whether 
the transgenic parasites could be used in drug screening. The goal of this study was to 
develop a 5 day assay in a 96-well plate format. After considering the surface area of a 
flat bottomed single well in a standard 96-well plate and the growth rate of the Vero 
line, the average seeding density of mammalian cells required was calculated to be 1500 
(1.5 x 10
4
 cells ml
-1
) per well; this value was designed to prevent the culture becoming 
too dense over the course of the assay. Next, a series of Vero cell infections were carried 
out using a range of bloodstream form trypomastigotes densities. From this, the 5 day 
end-point parasite infection levels were determined by evaluating the number of 
observed intracellular amastigotes. An optimised ratio of trypomastigote/mammalian 
cells was then estimated as 7:1 or 10,000 trypomastigotes to 1500 Vero cells for each 
well of a standard 96-well plate. 
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After establishing the above parameters, growth inhibition assays were performed using 
nifurtimox or benznidazole on Vero cells infected with the T. cruzi cells expressing 
luciferase (Section 3.12.2). After 5 days, all cultures were lysed and their luminescence 
activity determined. For both nitroheterocyclic compounds, a dose response curve was 
observed (Figure 7.1.8). From these plots, the concentration of each compound that 
inhibited parasite growth by 50% (IC50) was calculated. All assays were conducted in 
triplicate and the mean IC50 values were determined ± the standard deviation between 
the replicates. In these assays, nifurtimox generated an IC50 value of 0.24 ± 0.04 µM 
while benznidazole produced a value of 2.88 µM ± 0.27. As a comparison, a previous 
assay with the β-galactosidase colorimetric assay system (Buckner et al., 1996) showed 
nifurtimox to generate an IC50 value of 0.52 µM using the modified Tulahuen C4 strain 
and Vero cells (Aponte et al., 2008).   
A notable feature of these two validation assays is that luminescence values can vary. 
For example in Figure 7.1.8 the non-drug treated infection in the nifurtimox assay 
results in a luminescence reading of approximately 150 units while an equivalent 
untreated culture in the benznidazole assay gave around 600 units. Each set of assays 
were performed on separate occasions, and the observed difference probably reflects the 
initial level of infectivity of the bloodstream form trypomastigotes at that particular 
time. This should not greatly affect the final IC50 values, since the level of infectivity 
within a single assay should be equivalent. Also, in the benznidazole assay, it was 
apparent that sub-lethal levels of compound actually promote parasite growth. This 
phenomenon is often observed in drug assays with T. cruzi and T. brucei, both within 
our laboratory and in neighbouring laboratories, and could potentially be a form of 
parasite stress response. In conclusion, the pilot assays proved successful in generating 
dose dependant growth inhibition curves facilitating the calculation of replicable IC50 
values.   
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Figure 7.1.8.  Susceptibility of luciferase expressing T. cruzi amastigotes to nifurtimox 
and benznidazole.  
In a 96-well plate format,  mammalian Vero cells were infected overnight  with luciferase 
expressing T. cruzi  bloodstream form trypomast igotes.  Non-internalised parasites were 
removed by extensive washing in culture medium. Amast igote parasites were grown for 3 
days in the presence of different  concentrat ions of nifurt imox or benznidazole and the 
luciferase act ivity,  as measured in light  units,  determined for each infected mammalian 
culture.  A dose response curve for nifurt imox and benznidazole was plotted from which 
the drug concentrat ion that  inhibited parasite growth by 50% (IC 50) was established. The 
data are the means from 3 experiments ± standard deviat ions.  
 
7.2 Compound Screening with T. cruzi CL BrenerRibo-Luc 
Following the development and validation of the luciferase-based T. cruzi amastigotes 
screening system, a series of growth inhibition experiments were performed using three 
sets of nitroaromatic compounds. To facilitate throughput, all compounds were subject 
to an initial screen at a single concentration of 10 M. Any agent that failed to display 
activity at this concentration was considered a poor candidate and not analyzed further. 
For the compounds displaying anti-parasitic properties, IC50 values were determined 
against the transgenic T. cruzi amastigote and the Vero cell-lines. Comparison of these 
values allowed a therapeutic index to be calculated, which acts as a crude measure of a 
compound‟s selectivity against the parasite.  
The first series of compounds consisted of nine aziridinyl nitrobenzyl compounds 
(Helsby et al., 2004a) (Table 3.13.1). This included the lead compound CB1954 
(Section 6.3), an agent originally developed as an anti-cancer agent designed to be used 
in a nitroreductase-based gene therapy approach called GDEPT (Gene Directed Enzyme 
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Pro-drug Therapy) (Knox et al., 2003). It also has promising activity against T. brucei 
(Sokolova et al., 2010).  The second set of compounds comprised 24 nitrobenzyl 
mustards (Table 3.13.2 and Table 3.13.3). These compounds were originally designed as 
anti-cancer pro-drugs that undergo GDEPT activation via the same mechanism as 
CB1954 (Li et al., 2003). Again, some of these compounds have potent trypanocidal 
activity against bloodstream form T. brucei (Hall et al., 2010). The third class of 
compounds possess a common nitrofuran structure (Table 3.13.4) and were developed 
specifically as chemotherapeutic agents targeting T. cruzi (Aguirre et al., 2006). 
Currently these have mainly been screened against the epimastigote lifecycle stage, with 
a few progressing through into animal studies (Cabrera et al., 2009). For this reason, 
only a small sub-set of 6 compounds were tested here. 
All of the compounds selected for screening against amastigote parasites are believed to 
function as pro-drugs that undergo activation through the activity of a parasite type I 
nitroreductase (Section 6.1). 
7.2.1 Trypanocidal activity of aziridinyl nitrobenzamides  
Based on the number and relative positions of nitro groups and the position of any 
additional substituents, the azirindyl nitrobenzyl compounds can be split into three 
classes, designated class Ia, Ib and II. When all nine compounds were screened against 
T. cruzi amastigotes, only three displayed any anti-parasitic effects at 10 M. These 
(CB1954, NH1, and NH2) are all structurally related, and belong to the class Ia family 
of compounds. They all contain an amide (or related substituent) at position 1 on the 
benzyl ring, two nitro groups at positions 2 and 4, and an aziridinyl ring at position 5. 
The IC50 values for these trypanocides were determined using a range of drug 
concentrations (Table 7.2.1). Analysis of the data revealed that all had roughly similar 
growth inhibitory activities, generating IC50 values of around 1 µM. The IC50 value 
using nifurtimox was approximately 0.25 µM. CB1954 and NH1 were particularly 
potent, having values around 0.6 µM. When cytotoxicity studies were extended to 
mammalian cells, no growth inhibitory effects were observed at concentration up to 250 
µM, while in contrast nifurtimox yielded an IC50 of 64 µM. Further analysis to 
determine cytotoxicity could not be performed as the DMSO solvent used to dissolve 
183 
 
the azirindyl nitrobenzyl compounds, proved toxic to the Vero cell-line. Therefore, to 
establish a therapeutic index between T. cruzi and mammalian cells (Table 7.2.1), the 
published cytotoxicity data against a Chinese hamster fibroblast (V79) cell-line was used 
(De Conti, 1998; Helsby et al., 2004a). This indicated that CB1954, NH1, and NH2 
showed little toxicity towards V79 cells, generating IC50 values greater than 500 µM. In 
contrast, the nifurtimox IC50 was recorded at 35 µM. Evaluation of therapeutic index 
ratios clearly demonstrated that CB1954 and NH2 were >900-fold more effective at 
inhibiting parasite growth over the V79 cells, and approximately 6-fold more effective 
that nifurtimox. 
  
Compound 
IC50 (µM) 
Therapeutic Index 
T. cruzi ± S.D Vero V79 
Nifurtimox 0.24 ± 0.04 64.11 ± 0.57 35 146 
CB1954 0.57 ± 0.04 > 250 543 953 
NH1  1.59 ± 0.10 > 250 624 392 
NH2  0.68 ± 0.11 > 250 634 919 
NH3  >10 > 100 3838 - 
NH4  >10 > 100 766 - 
NH5  >10 > 100 122 - 
NH6  >10 > 100 1038 - 
NH7  >10 > 100 1269 - 
NH8  >10 > 100 131 - 
  
Table 7.2.1. Susceptibility of T. cruzi amastigotes to aziridinyl nitrobenzamides.  
The concentrat ion of azir inidyl nit robenzamide that  inhibits parasite and Vero cell 
growth by 50% (IC50) was determined. The lead compound (CB1954) and two derivat ives 
(NH1, and NH2) displayed potent  trypanocidal propert ies.  The remaining compounds 
showed no ant i-parasit ic act ivity up to 10 µM. As a posit ive control,  nifurt imox was 
analysed in parallel.  The three t rypanocidal azir inidyl compounds did not  inhibit  Vero 
cell growth at  concentrat ions up to  250 M. At  higher drug concentrat ions,  the solvent  
(DMSO) used to dissolve the azir inidyl nitrobenzamides began to affect  mammalian cell 
growth. All growth inhibit ion assays were performed in quadruplicate and the values are 
means ± standard deviat ions.  To obt ain therapeut ic indices,  toxicity data for Chinese 
hamster fibroblast  (V79) cells were taken from the work of Helsby et  al.  2004 (CB1954, 
NH1, and NH2) or De Co nt i et  al.  1998 (nifurt imox).  The  therapeut ic index of each 
compound was calculated as a rat io o f the V79 IC50 value to the parasite IC50 value.        
 
184 
 
7.2.2 Trypanocidal activity of nitrobenzyl mustards 
The nitrobenzyl mustard class of nitroaromatics can be divided into two types. For the 
first type, a phosphoramide component is incorporated into a fixed cyclic structure 
allowing for the formation of stereoisomers (Table 3.13.2), while in the second type, the 
phosphoramide is part of a linear side chain (Table 3.13.3). Screening of all 24 mustard 
compounds against T. cruzi amastigotes at 10 µM identified 6 promising trypanocidal 
candidates. Out of the 18 compounds rejected, all the cyclic phosphoramide-based 
chemicals failed to display any cytotoxicity along with 10 agents possessing the linear 
phosphoramide configuration. Of the remaining compounds, all possessed some form of 
halogenation on the nitroaromatic ring. Further growth inhibition assays now using six 
drug concentrations ranging from 0 to 10 µM, with four replicates of each assay, were 
performed to determine IC50 values (Table 7.2.2). For 5 of these, the calculated values 
were between 8 and 10 µM. However, one compound, LH37, yielded an IC50 of just 
below 1 µM (Table 7.2.2). This compound possesses two fluorine substitutions at 
positions 2 and 6 of the benzene ring, a nitro substituent at position 4 and a linear 
phosphoramide mustard chain at position 1. As with the aziridinyl nitrobenzyl 
compounds, most nitrobenzyl mustards displayed no toxicity to Vero cells up to 100 µM 
with only two (LH47 and LH48) inhibiting growth below this value. For LH47, a 
therapeutic index value of approximately 1 was observed with a value of around 8 
recorded for LH48. Intriguingly, the most promising trypanocidal compound, LH37, 
displayed no cytotoxicity up to 100 µM, suggesting that this compound may warrant 
further analysis, especially given that it displays potent activity against T. brucei (Hall et 
al., 2010). 
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Compound T. cruzi IC50 (µM) Vero IC50 (µM) 
Nifurtimox 0.24 ± 0.04 64.11 ± 0.57 
LH3 - LH9  >10 >100 
LH12 - LH19  >10 >100 
LH24 >10 >100 
LH27 >10 >100 
LH31 >10 >100 
LH32 9.54 ± 0.27 >100 
LH33 7.97 ± 1.13 >100 
LH34 9.14 ± 0.54 >100 
LH37 0.99 ± 0.01 >100 
LH47 8.69 ± 0.76 6.98 ± 0.69 
LH48 8.23 ± 0.30 64.38 ± 0.53 
  
Table 7.2.2. Susceptibility of T. cruzi amastigotes to nitrobenzyl -based mustards.  
The concentrat ion of nit robenzyl-based mustards that  inhibits parasite and Vero cell 
growth by 50% (IC50) was determined. Out of the 24 compounds analysed, six displayed 
trypanocidal propert ies.  The remaining compounds showed no ant i -parasit ic  act ivity up to 
10 µM. For four of the t rypanocidal compounds (LH32-34 and LH37),  no effect  o f Vero 
cell growth was observed. All growth inhibit ion assays were performed in quadruplicate 
and the values are means ± standard deviat ions.   
 
7.2.3 Trypanocidal activity of nitrofuryls 
As mentioned previously, only a sub-set of the 5‟ nitrofuryl compounds available were 
tested against T. cruzi. All of the six compounds examined displayed trypanocidal 
activity below the designated 10 µM cut-off point. Further growth inhibition assays 
against these compounds established an IC50 value for each agent. For four compounds, 
IC50 values of less than 1 µM were determined, with two compounds (HC-4 and HC-10) 
displaying an activity below 0.1 µM (Table 7.2.3). In contrast to the nitrobenzyl-based 
mustards or azirinidyl compounds, no relationship between the nitrofuryl structure and 
anti-parasitic activity was observed. However, the number of agents examined here is 
very small, and a more in depth investigation may be required to elucidate such 
associations. 
Analysis of the six nitrofuryls toxicity against mammalian cells generated IC50 values 
similar, or lower than nifurtimox. This illustrates that a potential drawback of these 
compounds may lie in their toxicity towards the mammalian cells. However, when the 
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resulting therapeutic values are considered, they are equivalent to the clinically used 
trypanocidal agent nifurtimox. Based on their anti-parasitic activities, the nitrofuryls 
represent the most potent trypanocidal compounds screened here and display 
encouraging therapeutic index values. 
The above screens against T. cruzi amastigotes using 39 nitroaromatic compounds 
identified seven promising trypanocidal compounds whose structures are shown in 
Figure 7.2.1. This represents a hit rate of just below 20%, and clearly demonstrates how 
understanding the mode of action for existing trypanocidal therapies can be exploited to 
identify new lead compounds, that warrant further evaluation to treat these neglected 
diseases. 
 
 
Compound T. cruzi IC50 (µM) Vero IC50 (µM) Therapeutic Index 
Nifurtimox 0.24 ± 0.04 64.11 ± 0.57 267 
HC-1 1.99 ± 0.04 23.80 ± 0.62 12 
HC-2 0.72 ± 0.08 23.93 ± 0.25 33 
HC-4 0.08 ± 0.03 20.34 ± 0.35 254 
HC-10 0.06 ± 0.01 13.61 ± 1.10 227 
HC-2b 0.20 ± 0.04 60.05 ± 1.31 300 
HC-4b 4.35 ± 0.41 23.70 ± 0.63 5 
  
Table 7.2.3. Susceptibility of T. cruzi amastigotes to 5’ nitrofuryls. 
The concentrat ion of 5‟ nit rofuryl that  inhibits parasite and Vero cell growth by 50% 
(IC50) was determined for compounds not previously screened against  T. cruzi  
amast igotes. All proved potent  trypanocidal agents ,  exhibit ing IC50  values below 5 µM, 
with two giving values of less than 100 nM. For each compound, the therapeut ic index 
was calculated as a rat io  of the Vero IC50  value to  the parasite IC50  value.  All growth 
inhibit ion assays were performed in quadruplicate and the values are means ± standard 
deviat ions.       
 
 
 
 
187 
 
 
 
Figure 7.2.1.  Structures of the most effective compounds ident ified in the T. cruzi 
amastigote screens.  
The compounds ident ified as potent  trypanocidal agents with respectable therapeut ic 
indices are derived from 3 classes o f nit roaromatic compounds including: the azir indyl 
nit robenzyls (A),  nit robenzyl mustards (B) and 5‟ nit rofuryls (C). 
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7.3 Chapter Summary 
The development of a luciferase reporter system for the drug screening of intracellular 
T. cruzi has demonstrated:  
 Integrating pGAP-Luciferase into the GAPDH region of T. cruzi X10/6 appears 
to impair parasite infectivity. 
 Using the ribosomal targeting sequence of pTRIX to express luciferase, results in 
no apparent effect on epimastigote growth and infectivity, or amastigote growth 
and trypomastigote infectivity. 
 Luciferase activity of lysed amastigotes is linearly proportional to cell number 
and sensitive down to 10 parasites per sample, so therefore the detected 
luminescence accurately represents parasite numbers.  
 A 5 day growth inhibition assay provides a clear drug dose dependent growth 
response, facilitating the calculation of IC50 values with low variation. 
 Three of the nine aziridinyl nitrobenzamides compounds displayed promising 
trypanocidal activities (~1 µM) and therapeutic indices (~900), and represent a 
class of potential drug candidates.  
 Most of the nitrobenzyl phosphoramides proved ineffective against amastigote T. 
cruzi, with only compound LH37 displaying significant trypanocidal activity at 
~1 µM. 
 The 5‟ nitrofuryl compounds showed the most potent trypanocidal activities of 
the three classes of compounds tested, although the compounds also displayed 
levels of cytotoxicity below 100 µM against mammalian cells. 
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7.4 Discussion 
Any drug development programme requires a reliable and high-throughput strategy for 
monitoring the growth or death of the target cell. Construction of the 96-well plate based 
luciferase drug screening system (Bot et al., 2010) has facilitated the rapid analysis of 
three series of nitroaromatic compounds for trypanocidal activity against the medically 
relevant amastigote life-cycle stage of T. cruzi.  
When this project was initiated, the only reliable high-throughput assay available to 
monitor the growth of intracellular T. cruzi relied on a β-galactosidase based 
colorimetric reporter (Section 7.1) (Buckner et al., 1996). Although useful, a potential 
drawback of the β-galactosidase system is that it may not be well suited for screening 
strongly coloured chemicals. As many nitroaromatic compounds are coloured, an 
alternative reporter system based on luciferase was developed. Recently, two other 
screening strategies have been reported. These either rely on the heterologous 
expression of the red fluorescent protein (Canavaci et al., 2010), or exploit the size 
difference displayed by the mammalian nuclei versus the much smaller trypanosomal 
kinetoplast DNA (Engel et al., 2010). Each approach has its advantages and 
disadvantages. For example, both have been successfully used to analyze the growth of 
in vitro cultured intracellular T. cruzi, but neither can currently be employed to monitor 
parasite growth within an animal model. The DNA staining based assay is of particular 
interest, as although it is dependent on specialized image capture technology and 
detection algorithms, its major advantage over other systems, including the luciferase 
system developed here, is that no genetic modification of the parasite cell-line is 
required. Therefore, it could easily be used against a range of laboratory and clinical 
strains. The limitations of the red fluorescent protein system led its authors to develop 
another T. cruzi cell-line, this time engineered to express the firefly luciferase gene 
(Canavaci et al., 2010), in a system analogous to that described here (Bot et al., 2010). 
They attempted to use their luciferase expressing cell-line to monitor parasite numbers 
in a mouse model. However, this assay only measured infection levels within a mouse 
footpad, and so falls short of representing a true in vivo model. One explanation behind 
this limitation is that to produce an effective and accurate luciferase-based animal 
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model, an even distribution of the luciferase substrate fully dispersed within the host is 
required, followed by an efficient transmission of the luminescence signal. Evidence 
observed using a T. brucei based luciferase reporter mouse model implies this is not 
necessarily achieved, especially with intraperitoneal dosage of the luciferase substrate 
(Claes et al., 2009). Here, the distribution of luminescence signal levels detected from 
live animal based imaging did not always correlate with the signals detected from 
individually extracted organs immediately post-mortem, such as the brain. This suggests 
that luciferase systems may not be the best way forward in developing mouse infectivity 
models.   
The first class of compounds screened with the luciferase reporter system was a series of 
aziridinyl nitrobenzamides based on the anti-cancer agent CB1954 (Section 6.3). These 
can be divided into 3 sub-classes, based on the number and positioning of nitro groups 
on the benzyl ring, coupled with the location of any substituent groupings (Section 
7.2.1). Out of the aziridinyl nitrobenzamides tested, 3 showed trypanocidal activity 
against amastigote T. cruzi (Bot et al., 2010). These 3 compounds (CB1954, NH1 and 
NH2) all belong to a single sub-class, as they contain an amide containing substituent at 
the 1- position, 2 nitro groups located at the 2- and 4- positions, and an aziridinyl ring at 
5- position on a benzyl ring. The other sub-classes either lack the 2- nitro group or 
contain a substituent (generally an amide) at the 6- position. A comparison of the 
trypanocidal activity and mammalian cytotoxicity data revealed that two of the three 
compounds (CB1954 and NH2) displayed high selectivity towards the parasites (Bot et 
al., 2010; Helsby et al., 2004a). Interestingly, biochemical screens using recombinant T. 
brucei type I nitroreductase revealed that these same three agents were the only 
compounds from this set that could be metabolized by the T. brucei enzyme. These were 
also the most effective at inhibiting bloodstream form T. brucei growth (Bot et al., 
2010). Moreover, T. brucei with elevated levels of the type I nitroreductase had 
increased susceptibility (>10 fold) to these compounds, as compared to controls. 
Together, these findings demonstrate the importance of the type I nitroreductase in the 
T. brucei anti-parasitic activity of this aziridinyl nitrobenzamide sub-class. By 
implication it is assumed that a similar activation mechanism underpins their activity 
within T. cruzi. Overall, two aziridinyl nitrobenzamide compounds displayed excellent 
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trypanocidal activity against T. cruzi amastigotes through a characterized mechanism, 
with strong potencies (IC50 < 1 µM) and high therapeutic indices (> 900). These have 
real potential as future drug candidates, and warrant further studies with an in vivo 
model. 
Many of the nitrobenzyl phosphoramides tested with the luciferase screening system 
were not effective trypanocidal agents against T. cruzi (Hu et al., 2011). This large series 
of chemicals contained 24 compounds that could be divided into those that possessed a 
cyclic phosphoramide component, and those containing a linear phosphoramide group 
(Section 7.2.2). None of the eight cyclic phosphoramides had an effect on the growth of 
T. cruzi amastigotes, a trait also observed in screens targeting bloodstream form T. 
brucei (Hall et al., 2010). One possible explanation for the lack of trypanocidal activity 
could relate to how they interact with the T. brucei type I nitroreductase, as many of the 
cyclical phosphoramide analogues do not function as substrates for the parasite enzyme, 
while the few that are turned over, do so at a low rate (Hall et al., 2010). This may 
reflect an electron withdrawing tendency displayed by the cyclic phosphoramide, 
limiting the vulnerability of the nitro group on the benzyl ring to type I nitroreductase-
mediated reduction. For the remaining linear nitrobenzyl phosphoramides, 6 compounds 
(LH32-34, LH37, LH47 and LH48) demonstrated activity against T. cruzi amastigotes 
(IC50 < 10 M) with LH37 having the highest potency (IC50 ~ 1 M) (Hu et al., 2011). 
This mirrors what had previously been reported against bloodstream form T. brucei, 
although against this parasite the most potent compounds (LH34 and LH37) exhibited 
IC50 values of less than 10 nM (Hall et al., 2010). Biochemical studies using 
recombinant T. brucei type I nitroreductase demonstrated that out of all 16 linear 
nitrobenzyl phosphoramides, four generated very high specific activity values (LH32-34 
and LH37) (Hall et al., 2010). The remaining compounds (LH47 and LH48) that 
displayed activity against T. cruzi have not been subject to biochemical analysis. When 
the biochemical studies were extended to the T. cruzi type I nitroreductase, the highest 
activities were also achieved with the same sub-set of compounds, although the specific 
activity values were generally between 5 to 10 fold lower for the T. cruzi enzyme as 
compared with that of the T. brucei protein (Hall and Wilkinson, unpublished data). 
This, in conjunction with susceptibility studies on T. brucei with altered levels of the 
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type I nitroreductase, shows that for this series of compounds, there is a direct 
relationship between parasite growth inhibition and enzyme activity. Structure-activity 
relationships for the linear nitrobenzyl phosphoramides show that the compounds 
displaying anti-T. cruzi properties contain either chlorine, fluorine or tri-fluoromethyl 
groups at the 2- position on the benzyl ring relative to the leaving phosphoramide. It is 
postulated that on a benzyl ring, the electron withdrawing substituents when coupled 
with the electronic properties displayed by the nitro group favour the reduction of the 
latter grouping by type I nitroreductases (Hall et al., 2010). Alternatively, such 
configurations could affect other biological properties displayed by these chemicals, 
such as drug uptake. In summary, although some of the nitrobenzyl phosphoramides 
display interesting trypanocidal effects on T. cruzi, their IC50 and therapeutic index 
values indicate that they would be better developed as African sleeping sickness pro-
drugs. 
The final series of compounds tested with the luciferase system were a sub-set of 5‟ 
nitrofuryls (Section 7.2.3). While some of the compounds had already been tested in 
vivo (Cabrera et al., 2009), it was interesting to see how some of the untested nitrofuryls 
would compare against the other chemical series tested here. Indeed, the nitrofuryls 
displayed the highest potencies of all compounds tested towards T. cruzi amastigotes, 
highlighting why this class has received so much attention in the past. Although these 
compounds also generated cytotoxicity when analyzed against mammalian cells, the 
therapeutic index values from T. cruzi and Vero cells were similar to that observed for 
nifurtimox. In addition, since the sampled set of nitrofuryls was so small, no meaningful 
structure-activity relationship can be inferred. As there is a greater understanding in how 
these nitroheterocyclic compounds function (Wilkinson et al., 2011), it is now worth 
revisiting this class against T. brucei.  
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8 Trypanocidal activity of 5‟ nitrofuryls against T. brucei 
This chapter investigates the efficacy of a larger number of 5‟ nitrofuryl compounds 
against the bloodstream form of T. brucei. In addition, how these agents mediate their 
trypanocidal activity in relation to a range of bio-reductive enzymes, including a type I 
nitroreductase is explored. 
8.1 Trypanocidal Activity of 5’ Nitrofuryl Compounds 
Interest in using nitrofuryls to treat African sleeping sickness and Chagas disease began 
in the 1950s after a trypanocidal screening programme identified nitrofurazone as a lead 
compound (Evens et al., 1957; Packchanian, 1955). The effectiveness of this agent in 
humans was demonstrated, but failure to totally eradicate parasitaemia, coupled with 
neuropathological toxicity resulted in these trials being suspended (Rodriques Coura and 
de Castro, 2002). However, these findings led to investigations into the activity of other 
nitroheterocyclic compounds, with nifurtimox emerging as a promising candidate.  
Nifurtimox, marketed under the brand name Lampit™, was initially used as the front-
line treatment against acute Chagas disease throughout Latin America. However, due to 
GI tract and CNS side effects, coupled with the refractory nature of some T. cruzi 
strains, its limited efficacy and genotoxicity, nifurtimox use has now been discontinued 
in Brazil, Argentina, Chile and Uruguay, and it is not available for use in the USA 
except via the CDC (Alejandre-Duran et al., 1988; Moraga and Graf, 1989; Rodriques 
Coura and de Castro, 2002). Despite these problems, nifurtimox, as part of nifurtimox-
eflornithine combination therapy (NECT), has been successfully trialled as a treatment 
for late-stage West African sleeping sickness (Section 1.2.1) and has recently been 
added to the WHO Essential Medicines List (Priotto et al., 2009). Given the renewed 
interest in nitroheterocyclic compounds for the treatment of trypanosomal infections, a 
series of 5‟ nitrofuryl compounds is investigated here against bloodstream form T. 
brucei. Included in this set is nitrofurazone, the initial lead compound, and a series of 
other agents proposed to mediate their activity through the inhibition of sterol 
biosynthesis. 
194 
 
8.1.1 Trypanocidal activity of 5’ nitrofuryls 
The growth inhibitory properties of 18 nitrofuryl compounds (Table 3.13.4), including 
nitrofurazone, was tested against wild-type bloodstream form T. brucei 427 and 
compared against the potency of nifurtimox. For each compound, a total of 12 
concentrations were analysed in quadruplicate and the parasite load in each culture 
determined using the alamarBlue® reporter system (Section 3.12.1). From each data set, 
dose response curves were drawn and the mean nitrofuryl concentration that inhibits 
parasite growth by 50% (IC50) and 90% (IC90) ± standard deviation was determined 
(Table 8.1.1). 
This initial screen revealed that only one of the compounds (HC-5) did not affect growth 
of bloodstream form trypanosomes at concentrations up to 20 M, so this was omitted 
from further tests. For the remaining 17 structures, all displayed a higher trypanocidal 
activity than nifurtimox, with 13 having IC50 values below 1 M, and six yielding 
values lower than 250 nM: these were the thiosemicarbazones HC1, HC2 and HC4, the 
carbazonates HC10 and HC11, and the semicarbazone nitrofurazone. In contrast to other 
nitroaromatic compounds (Bot et al., 2010; Hall et al., 2010), no relationship between 
the nitrofuryl‟s anti-parasitic properties and chemical structure was observed. As the 
compounds used here were generally selected on the basis of their growth inhibitory 
properties against T. cruzi, less potent compounds that could have facilitated a 
meaningful structure activity relationship may have already been excluded from this 
analysis. 
The six compounds displaying the highest trypanocidal activities against bloodstream 
form T. brucei were assayed for cytotoxicity against Vero cells (Table 8.1.1). The 
therapeutic selective index values (S.I), a ratio of the IC50 against the mammalian line 
versus the IC50 against the parasite, for each agent was then determined. In all cases, the 
6 compounds displayed selective toxicity in vitro toward the parasite, having SI values 
between 3- and 11-fold greater than nifurtimox. 
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Compound T. brucei 
IC50 (µM) 
T. brucei 
IC90 (µM) 
Vero IC50 
(µM) 
S.I 
Nifurtimox 2.78 ± 0.20 3.86 ± 0.08 64.11 ± 0.57 23 
HC-1 0.18 ± 0.00 0.30 ± 0.05 23.80 ± 0.62 133 
HC-2 0.20 ± 0.01 0.38 ± 0.03 21.93 ± 0.25 110 
HC-2b 0.67 ± 0.02 0.88 ± 0.04 - - 
HC-3 0.50 ± 0.05 0.85 ± 0.07 70.06 ± 1.35 140 
HC-4 0.24 ± 0.03 0.38 ± 0.01 20.34 ± 0.35 83 
HC-4b 0.79 ± 0.04 1.34 ± 0.01 - - 
HC-5 > 20 > 20 - - 
HC-6 0.54 ± 0.07 0.93 ± 0.01 - - 
HC-7 1.43 ± 0.09 2.31 ± 0.02 - - 
HC-8 2.52 ± 0.33 5.90 ± 0.09 - - 
HC-9 1.65 ± 0.06 4.10 ± 0.13 - - 
HC-10 0.12 ± 0.02 0.19 ± 0.00 13.61 ± 1.10 116 
HC-11 0.17 ± 0.01 0.24 ± 0.01 44.83 ± 2.42 264 
HC-12 0.38 ± 0.04 0.65 ± 0.08 - - 
HC-12b 0.43 ± 0.06 0.77 ± 0.01 - - 
Nitrofurazone 0.23 ± 0.01 0.29 ± 0.02 35.73 ± 3.02 157 
HC-13 1.28 ± 0.06 2.31 ± 0.01 - - 
HC-14 0.57 ± 0.03 0.74 ± 0.00 - - 
 
 
Table 8.1.1.  Susceptibility of bloodstream form T. brucei and mammalian cells to 
nitrofuryl compounds.  
The 50% growth inhibitory concentrat ions (IC 50) and 90% growth inhibitory 
concentrat ions (IC90) of the 5‟ nit rofuryls (Table 3.13.4) are measured against  T. brucei  
427 (Sect ion 3.12.1).  Almost  all compounds show a higher t rypanocidal act ivity than 
nifurt imox. For select  compounds, toxicity against  Vero cells was also measured. The 
result ing IC50 values were compared to the respect ive T. brucei results to  calculate the 
therapeut ic select ive index (S.I = Vero IC 50 /T. brucei  IC50).  All of the selected drugs 
displayed higher therapeut ic index values compared to nifurt imox.  
 
8.1.2 Trypanocidal activity of 5’ nitrofuryls by a type I nitroreductase 
A type I nitroreductase has been strongly implicated in the activation of 
nitroheterocyclic pro-drugs including nifurtimox (Bot et al., 2010; Hall et al., 2010; 
Wilkinson et al., 2008). Here, the question of whether this activation mechanism extends 
to other 5‟ nitrofuryls, including nitrofurazone was evaluated. Using a T. brucei type I 
nitroreductase heterozygous line (designated TbNTR
+/-
) the question of whether cells 
with reduced levels of this reductase had altered susceptibility toward the 5‟ nitrofuryls, 
relative to the wild-type parasites was examined (Table 8.1.2; Figure 8.1.1). For most 
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compounds, trypanosomes containing a single copy of the type I nitroreductase gene 
displayed resistance to the nitroheterocycle under investigation as compared to wild-
type cells. However, when examining the susceptible of TbNTR+/- line to HC-6 or HC-
10, IC50 values similar to that observed for wild-type parasites were recorded. This may 
reflect a combination of contributory factors such as parasite permeability and their 
affinity for the nitroreductase enzyme. To demonstrate that the increase in drug 
resistance upon elevated nitroreductase levels is specific to the nitrofuryls, the non-
nitroheterocyclic drug G418, which is a protein synthesis inhibitor, was used as a 
negative control. 
 
Compound 
 
T. brucei IC50 (nM) 
Wild-type TbNTR
+/-
 
Nifurtimox 2800 ± 195 4200 ± 290 
G418 580 ± 10 625 ± 25 
HC-1 180 ± 5 320 ± 10 
HC-2 200 ± 15 560 ± 35 
HC-2b 665 ± 20 1080 ± 125 
HC-3 500 ± 45 760 ± 5 
HC-4 240 ± 35 1295 ± 30 
HC-4b 790 ± 40 1350 ± 95 
HC-5 - - 
HC-6 535 ± 70 620 ± 25 
HC-7 1430 ± 90 2100 ± 135 
HC-8 2520 ± 330 4595 ± 550 
HC-9 1650 ± 65 2930  ± 250 
HC-10 120 ± 15 140 ± 15 
HC-11 170 ± 5 310 ± 55 
HC-12 380 ± 40 700  ± 75 
HC-12b 430 ± 60 765 ± 1250 
Nitrofurazone 225 ± 10 540 ± 15 
HC13 1275 ± 55 1720 ± 85 
HC14 575 ± 25 905 ± 30 
   
Table 8.1.2.  Susceptibility of bloodstream form T. brucei with reduced nitroreductase 
gene copy number.  
Growth-inhibitory effect s as indicated by IC50  values ( in nM) of all nit rofuryl compounds 
on T. brucei wild-type parasites and  the nit roreductase heterozygous line (designated 
TbNTR
+ / -
).  Data are means from four experiments ± standard deviat ion. G418 and 
nifurt imox were used as drug controls.  
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Figure 8.1.1.   Susceptibility of bloodstream form T. brucei with reduced nitroreductase 
gene copy number to the 6 most potent nitrofuryls.  
Growth inhibitory effect s as indicated by IC50  values of the six most  potent  nit rofuryl 
compounds as ident ified from the init ial t rypanocidal screen on T. brucei wild- type 
(white bars) and nit roreductase heterozygous cell (TbNTR
+ / -
) cells (black bars). The 
compounds screened are HC-1, HC-2, HC-4, HC-10, HC-11 and nit rofurazone. Data are 
means from four experiments ± standard deviat ion. G418 and nifurt imox were used as 
drug controls.  
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As the reduction of the nitroreductase gene copy number leads to resistance toward most 
5‟ nitrofuryls, then it is implicit that elevated levels should lead to hyper-sensitivity. 
This hypothesis was investigated using a tetracycline based inducible cell-line that 
facilitates the over-expression of a tagged version of the nitroreductase (Wilkinson et al., 
2008). The effect of all trypanocidal nitrofuryls on the growth of this line was monitored 
in the presence of tetracycline (Table 8.1.3; Figure 8.1.2). For most compounds, cells 
with elevated levels of nitroreductase were shown to be between 4 and 15-fold more 
sensitive to the nitroheterocycle, relative to control cells. These control cells consisted of 
the same parasite line, but grown in the absence of tetracycline. This shift in resistance 
was shown to be specific to the nitroheterocycles, as cells induced to express additional 
nitroreductase were no more susceptible to the non-nitroheterocycle G418 control drug. 
Compound 
 
T. brucei IC50 (nM) 
-Tet +Tet 
Nifurtimox 2890 ± 30 315 ± 15 
G418 640 ± 10 540 ± 20 
HC-1 290 ± 20 70 ± 5 
HC-2 200 ± 5 35 ± 5 
HC-2b 880 ± 60 65 ± 5 
HC-3 500 ± 40 70 ± 5 
HC-4 270 ± 15 35 ± 5 
HC-4b 760 ± 45 75 ± 5 
HC-5 - - 
HC-6 475 ± 40 320 ± 20 
HC-7 1620 ± 15 145 ± 30 
HC-8 2065 ± 225 35 ± 5 
HC-9 2165 ± 140 180 ± 5 
HC-10 100 ± 10 25 ± 5 
HC-11 385 ± 40 50 ± 5 
HC-12 2765 ± 240 835 ± 25 
HC-12b 1945 ± 134 145 ± 10 
Nitrofurazone 165 ± 5 40 ± 5 
HC13 1165 ± 140 75 ± 5 
HC14 625 ± 15 160 ± 5 
   
Table 8.1.3. Susceptibility of bloodstream form T. brucei with elevated levels of 
nitroreductase to nitrofuryls.  
Growth-inhibitory effect s as judged by IC50  values ( in nM) of all nit rofuryl compounds 
on T. brucei control (-Tet) and nit roreductase  over-expressing (+Tet) cells.  Data are 
means from four experiments ± standard deviat ion. G418 and nifurt imox were used as 
drug controls.  
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Figure 8.1.2. Susceptibility of bloodstream form T. brucei with elevated levels of 
nitroreductase to the 6 most potent nitrofuryls.  
Growth inhibitory effect s as judged by IC5 0  values ( in nM) of the 6 most  potent  nit rofuryl 
compounds as ident ified from the init ial trypanocidal sc reen on T. brucei control (-tet) 
and nit roreductase over-expressing (+tet) cells.  Data are means from four experiments ± 
standard deviat ion. G418 and nifurt imox were used as drug controls.  
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8.1.3 Activation of 5’ nitrofuryl pro-drugs by other mechanisms 
The above data strongly implies that the trypanosomal type I nitroreductase plays a key 
role in activation of nitrofuryl compounds within the parasite. However, other parasite 
enzymes have been postulated to interact with nitroheterocyclic compounds (Section 
6.2) including prostaglandin F2α synthase (PGS) and cytochrome P450 reductase (CPR) 
(Kubata et al., 2002; Viode et al., 1999). To examine whether these enzymes activate the 
6 most potent trypanocidal compounds identified through our screens, bloodstream form 
T. brucei lines expressing recombinant prostaglandin F2α synthase, cytochrome P450 
reductase 2, and cytochrome P450 reductase 3 (CPR numbering accordance to Portal et 
al. 2008) were generated in a similar way to that described for nitroreductase, and the 
phenotype of the engineered cells to the 5‟ nitrofuryls evaluated.  
The full length open reading frames, minus their stop codons, encoding for 
prostaglandin F2α synthase, cytochrome P450 reductase 2, and cytochrome P450 
reductase 3, were amplified from T. brucei genomic DNA and the resultant fragments 
cloned into pRPa
MYC
-NTR generating the expression plasmids pRPa
MYC
-PGSF2α, 
pRPa
MYC
-CPR-2, and pRPa
MYC
-CPR-3 (Figure 8.1.3). The plasmids were digested with 
AscI and the resultant fragments electroporated into bloodstream form T. brucei 
2T1/TAG
PURO
 cells (Alsford and Horn, 2008). Drug selection was performed with 
hygromycin, and recombinant parasite clones obtained (Section 3.10.1). To demonstrate 
expression of recombinant protein, extracts from parasite cultures grown in the absence 
(no induction) or presence (induction) of tetracycline, were prepared and analysed by 
western blot using an antibody raised against the c-myc (9E10) epitope. For each 
recombinant parasite line, a band corresponding to the tagged protein was detected in 
tetracycline treated parasites (Figure 8.1.4). 
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Figure 8.1.3.  Expression plasmids used to evaluate other potential nitrofuryl activator 
systems. 
To examine other potent ial mechanisms of nit rofuryl act ion, the T. brucei  genes encoding 
for prostaglandin F2α  synthase,  cytochrome P450 reductase 2,  and cytochrome P450 
reductase 3 were amplified from genomic DNA and cloned into the pRPa
MYC
 inducible 
gene expression system (Alsford and Horn, 2008).  The cloning st rategy involved 
replacing the nit roreductase gene in the plasmid pRPa
MYC
-NTR (A) with appropriate DNA 
fragment  result ing in format ion of pRPa
MYC
-PGSF2α  (B),  pRPaMYC-CPR-2 (C), and 
pRPa
MYC
-CPR-3 (D),  respect ively.   All plasmids were linear ized with an AscI restrict ion 
digest  and the resultant  fragments int ro duced into bloodstream form T. brucei . 
 
 
The growth inhibition properties of nifurtimox and the six most potent trypanocidal 
nitrofuryls (nitrofurazone, HC-1, HC-2, HC-4, HC-10, and HC-11) were then carried out 
on the 3 recombinant parasite lines grown in the absence (control) or presence (induced) 
of tetracycline (Table 8.1.4;  Figure 8.1.5). In all cases, elevated levels of prostaglandin 
F2α synthase, cytochrome P450 reductase 2 or cytochrome P450 reductase 3 had no 
effect on parasite susceptibility to any of the agents screened, indicating that these 
enzymes, previously implicated in the activation of nifurtimox, play no observable role 
in metabolizing nitrofuryl compounds, including nifurtimox. 
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Figure 8.1.4. Western blots of alternative enzymes implicated in nitrofuryl activation 
mechanisms.  
Tetracycline inducible gene expression is demonst rated by western blot  to  the C-termina l 
myc tag of (A) prostaglandin F2α  synthase,  (B) cytochrome P450 reductase 2,  and ( C) 
cytochrome P450 reductase 3 (Sect ion 3.9.4). In each case,  a protein sample originat ing 
from a tetracycline t reated culture is run parallel to  an untreated control.  A band of the 
expected size is observed for each enzyme.   
 
Compound TbPGS TbCPR-2 TbCPR-3 
-Tet +Tet -Tet +Tet -Tet +Tet 
Nifurtimox  2935 ± 100 2870 ± 20 2775 ± 100 2740 ± 90 2865 ± 25 2860 ± 95 
HC-1 160 ± 5 165 ± 5 160 ± 5 175 ± 15 165 ± 10 170 ± 15 
HC-2 305 ± 20 325 ± 30 190 ± 20 210 ± 25 180 ± 20 195 ± 25 
HC-4 635 ± 5 640 ± 25 390 ± 15 375 ± 20 440 ± 15 495 ± 35 
HC-10 95 ± 10 120 ± 20 150 ± 10 125 ± 20 250 ± 15 295 ± 10 
HC-11 650 ± 45 630 ± 65 370± 20 345 ± 10 495 ± 90 465 ± 90 
Nitrofurazone 360 ± 5 350 ± 5 305 ± 25 300 ± 15 345 ± 5 350 ± 5 
       
Table 8.1.4. Susceptibility of bloodstream form T. brucei to nitrofuryls  with elevated 
levels of specified activating enzymes. 
The growth inhibitory effects of select  nit rofuryl compounds in terms of IC50 values (in 
nM) on the over-expressing cell- lines of prostaglandin F2α  synthase (TbPGS), 
cytochrome P450 reductase 2 (TbCPR-2), and cytochrome P450 reductase 3  (TbCPR-3). 
Induct ion of over-expression is generated by tetracycline t reatment  (+Tet) and is shown 
next  to  an untreated control (-Tet).  Data are means from four experiments ± standard 
deviat ion.   
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Figure 8.1.5.  Susceptibility of bloodstream form T. brucei ectopically expressing other 
enzymes proposed to interact with nitrofuryls.   
Growth-inhibitory effect s as judged by IC50values ( in nM) of nifurt imox, HC-2 and 
nit rofurazone on T. brucei cells induced to express recombinant  prostaglandin F2α  
synthase (TbPGS), cytochrome P450 reductase 2 (TbCPR -2), or cytochrome P450 
reductase 3 (TbCPR-3) (+tet),  as compared to  non-induced controls ( -tet) .  The other four 
most  potent  nit rofuryls behaved similar ly ( see Table 8.1.4).  Data are means from four 
experiments ± SD. 
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8.1.4 Investigating whether 5’ nitrofuryls inhibit sterol biosynthesis  
Many of the nitrofuryls used in this project were originally designed to inhibit squalene 
epoxidase (SQE), a key enzyme in sterol biosynthesis pathway (Petranyi et al., 1984). 
The core feature of these molecules consists of a 5‟ nitrofuran ring linked to a side chain 
containing derivatives of antifungal drug terbinafine (Gerpe et al., 2009). Following 
initial trials against T. cruzi it became apparent that many of the trypanocidal variants 
that lacked the allylamine substituent still caused the accumulation of squalene (Gerpe et 
al., 2009). Based on these preliminary findings it was proposed that the nitro component 
of the nitrofuryl undergoes an unspecified nitroreductase activation reaction generating 
metabolites that subsequently inhibit sterol biosynthesis. Here, we evaluated the 
susceptibility of bloodstream form T. brucei over-expressing squalene epoxidase to the 6 
most potent nitrofuryl compounds. It must be noted that bloodstream form T. brucei are 
able to scavenge cholesterol from their environment (Coppens et al., 1987), thus 
potentially circumventing the need for a sterol biosynthetic pathway. This would suggest 
that in this particular parasite life-cycle stage, the nitrofuryl‟s trypanocidal activity may 
not be mediated through squalene epoxidase. Conversely, it has been noted that sterols 
may function in as yet unknown pathways in bloodstream form T. brucei and so could 
prove to be an important target (Zhou et al., 2007). 
To assess whether the trypanocidal properties of 5‟ nitrofuryls (or their metabolites) 
target squalene epoxidase activity, the squalene epoxidase open reading frame minus its 
stop codon, was amplified from T. brucei genomic DNA and the resultant fragment used 
to replace the nitroreductase gene in pRPa
MYC
-NTR (Figure 8.1.3a) to form pRPa
MYC
-
SQE (Figure 8.1.6). The plasmid was digested with SacII and NotI, and the purified 
DNA fragments transfected into the bloodstream form T. brucei 2T1/TAG
PURO
 line 
(Alsford and Horn, 2008). Drug selection was performed with hygromycin and 
recombinant parasite clones obtained (Section 3.10.1). To demonstrate expression, 
extracts from parasite cultures grown in the absence (no induction) or presence 
(induction) of tetracycline, were prepared and analysed in western blots using an 
antibody raised against the c-myc (9E10) epitope (Figure 8.1.7). For the recombinant 
parasite line, a band of the correct size corresponding to tagged squalene epoxidase was 
detected in tetracycline treated parasites. 
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Figure 8.1.6.  A plasmid used to over-express squalene epoxidase in T. brucei.  
The  full length squalene epoxidase gene lacking its stop-codon was amplified from T. 
brucei  genomic DNA and cloned into the pRPa
MYC
-NTR plasmid (Wilkinson et al. ,  2008), 
replacing the nit roreductase gene ( Sect ion 3.6.15).  The result ing plasmid pRPa
MYC
-SQE 
was used in conjunct ion with the 2T1/TAG
PURO
 cell- line (Alsford and Horn, 2008)  for 
tetracycline mediated inducible gene expression of squalene epoxidase.   
 
 
 
 
Figure 8.1.7.  A Western blot showing the inducible expression of squalene epoxidase . 
Inducible gene expression upon tetracycline treatment  is demonstrated by wester n blot to 
the C-terminal myc tag of squalene epoxidase (Sect ion 3.9.4). Under tetracycline 
treatment  condit ions,  a band of the predicted size is generated.    
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The growth inhibition properties of nifurtimox and the six most potent trypanocidal 
nitrofuryls (nitrofurazone, HC-1, HC-2, HC-4, HC-10, and HC-11) were then evaluated 
on trypanosomes induced to over-express squalene epoxidase (Figure 8.1.5). This group 
of compounds includes HC-4 which is reported to be one of the most effective agents at 
causing squalene accumulation in T. cruzi (Gerpe et al., 2008). As with the T. brucei 
over-expressing prostaglandin F2α synthase, cytochrome P450 reductase 2 or 
cytochrome P450 reductase 3 lines, elevated levels of squalene epoxidase had no effect 
on parasite susceptibility to any of the agents screened. Intriguingly, no effect on 
parasite growth at concentrations up to 20 µM was observed using terbinafine, 
suggesting that this drug does not effectively inhibit squalene epoxidase, and/or any 
inhibitory effect on this enzyme is not trypanocidal to bloodstream form T. brucei. 
 
Figure 8.1.8. Susceptibility of bloodstream form T. brucei with elevated levels of 
squalene epoxidase to the 6 most potent nitrofuryls.  
Growth-inhibitory effect s as judged by IC50 values ( in nM) of the six most  potent 
trypanocidal 5‟ nit rofuryls on T. brucei cells induced to express recombinant  squalene 
epoxidase (+tet) in comparison to  controls ( -tet).  Data are the means from four 
experiments ± SD.  
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8.1.5 Profiling the nitroreductase generated 5’ nitrofuryl reduction products 
Using a functional genomics based approach, it has now been shown that a 
trypanosomal type I nitroreductase plays a key step in mediating the trypanocidal 
activity of 5‟ nitrofuryl compounds, in agreement with other findings relating to other 
nitroaromatic agents (Bot et al., 2010; Hall et al., 2010; Wilkinson et al., 2008). Our 
next goal was to determine what happens following this initial activation step. Reaction 
of bacterial type I nitroreductases with 5‟ nitrofuryls can lead to the formation of various 
products (Figure 8.1.9). Invariably, the first step involves a series of 2 electron reduction 
steps resulting in conversion of the nitro group to a hydroxylamine derivative via a 
transient nitroso intermediate. A hydroxylamine could then be processed further to form 
an aminofuran (Beckett and Robinson, 1959), a saturated open chain nitrile (Gavin et 
al., 1966) or nitrenium ion (Streeter and Hoener, 1988).  
To identify which metabolites were generated following nitroreductase reduction, the 6 
most potent nitrofuryls were enzymatically reduced using recombinant nitroreductase 
(provided by Dr. Belinda Hall) and the resultant material analysed by tandem mass 
spectrometry (LC-MS/MS). For the three thiosemicarbazones HC-1, HC-2 and HC-4, 
LC-MS analysis identified a single analyte whose mass spectrum was compatible with 
the saturated open chain nitrile form of the parent compound. Unfortunately, further 
characterisation of the HC-1 derived product was hampered because this metabolite 
fragmented poorly when performing tandem-MS in either negative or positive ion 
modes. Therefore, this compound was not studied further. In the case of the other 
thiosemicarbazones, negative tandem MS unequivocally confirmed the nature of the 
saturated open chain nitrile structure. For HC-2, reduction leads to formation of an [M-
H]
-
  ion at 197 (Figure 8.1.10a; peak i). Secondary fragmentation of this yields 4 ions 
with m/z values of 89, 97, 107 and 124 (Figure 8.1.10b). These ions are the result of 
eliminative cleavage of weak N-N or N-C bonds to give thioamide (89) and truncated 
open chain nitrile (107 and 124) forms, with the 124 ion undergoing further 
fragmentation to release a nitrile moiety (97). 
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Figure 8.1.9.  Reduction of 5’ nitrofuryls by type I nitroreductases.  
In react ions mediated by type I nit roreductases, the conserved nit ro group on the 
nit rofuryl pro-drug undergoes a series of 2-electron reduct ions to  generate the 
hydroxylamine derivat ive via an unstable nit roso intermediate.  A hydroxylamine can then 
be metabolised further with several pathways proposed. These include:  format ion of a  
nit renium ion (Streeter and Hoener,  1988),  reduct ion to  the amine form (Beckett and 
Robinson, 1959),  or cleavage of the furan ring forming unsaturated then saturated open 
chain nit riles (Gavin et  al. ,  1966).  Important ly for the downstream experiments reported 
here,  the aminofuran and saturated open chain nit rile  metabolites have the same 
molecular mass.  Figure reproduced from Hall et al. ,  2011.  
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Figure 8.1.10. Characterizing the nitroreductase mediated HC-2 reduction products.  
Negat ive ESI LC-MS analysis (A) of the nit roreductase-mediated HC-2 reduct ion product 
ident ifies a single analyte (i)  whose mass spectrum conta ined a molecular ion for [M-H]
-
 
at  197 and corresponds to  a saturated open chain nit r ile  with a molecular weight  of 198. 
Negat ive ESI MS-MS analysis (B) of this ion generates secondary ions with m/z values of 
89, 97, 107 and 124 whose predicted st ructures are given (C).  
 
The nitroreductase-mediated reduction of HC-4 generated a single metabolite with a 
parent ion for [M-H]
-
 of 223. Secondary fragmentation yields five ions with m/z values 
of 91, 97, 106, 117 and 124 (Figure 8.1.11). The major ion (124) was generated by 
breakage of an N-C bond in the thiourea side chain that then undergoes further 
fragmentation to release a nitrile moiety (97). These two ions (97 and 124) have the 
same m/z values as described for HC-2, supporting the hypothesis that these fragments 
are derived from a common 5‟ nitrofuryl structure. 
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Figure 8.1.11. Characterizing the nitroreductase mediated HC-4 reduction products.  
Negat ive LC-MS analysis  of the nit roreductase mediated HC-4 reduct ion product 
ident ifies a single analyte whose mass spectrum contained a molecular ion for [M -H]
-
 at 
223. This corresponds to  a saturated open chain nit r ile  with a molecular weight  of 224. 
Negat ive MS-MS analysis (A) of this ion generates secondary ions with m/z values of 81, 
97, 107, 115 and 124, whose predicted st ructures are given (B).  
 
In the case of the semicarbazone nitrofurazone, LC-MS analysis of the nitroreductase 
generated reduction products under negative ionization identified two major products 
with m/z values of 165 and 167 (Figure 8.1.12a; peaks ii and i respectively). The mass 
spectrum of the smaller ion corresponded to an unsaturated open chain nitrile structure 
with the 167 ion representing either a saturated open chain nitrile or an aminofuran 
form. To characterize the larger ion further, it was then subject to a second round of MS, 
resulting in the formation of two distinct ions with m/z values of 140 and 123 (Figure 
8.1.12b). Fragment reconstruction analysis of these two ions indicate that the 140 ion 
was generated by loss of the nitrile from the nitrofurazone-derived saturated open chain 
nitrile structure, while the 123 ion corresponds to loss of an amide group at the opposite 
end of the molecule. 
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Figure 8.1.12. Characterizing the nitroreductase mediated nitrofurazone reduction 
products. 
Negat ive LC-MS analysis (A) of the nit roreductase generated nit rofurazone reduct ion 
products ident ifies two ions ( i and ii)  with m/z values of 167 ( i)  and 165 ( ii) .  These 
correspond to the saturated ( i)  and unsaturated ( ii)  open chain nit r ile st ructure, 
respect ively.  Negat ive MS/MS analysis (B) of the 167 ion ( ident ified in A) generates [M-
H]
-
 ions with m/z values of 124 and 140. These two ions were obtained following 
eliminat ion from parental saturated open chain nit rile ion of the amide  (123) or nitrile  
(140) groups.  
 
When the nitroreductase mediated reduction products from the two carbazonates HC-10 
and HC-11 were analysed by LC-MS analysis under negative ionization, two major 
metabolites were detected. For HC-10, the m/z values were 264 and 266 while for HC-
11 the values were 278 and 280. As for nitrofurazone, the mass spectrum of the smaller 
ions corresponded to an unsaturated open chain nitrile derivatives with the larger ions 
representing either the saturated open chain nitrile or aminofuran forms. For both 
compounds, the larger ions (266 for HC-10 and 280 for HC-11) were analysed by 
tandem-MS, and in both cases a major ion corresponding to elimination of a nitrile 
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moiety was detected (m/z vales of 239 for the HC-10 derived metabolite and 253 for the 
HC-11 derived product) (Figure 8.1.13).  
Of note, the three compounds generating 2 detectable metabolites possess a urea group 
off the furan side-chain, whereas the compounds that produce only one metabolite 
contain a thiourea group. This suggests the oxygen of the urea group may have an 
electronic stabilising effect on the unsaturated molecule, or potentially the greater size 
of the sulphur atom generates a steric hindrance effect, reducing the stability of an 
intermediate structure.    
 
Figure 8.1.13. Characterizing the nitroreductase mediated HC-10 and HC-11 derived 
reduction products.  
Negat ive LC-MS analysis of the nit roreductase generated reduct ion products of HC-10 
and HC-11 ident ified two ions with m/z values of 264 and 266 (for HC-10),  and of 278 
and 280 (from HC-11).  In each case,  the smaller ion corresponds to the unsaturated open 
chain nit rile form while the larger ion corresponds to the saturated form. To confirm the 
assignment  for the larger ions,  negat ive MS/MS analysis was performed. In both cases, 
secondary fragmentat ion resulted in a major ion whose m/z values correspond to the loss 
of a nit rile  group from the parental ion. For HC -10, secondary fragmentat ion of the 266 
parental ion generated a fragment  with an m/z value of 239 (A) while secondary 
fragmentat ion of the 280 ion from HC-11 generated a fragment  with an m/z value of 253 
(B). 
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8.2 Chapter Summary 
This chapter has focussed on a small series of nitrofuryl compounds and their 
trypanocidal effectiveness against T. brucei. In summary this study has revealed: 
 A drug screen against wild-type T. brucei showed that all except one compound 
(HC-5), was more potent than nifurtimox (2.8 µM IC50), with over half the 
compounds generating IC50 values of less than 1 µM. 
 Selected 5‟ nitrofuryls screened against Vero cultures all demonstrated higher 
therapeutic index values than nifurtimox. 
 Screens against T. brucei cell-lines with modified nitroreductase levels 
implicate this enzyme as the major contributor of trypanocidal activity via a 
pro-drug activation mechanism, as observed previously for nifurtimox 
(Wilkinson et al., 2008). 
 Further screens against other modified T. brucei cell-lines designed to test 
alternative hypotheses of trypanocidal activity mechanisms did not support a 
major role for prostaglandin F2α synthase, cytochrome P450 reductase 2, or 
cytochrome P450 reductase 3. These alternative hypotheses were originally 
proposed for the activity of nifurtimox in T. cruzi (Docampo et al., 1981a; 
Portal et al., 2008). 
 The nitrofuryl compounds examined here were designed as T. cruzi sterol 
biosynthesis inhibitors, potentially targeting squalene epoxidase (Gerpe et al., 
2009). Using an inducible squalene epoxidase expression system no evidence of 
squalene epoxidase inhibition mediated trypanocidal activity was detected in T. 
brucei. 
 Analysis of metabolites derived from nitroreductase mediated in vitro reduction 
of a sample of nitrofuryls show in each case a saturated open chain nitrile 
structure is formed. Compounds possessing a urea side group also generated a 
second detectable unsaturated open chain nitrile metabolite. The saturated open 
chain nitrile observation for nitrofurazone is in accordance with other published 
material (Peterson et al., 1979; Wang et al., 2010).    
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8.3 Discussion 
The effectiveness of 5‟ nitrofuryl compounds against T. brucei was first demonstrated 
more than 50 years ago with nitrofurazone, and then nifurtimox emerging as potential 
trypanocidal therapies (Section 6.2). The experimental promise shown by both agents 
did not immediately translate to clinical treatments against African sleeping sickness, 
primarily due to unwanted side effects, although nifurtimox was made available as a 
monotherapy to treat Chagas disease. However, due to the toxicity, expense and 
resistance issues relating to other African sleeping sickness drugs, there has been 
renewed interest in using nitroheterocyclic drugs against T. brucei infections. In light of 
the toxicity issues relating to the use of nifurtimox, we have conducted a screening 
programme against T. brucei making use of 17 novel 5‟ nitrofuryl compounds originally 
developed against Chagas disease (Aguirre et al., 2004a; Aguirre et al., 2004b; Gerpe et 
al., 2008). All except 1 compound exhibited a higher potency towards the bloodstream 
form parasites than nifurtimox (Section 8.1.1). Unfortunately, many of the most potent 
compounds (IC50 values < 0.5 M) showed some toxicity towards mammalian cells, 
despite generating better therapeutic index values than nifurtimox. Understanding how 
these drugs mediate their trypanocidal properties may help in designing structural 
modifications to these compounds to reduce their host toxicity, while maintaining their 
potency against the parasite.  
Previous studies on both T. brucei and T. cruzi has shown that a key step in the 
cytotoxic and selective activities displayed by nifurtimox stems from how it is activated 
(Wilkinson et al., 2008). Using biochemical and genetic approaches, a type I 
nitroreductase has been shown to interact with this pro-drug to generate trypanocidal 
metabolites. All 5‟ nitrofuryl compounds identified as inhibitors of bloodstream form T. 
b. brucei growth from the primary screen were subject to a secondary screen using T. 
brucei cell-lines with altered expression levels of the type I nitroreductase (Section 
8.1.2). For most compounds, a small increase in resistance toward the nitrofuryl was 
observed when using the nitroreductase heterozygous parasite line, relative to wild-type 
cells, although for some agents no difference in susceptibility was detected. One 
possible explanation for this is that a reduction in the functional gene copy number from 
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two to one is not necessarily accompanied by a 50% reduction in the concentration of 
nitroreductase enzyme within the parasite. Therefore, it would not be expected that a 
nitroreductase gene deletion would be directly 50% more resistant to certain 
nitroheterocyclics. A much better approach to studying pro-drug activation involved the 
implementation of the type I nitroreductase over-expressing line, where cells induced to 
over-express this enzyme were hypersensitive to most of the nitroheterocyclics tested, 
relative to non-induced controls (Section 8.1.2). This confirms that in the parasite, the 
type I nitroreductase plays a major role in the activation of most 5‟ nitrofuryls pro-
drugs. Intriguingly, the susceptibility of parasites with altered levels of the type I 
nitroreductase towards one compound (HC-6; IC50 ~0.5 M) was not greatly affected, 
indicating that its trypanocidal activity occurs through a mechanism distinct from all the 
other 5‟ nitrofuryls tested. 
To definitively characterize any stable products arising from the T. brucei type I 
nitroreductase mediated reduction of selected 5‟ nitrofuryls, an analysis of the 
metabolites was performed using liquid chromatography coupled to tandem mass 
spectrometry. Using the semicarbazone nitrofurazone as a reference compound, two 
major end products were isolated. These were identified as open chain nitrile 
derivatives, with one having a saturated open-chain conformation, while the other 
having an unsaturated arrangement (Section 8.1.5). During nitrofuryl reduction with 
bacterial type I nitroreductases, the saturated form has frequently been detected whereas 
the unsaturated structure, although postulated as an intermediate that leads to the 
saturated form (Peterson et al., 1979), had not been reported. Toxicity studies have 
shown that the stable, saturated nitrofuryl form does not affect cell growth, resulting in 
the hypothesis that intermediates generated during its formation are responsible for this 
pro-drug‟s anti-microbial properties (Section 6.2). In contrast, analysis of the 
metabolites generated following nifurtimox reduction by the trypanosomal (T. cruzi and 
T. brucei) type I nitroreductase identified the unsaturated open chain nitrile as the major 
end product, with this then undergoing further reduction to the saturated form, albeit at a 
very slow rate (Hall et al., 2011). Analysis of the toxicity of the unsaturated form 
demonstrated that this affected T. brucei and mammalian cells at equivalent levels, 
unlike the parental pro-drug that shows selectivity toward the parasite. The data reported 
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here clearly shows that following the initial nitrofurazone reduction, conversion of the 
unsaturated to saturated form occurs more readily than for nifurtimox. Based on the 
above reports, it is tempting to speculate that the trypanocidal activity displayed by 
nitrofurazone stems from the unsaturated open chain nitrile, at least in part. However the 
effects of other, unstable intermediaries cannot be ruled out at this stage. When 
analyzing two structurally related carbazonate compounds (HC-10 and HC-11), the 
corresponding unsaturated and saturated end products were also observed, indicating 
that this reaction is common to many semicarbazone- and carbazonate-based nitrofuryl 
compounds, and is therefore unlikely to be an experimental artefact (Section 8.1.5).  
When these studies were extended to thiosemicarbazone compounds (HC-1, HC-2 and 
HC-4), only the common saturated open chain nitrile end metabolite was observed 
(Section 8.1.5). Presumably, the unsaturated open chain nitrile metabolites resulting 
from the type I nitroreductase mediated reactions are too unstable to isolate with this 
analytical technique. The obvious difference between these compounds and those 
described earlier is the presence of the much bulkier sulphur containing thiourea group 
in place of the oxygen based urea group, which may influence the stability of any 
intermediates.   
For all types of 5‟ nitrofuryls tested, the other proposed end metabolites theoretically 
possible following the initial 2-electron nitroreductase mediated reduction such as the 
aminofuran and nitrenium ion (Figure 8.1.9), were not detected. These potential 
metabolites have not been reported with a bacterial type I nitroreductase, although they 
have been observed during in vitro reactions using type II nitroreductases (Peterson et 
al., 1979; Streeter and Hoener, 1988). Therefore, the detection of the saturated (and 
unsaturated, where applicable) open-chain nitrile derivatives indicate that the T. brucei 
type I nitroreductase functions via a classical pathway identical to the characterized 
prokaryotic orthologues (Figure 6.2.2). The nature and stability of the toxic metabolite 
intermediates may well be the defining factors in causing their trypanocidal activity and 
host side-effects.  
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Several other parasite enzymes have been reported to interact with 5‟ nitrofuryls and/or 
any metabolites. The cytochrome P450 reductases have received considerable attention 
with regard to the trypanocidal activity of nifurtimox in T. cruzi (Section 6.2.2). To 
investigate whether two of these enzymes play a role in pro-drug activation in T. brucei, 
the over-expression approach that proved so effective when applied with the type I 
nitroreductase was used. Here, parasites induced to over-express the cytochrome P450 
reductases displayed the same susceptibility to any of the tested compounds, as 
compared to non-induced controls (Section 8.1.3), including nifurtimox. It therefore 
appears that these enzymes play no major role in mediating the trypanocidal activity of 
5‟ nitrofuryls in T. brucei. This, coupled to a similar finding where T. cruzi cells over-
expressing cytochrome P450 reductase were only slightly more resistant to nifurtimox 
(Portal et al., 2008), indicates the same is most likely true in T. cruzi as well. This is not 
to say that 5‟ nitrofuryl compounds such as nifurtimox do not act as substrates for 
cytochrome P450 reductases in trypanosomes, or even within their human hosts, merely 
that any interaction is not the primary route of parasite growth inhibition.  
The prostaglandin F2α synthase „Old Yellow Enzyme‟ has also been implicated in 
nifurtimox metabolism within T. cruzi (Kubata et al., 2002). Again, using the over-
expression system, the contribution made by this enzyme to the trypanocidal activity of 
this nitrofuryl in T. brucei was assessed by observing any alterations to drug 
susceptibility upon an increase in ectopic enzyme expression. This demonstrated the 
„old yellow enzyme‟ orthologue in T. brucei, also called prostaglandin F2α synthase, did 
not noticeably contribute to the trypanocidal activity of any 5‟ nitrofuryl compounds 
tested, including nifurtimox (Section 8.1.3). Unlike for the cytochrome P450 reductases, 
it is difficult to extend these conclusions to the T. cruzi enzyme because a comparison of 
protein sequence between the T. cruzi „Old Yellow Enzyme‟ and the T. brucei 
prostaglandin F2α synthase shows that although they fulfil the same function, they are 
remarkably different enzymes (Kubata et al., 2002). 
A previous study assessing the trypanocidal properties of furyls against T. cruzi revealed 
that treatment with certain derivatives led to an intracellular build-up of squalene, a 
phenomenon attributed to the inhibition of squalene epoxidase (Gerpe et al., 2009). As 
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the accumulation of squalene was associated only with compounds possessing a nitro 
group on the furan ring, a possible explanation was that 5‟ nitrofuryl metabolites derived 
from nitroreductase activity acted to inhibit the squalene epoxidase enzyme. To address 
this hypothesis in T. brucei, the over-expression system featuring the native T. brucei 
squalene epoxidase was exploited. Upon induction of over-expression, the T. brucei line 
displayed no alteration in its resistance patterns as compared to controls for any of the 
compounds tested, suggesting that none of these agents exerted their toxic effects 
through squalene epoxidase inhibition (Section 8.1.4). One reason for this could be that 
unlike in T. cruzi, the bloodstream form T. brucei does not require a functional sterol 
biosynthesis pathway, as they can scavenge the end-product from their environment 
(Coppens et al., 1987). Another possibility is that the build-up of squalene is a 
consequence of nitrofuryl mediated trypanocidal activity (and its metabolites), and is not 
the cause of the toxicity itself. The activity of squalene epoxidase is dependent on the 
donation of electrons from cytochrome P450 reductase (Ono et al., 1982). If the 
physiological cytochrome P450 reductase activity is impeded in some way by the 5‟ 
nitrofuryls, this may reduce the rate of squalene epoxidase action, and explain the build-
up of squalene in T. cruzi. In this setting, the observed accumulation of squalene would 
be coupled to 5‟ nitrofuryl treatment but not part of a type I nitroreductase mediated 
toxicity process. 
Nitroheterocyclic drugs are experiencing a renaissance as treatments for African 
sleeping sickness. As noted, nifurtimox has been deployed against the West African 
form of the disease as part of a co-therapy alongside eflornithine (Priotto et al., 2009), 
while the nitroimidazole compound fexinidazole, is now entering phase I clinical trials 
(www.dndi.org). Fexinidazole activity against T. brucei was first discovered almost 30 
years ago (Jennings and Urquhart, 1983), yet its full potential has only recently been 
appreciated (Torreele et al., 2010). While it has yet to be explicitly demonstrated that 
fexinidazole is activated by the trypanosomal type I nitroreductase, it is noteworthy that 
a T. brucei cell-line resistant to nifurtimox, benznidazole, and nitrofurazone, is also 
resistant to fexinidazole (Sokolova et al., 2010). Like many nitroheterocyclic drugs, 
fexinidazole fails the “classical” Ames test of mutagenicity, yet it is not mutagenic to 
type I nitroreductase deficient bacteria, or to mammalian cells (Torreele et al., 2010). 
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Whether the type I nitroreductase mediated activation of nitroheterocyclic drugs such as 
nifurtimox and fexinidazole to their toxic metabolites is the sole cause of all short- and 
long-term cytotoxic effects observed, remains unclear and seems unlikely, given the 
observation of nitroheterocyclic drug metabolites in animal tissues (Section 6.2). 
Therefore, perhaps the more subtle question to be addressed is: do nitroheterocyclic 
drugs have the potential to be designed specific enough to the trypanosomatid type I 
nitroreductase, so as to present only a reasonable risk for acceptable associated side-
effects to human patients over both the short- and longer term? Appreciating the shared 
mechanism of nitroaromatic drug activation and predicting the downstream metabolites 
across many classes of compounds by the trypanosomal nitroreductase is a fundamental 
aspect in overcoming this challenge.  
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9 Concluding Remarks 
This thesis describes two separate and distinct research projects. In the first section, the 
process of mitosis is addressed in the African trypanosome. Little is currently known 
about the mechanisms of chromosome segregation in this organism, with many of the 
conserved mitotic proteins found in other eukaryotes appearing absent in the T. brucei 
genome database (Berriman et al., 2005; Logan-Klumpler et al., 2012). To begin 
exploring the procedure of chromosome segregation, the centromeric loci of T. brucei 
megabase chromosomes were identified using topoisomerase-II mediated cleavage 
biochemical mapping experiments. These DNA regions each contain a period of AT-
rich repeat sequence, as well as an abundance of retroelements (Obado et al., 2007). 
Given the variation in centromeric DNA sequence between T. brucei chromosomes, and 
also previous observations in other model systems (Section 2.2.1), it is unlikely that 
DNA sequence alone constitutes a centromere. However, knowledge of these 
chromosomal sites can in future facilitate the identification of centromere specific 
proteins. For example, techniques such as ChIP-Seq could be employed to detect any 
unusual histone modifications, or possibly a unique histone variant that may fulfil the 
role performed by CENP-A in other eukaryotes (Section 2.2.2). In addition, a novel 
strategy of using biotin labelled centromeric DNA probes could be deployed as 
hybridization „bait‟ to isolate this region of DNA with any bound proteins, with mass 
spectrometry then used to identify those protein components (Dejardin and Kingston, 
2009). Also, based on the observation that only the topoisomerase-IIα isoform of T. 
brucei is active at the centromere (Obado et al., 2011), the tandem affinity purification 
system devised as part of this thesis may be used to dissect enzyme modifications and 
protein associations which guide the centromere targeted activity of topoisomerase-IIα. 
Together, these experiments could shed light on novel proteins involved in chromosome 
segregation in trypanosomes, which may in turn reveal suitable drug targets to develop 
chemotherapies against these parasites. 
The second section of this thesis explores a drug target directly, specifically a 
trypanosomal type I nitroreductase which catalyses the activation of nitroaromatic pro-
drugs to their cytotoxic forms. The initial goal of this project was to develop a luciferase 
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reporter system for T. cruzi, which could then be adapted for drug screening in a 96-well 
plate format. The establishment of this system facilitated the rapid screening of novel 
nitroaromatic compounds against the medically relevant amastigote life-cycle stage of T. 
cruzi (Bot et al., 2010). In total, three sets of nitroaromatic compounds were screened in 
this way, which resulted in the identification of a selection of potential drug candidates 
that possessed improved potency and therapeutic index values over the current drug, 
nifurtimox (Bot et al., 2010; Hu et al., 2011). Given that many of these compounds are 
potential DNA alkylating agents, the next stage in the drug development process would 
be to assess these agents for host DNA mutagenicity. Firstly systems such as the Ames 
test, incorporating both the wild-type and nitroreductase deficient bacterial strains can 
be employed to perform this task. The use of either a Drosophila or mouse system 
would also be appropriate for these studies. If these compounds perform satisfactorily in 
mutagenicity assays, then further drug trials using a mouse model to analyse the in vivo 
drug properties appraising their suitability as safe and effective chemotherapies would 
be required. Experiments performed with a selection of nitrofuryl compounds, including 
nifurtimox, have shown that within the trypanosome, cytotoxicity appears mediated 
predominantly through pro-drug activation by the type I nitroreductase (Hall et al., 
2011). It would be interesting to investigate how this trypanocidal activity is derived. 
For example observing drug metabolites such as those previously identified for the 
nitrofuryl series conjugated to DNA or proteins may reveal whether there are specific 
downstream metabolite targets, or if there is simply widespread non-specific cell 
damage. Overall, the second section of this thesis has demonstrated that nitroaromatic 
compounds can be rationally designed to be highly selective in killing trypanosomes by 
targeting nitroreductase. It remains to be seen whether they can also be designed to 
generate minimal host side-effects.    
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10 Appendix 
10.1 Alignments 
                    10        20        30        40        50        60        70              
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   -----------------------------------------MANRTVEEIYQKKTQHEHILSRPDMYIGT  
LmfTopoII  ------------------------------------------MGKTVEQIYQKKTQHDHILTRPDMYIGT  
TbTopoIIα  -----------------------------------------MSGRTVEEIYQKKTQHEHILARPDMYIGT  
TbTopoIIß  MTEILLQHEINVGSAQLGRQLSFFQPCDAWEEEIGTGPESTMSGRTVEEIYQKKTQHEHILARPDMYIGT  
Consensus                                             .:***:********:***:********  
  
                    80        90       100       110       120       130       140         
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   IEPVTEDMWLYDEAENIMKLRKCTWTPGLYKIFDEILVNAADNKVRDPLGQTAIKVWIDAERGMVRVYNN  
LmfTopoII  LEPVTDDIWVYDDAENSMKQRKCTWTPGLYKIFDEILVNAADNKVRDPIGQTVIRVWMTES--YVRVYNN  
TbTopoIIα  IEPVTEDVWVYDEADNVMKLRKCTWTPGLYKIFDEILVNAADNKVRDPHGQTTIKVWVDAARGLVRVYNN  
TbTopoIIß  IEPVTEDVWVYDEADNVMKLRKCTWTPGLYKIFDEILVNAADNKVRDPHGQTTIKVWVDAARGLVRVYNN  
Consensus  :****:*:*:**:*:* ** **************************** ***.*:**:      ******  
 
                   150       160       170       180       190       200       210       
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   GEGIPVQRHREHNLWVPEMIFGYLLTSSNYDDTEAKVTGGRNGFGAKLTNVFSTRFEVETVHSRSRKKFF  
LmfTopoII  GEGIPIQKHREHDLWVPEMIFGHLLTSSNYDDEEAKVTGGRNGFGAKLTNVFSKQFEVETVHSRSRKKFY  
TbTopoIIα  GEGIPVQRHREHDLWVPEMIFGHLLTSSNYDDTEAKVTGGRNGFGAKLTNVFSTRFEVETVHSRSRKKFF  
TbTopoIIß  GEGIPVQRHREHDLWVPEMIFGHLLTSSNYDDTEAKVTGGRNGFGAKLTNVFSTRFEVETVHSRSRKKFF  
Consensus  *****:*:****:*********:********* ********************.:**************:  
 
                   220       230       240       250       260       270       280       
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   MRWRNNMLESEEPVITPSEGPDYTVVTFYPDFAKFNLQGFGEDMVHMMRRRVYDVAGCTDKSLRCYLNDT  
LmfTopoII  MKWTNNMLQHDDPVIVPCDSADYTMVTFYPDFALFHVDKFTEDMLLMMKRRVYDIAGCTDKTLKCFLNDE  
TbTopoIIα  MRWRNNMLENEEAVITPCDGPDYTVVTFYPDFEKFNLEGFTEDMVLIMQRRVYDIAGCTDKSLCCYLNDT  
TbTopoIIß  MRWRNNMLENEEAVITPCDGPDYTVVTFYPDFEKFNLEGFTEDMVLIMQRRVYDIAGCTDKSLCCYLNDT  
Consensus  *:* ****: ::.**.*.:..***:*******  *::: * ***: :*:*****:******:* *:***   
 
                   290       300       310       320       330       340       350       
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   KIACSSFLEYVDLYPMMGEERKAASYARVNGRWEVCVRVSNIGFQQVSFVNSIATTRGGTHVRYITDQVI  
LmfTopoII  RIACTTFPEYVDLYPTMGEERKAASYSRVNDRWEVCVRVSNIGPQQVSFVNSIATTRGGTHVKYIMDQIT  
TbTopoIIα  RIACRSFPEYVDLYPTMGEERKPSSYSRVNDRWEVCVRVSNVGFQQVSFVNSIATTRGGTHVKYIVDQII  
TbTopoIIß  RIACRSFPEYVDLYPTMGEERKPSSYSRVNDRWEVCVRVSNVGFQQVSFVNSIATTRGGTHVKYIVDQII  
Consensus  :*** :* ******* ******.:**:***.**********:* ******************:** **:   
 
                   360       370       380       390       400       410       420       
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   AKVTEQAKRKSKTEVKPHMIRPHLFVFINCLVENPGFDSQTKETLNTPKNRFGSTCDLPPSMIDCILKSS  
LmfTopoII  SKVMEQAKKKKKTDVKPHMIRPHIFLFVNCLIENPGFDSQTKETLNTVKSKFGSTCDLPNSIVDYIMSSG  
TbTopoIIα  AKVTDQAMRKSKTEVKPHMIRPHLFIFVNSLIENPSFDSQTKETLNTPKARFGSTCDLPASLIDCVLKSS  
TbTopoIIß  AKVTDQAMRKSKTEVKPHMIRPHLFIFVNSLIENPSFDSQTKETLNTPKARFGSTCDLPASLIDCVLKSS  
Consensus  :** :** :*.**:*********:*:*:*.*:***.*********** * :******** *::* ::.*.  
 
                   430       440       450       460       470       480       490       
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   IVERAVEMANSKLTREIASKLRNADRKQILGIPKLDDANEAGGKYSHRCTLILTEGDSAKALCTAGLAVK  
LmfTopoII  IVERSVEMANSKIAREMASKMRSSDRKQIMGIPKLDDANEAGGKHSHRCTLILTEGDSAKTLCTAGLAVK  
TbTopoIIα  IVERAVEMANSRLNREMAMKMRNTNRKQILGIPKLDDANEAGGKYSQRCTLILTEGDSAKALCTAGLAVE  
TbTopoIIß  IVERAVEMANSRLNREMAMKMRNTNRKQILGIPKLDDANEAGGKYSQRCTLILTEGDSAKALCTAGLGVK  
Consensus  ****:******:: **:* *:*.::****:**************:*:*************:******.*:  
 
                   500       510       520       530       540       550       560       
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   DRDYFGVFPLRGKPLNVRDATLKKVMACAEFQAVSKIMGLDIRQKYSGVERLRYGHLMIMSDQDHDGSHI  
LmfTopoII  DRDYFGVFPLRGKPLNVREASLKKLAACEEIQCVMKIMGLDIRQTYENSDGLRYGHLMIMSDQDHDGSHI  
TbTopoIIα  NRDYFGVFPLRGKPLNVRDASVKKVMGCAEFQAVSKIMGLDLSQKYTSTEGLRYGHLMIMSDQDHDGSHI  
TbTopoIIß  NRDYFGVFPLAGKPLNVRDVSLKKASENSEIISICKIMGLDFNQKYTSTEGLRYGHLMIMSDQDHDGSHI  
Consensus  :********* *******:.::**     *: .: ******: *.* . : *******************  
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                   570       580       590       600       610       620       630       
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   KGLIINMIHHYWPDLIKTPGFLQQFITPIVKARKKGRSDGDDRAISFFSMPDYFEWKNAIGDGIRNYEIR  
LmfTopoII  KGLLINFIHCFWPNLLRVPGFLQQFITPIVKARPKGRG-GAGKAISFFSMPDYFEWKKAIGDNLSNYQIR  
TbTopoIIα  KGLIINMIHNYWPDLLKVPGFLQQFITPIVKARKKGRGNSDEGTISFFSMPDYFEWKNAVGEGIKNYELR  
TbTopoIIß  KGLIINMIHNYWPDLLKVPGFLQQFITPIVKARKKGRGNSDEGTISFFSMPDYFKWKNAVGEGISDYEVK  
Consensus  ***:**:** :**:*::.*************** ***. .   :**********:**:*:*:.: :*:::  
 
                   640       650       660       670       680       690       700       
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   YYKGLGTSGAKEGREYFENIDRHRLDFVHEDATDDARIVMAFAKDKVEERKHWITQFKANTNVNESMNYN  
LmfTopoII  YYKGLGTSGAEEGREYFENIDRHRLNFVEQEQSEEDRIVMAFGKDRVEDRKEWITNFKTNVNVNESMDYN  
TbTopoIIα  YYKGLGTSGAKEGREYFENIDRHRLNFVYEDRKDDDDIVMAFAKDKVDERKRWITEFKANTNINESMNYN  
TbTopoIIß  YYKGLGTSSAKEGREYFENIDRHRLNFVYEDRKDDDSIVLAFAKDKVDERKRWVMESMSSARRFESLSYN  
Consensus  ********.*:**************:** :: .::  **:**.**:*::**.*: :  :...  **:.**  
 
                   710       720       730       740       750       760       770       
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   VRTVRYSEFVDKELILFSVADCERSIPSVIDGLKPGQRKIIFSSFKRRLTRSIKVVQLAGYVSEHAAYHH  
LmfTopoII  VRQVSYRDFVDKELILFSIADCERSIPSVIDGFKPGQRKILFSCFKRNLVNSIKVVQLAGYVSEHSAYHH  
TbTopoIIα  VRNVSYSEFVHKELILFSVADCERSIPSVVDGLKPGQRKIMFSAFKRNLVRSLKVAQLAGYVSEHAAYHH  
TbTopoIIß  ARDVSYSEFVHKELILFSVADCERSIPSVVDGLKPGQRKIMFSAFKRNLVRSLKVARFAGYVSEHAAYHH  
Consensus  .* * * :**.*******:**********:**:*******:**.***.*..*:**.::*******:****  
 
                   780       790       800       810       820       830       840       
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   GEQSLVQTIVGLAQNFVGSNNVPLLQQDGQFGTRLQGGKDHAAGRYIFTRLTNIARYIYHPSDDFVVDYK  
LmfTopoII  GEQSLVQTIVGMAQDFVGSNNVPLLRKDGQFGTRLHGGKDHAAGRYIFTRLMQVARAIFHPADDFVVEYK  
TbTopoIIα  GEQSLVQTIVGLAQDYVGANNVPLLYRDGQFGTRLQGGKDHAAGRYIFTRLTDIARRIYHPSDDFIVEYR  
TbTopoIIß  GEQSLVQTIVGLAQDYVGANNVPLLYRDGQFGTRLQGGKDHAAGRYISTRLTDIARRIYHPSDDFIVEYR  
Consensus  ***********:**::**:****** :********:*********** *** ::** *:**:***:*:*:  
 
                   850       860       870       880       890       900       910       
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   DDDGLSVEPFYYVPVIPMVLVNGTSGIGTGFATNIPNYSPLEVIDNLMRLLRGEEVQPMKPWYFGFAGTI  
LmfTopoII  DDDGLSVEPFFYIPVIPMVLVNGTTGIGTGFSTSIPNYNPLEIISNLERLMRGEEVHKMQPWYFGFTGTM  
TbTopoIIα  DDDGLSVEPFYYVPVIPMVLVNGTAGIGTGFATNIPNYSPLDVIDNLNRLLSGEELQPMKPWYFGFTGTI  
TbTopoIIß  DDDGLSVEPFYYVPVIPMVLVNGTAGIGTGFATNIPNYSPLDVIDNLNRLLSGEELQPMKPWYFGFTGTI  
Consensus  **********:*:***********:******:*.****.**::*.** **: ***:: *:******:**:  
 
                   920       930       940       950       960       970       980       
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   EEKEKGKFVSTGCANVRPDGVVQITELPIGTWTQGYKKFLEELREKEVVVQYREHNTDVTVDFEVFLHPE  
LmfTopoII  EEKEPGKFISHGRYEIRPDGVVCITELPIGVWTQAYKKFLEDMREKELVVQYREHTTDVTVDFEVFLHPQ  
TbTopoIIα  EEREKGKFVSSGCATVRPDGVVHITELPIGTWTQQYKKFLEDLREREIVIQYREHNTDVTVDFEVFIHPE  
TbTopoIIß  EEREKGKFVSSGCATVRPDGVVHITELPIGTWTQQYKKFLEDLREREIVIQYREHNTDVTVDFEVFIHPE  
Consensus  **:* ***:* *   :****** *******.*** ******::**:*:*:*****.**********:**:  
 
                   990       1000      1010      1020      1030      1040      1050      
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   VLHHWVAQGCVEERLQLREYIHATNIIAFDREGQITKYRDAEAVLKEFYLVRLEYYAKRRDFLIGDLRSV  
LmfTopoII  VLEQWVAQDVVEERLQLKEYVHATNIIAFNKEGQITKYSDAESVLKEFYLVRLDYYAKRKQYLLGELRRL  
TbTopoIIα  VLRQWVAQGCVEERLQLREYIHATNIIAFDREGKITKYLDAESVLKEFYLVRLEYYARRREFLLEQLQRA  
TbTopoIIß  VLRQWVAQGCVEERLQLREYIHATNIIAFDREGKITKYLDAESVLKEFYLVRLEYYARRREFLLEQLQRA  
Consensus  **.:****. *******:**:********::**:**** ***:**********:***:*:::*: :*:    
                  
    1060      1070      1080      1090      1100      1110      1120      
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   ASKLENMVRFVTEVVDGRLIVTRRRKKELLEELRQRGYAPFPLQQKKKVSSTTIQQGEEEGAAD---ATH  
LmfTopoII  TSKLENMVRFVREVVEGTLVVTKRKKKELLEDLQRRMYLPFPPHTKKKLSSTTVEEGDDEGAPD---AQN  
TbTopoIIα  ALKLENMVRFVNEVIDGTFIVTRRSMKDVLKDLKQRGYTPFPPQQKKKMSSTTIVDEEEETERRNTAATS  
TbTopoIIß  ALKLENMVRFVNEVIDGTFIVTRRSMKDVLKDLKQRGYTPFPPQQKKKMSSTTIVDEEDNDGARKILPDV  
Consensus  : ********* **::* ::**:*  *::*::*::* * *** : ***:****: : :::       .    
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                   1130      1140      1150      1160      1170      1180      1190      
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   ATAEDVFLVLQPAVDEGGDEDNQETPEMRRAARDYDYLLGMRLWNLTAEMIARLQSQLQKARDELAALEK  
LmfTopoII  S-EEDVLGVGN-AADSGADDGAAEPPEMRRATRDYDYLLGMKLWSLTAEMIARLEAQMARARRDTAAMEA  
TbTopoIIα  ADAEEAIVLQPDELIGPGGGGAQEEPEVKQNARDYDYLLGLRLWNLTAEMSARLKAQLDAAREKYENIAK  
TbTopoIIß  FEFESVPLCEQVIGKMLCTAEPEEINMWKGVLVEYDYLLSLRMVDLTVEMAMYFRTKREQMLNKHNFVLS  
Consensus     *..                 *    :    :*****.::: .**.**   :.::      .   :    
                   1200      1210      1220      1230      1240      1250      1260      
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   RTPKDLWAEDLNQLRPRIENLFEERAKEIASIQRKKMEKKRSFDPRRLRVPLLSEKARQALAKEFIKTEK  
LmfTopoII  RTPKDMWMEDLKVLRTKLESFYADREVEIATIQRKKVKKP--FDARRLRVPILSDKARSLLQKEAEKSLK  
TbTopoIIα  RTPKDLWREDLDLLRPDVEKLFDERRKEIASIQRKKREKKRPFDASRLRVPLLSDAARKALLRETIKEEK  
TbTopoIIß  ASSKDLWREDLDLLRSDVEKLFDERRREIALIQCKKLEKRQFFDVSRLRVPLLSDAARKADRSLALRQS-  
Consensus   :.**:* ***. **. :*.:: :*  *** ** ** :*   **  *****:**: **.       :     
 
                   1270      1280      1290      1300      1310      1320      1330      
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   K---GGRAARVDGD---AGGDRKNP-SVGR----KPAAKRRRKKNSDDDSDDVDGDDDLFMSDASGG---  
LmfTopoII  ANGVGGRRRVGGGDDTLAGGAASAVGEVARPKPKKAAAKKRRKAKDSDDDDDSDSDEEWMFDNSDNDDEG  
TbTopoIIα  KSVRGDTSTRGGDG-----PSAGGDGKNPRGVKTASSGKRGRKKKDSDDEDDFDDFTGFSDDGDDYR---  
TbTopoIIß  -NCKREMSSKCASE-----SFA----------LLVDAGVR---------------VSGLTEGSSICD---  
Consensus              .                       :. :                     ..         
 
                   1340      1350      1360      1370      1380      1390      1400      
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   ----GGGRGWRPDDDDEDGGSDGVVLGDDGPGNNAGGGAKK-----------PQPKRPAAKRAPRKPKEE  
LmfTopoII  ENIVGMGDAGAPPVPERARVCGSPKKPRAAPKRHAASKPRKKVRNSDDDDSGDNSNSGSSKPVRRRPKKD  
TbTopoIIα  ------------PDDSDNGGATAASGGSTAKVKRAPAKQPA------------------PKQAAVKPRSG  
TbTopoIIß  ------------INEARRKYGHSVAGGKRRLVRHDEVSKRG------------------KFSSCGDQRHV  
Consensus                        .         ..                                 :    
 
                   1410      1420      1430      1440      1450      1460      1470      
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   GLKRVKKEAAKKVVVTDDFDIDDFGIEALTRTAPKCNNKNTTTTAKTTTAAFIPPPPQSTRVAPVIDTDT  
LmfTopoII  AIS--AAAAAATKTALDDLDLDGFGLDALASAS-------AVSAAPKMAMTAAPPSNGGAARSTKPTADA  
TbTopoIIα  RAKTLKKEEETKLGASDDLDLDCFGIEALTGSL------------------QKTTSSSKLPSPPSTGVFA  
TbTopoIIß  SLSDGSDTDDCSIGAPSVSPSDAT--PATQKSR------------------KISDSSYGFGIEGEVDIFF  
Consensus    .        .  . .    *     *   :                     . .                
 
                   1480      1490      1500      1510      1520      1530      1540      
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TcTopoII   DDDLALLGVSSVDKKKLAPVPPAK-RSPQRPKSQPKKSQGSRKRRRSSSRSSSRSSSDEDSFFDDDDDDD  
LmfTopoII  DDDLLLLGLVKAKTETAPPAATAASKRATAASARPAKPHAKPAARRRRRGSSSDSSDDDDEDSTDASASS  
TbTopoIIα  EDEEEALLLGITSAQGKPTPSRVASKGRVKRSSGKPSTQAKVPKKRRRGGSSDDSVSDEDNIVDDDDDDD  
TbTopoIIß  ED---TVGEDFSEPATQANIVRSKSESPVLDFSAEYATEPKSRKRPRSIKDNDENTCPFYVDVVGEDVEY  
Consensus  :*    :     .    .       .      :    .. .   :     ... .         . . .   
 
                   1550      
           ....|....|....|... 
TcTopoII   EDDDDEASSGSSSYDFSD  
LmfTopoII  LEESSASSDSDSDYSFSD  
TbTopoIIα  DDDDESSLDFSD------  
TbTopoIIß  DSDQCIGFDACVF-----  
Consensus   .:.  . .           
 
Figure 10.1.1. Alignment of trypanosomatid topoisomerase-II protein sequences . 
A protein alignment  of the L. major  and T cruzi  genes from the genome database,  with 
the published mRNA sequences of the  T. brucei  paralogues (Kulikowicz and Shapiro, 
2006) generated using ClustalW (Thompson et  al. ,  1994) .  The N-terminal ATPase domain 
(first  ~500 amino acids),  linker domain, and catalyt ic domain (amino acids ~650 -1100) 
are highly conserved between trypanosomatids.  The C -terminal domain protein sequences 
(residues ~ 1100 onwards) are highly var iable,  a feature which was explo ited to facilitate 
different iat ion between orthologues with the topoisomerase -IIα ant ibody (gift  from the 
Shapiro laboratory),  and with radio-labelled DNA probes at the nucleot ide level.  
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10.2 Primer Sequences 
 
Primer Gene 
(GeneDB ID) 
Sequence 
Tb1 forward Tb927.1.2340 
Existing α-tubulin probe used 
Tb1 reverse Tb927.1.2340 
Tb2 forward Tb927.1.3560 ATGTCCGTAGTTCTAGATGTTGTG 
Tb2 reverse Tb927.1.3560 TGGTATCTGCGTTATGGTTGCACG 
Tb3 forward Tb927.1.3830 ATGAGCAATTACTTGGATGATTTG 
Tb3 reverse Tb927.1.3830 CTCCAATTCACGACGAACCTCACT 
Tb4 forward Tb927.1.4720 
Existing cloned gene used 
Tb4 reverse Tb927.1.4720 
Tb5 forward Tb927.2.1380 GAACGTGCCAGCTTTTGACT 
Tb5 reverse Tb927.2.1380 CACGGTCCCATTGATATGTG 
Tb6 forward Tb927.2.2090 AAAGCTGGAGAGATGCCAAA 
Tb6 reverse Tb927.2.2090 TCTTTCGTAGGGGAGTGGTG 
Tb7 forward Tb927.5.570 TGACCCAGACAGTGAATGGA 
Tb7 reverse Tb927.5.570 TGAGGTCGCTGCTGTATCTG 
Tb10 forward Tb927.5.670 GCCGTTTGCGACTTTATGAT 
Tb10 reverse Tb927.5.670 ACGCCTGTTGGACGTTTATC 
Tbmini forward 177 bp repeat ATTAAACAATGCGCAGTTAACG 
Tbmini reverse 177 bp repeat GTGTATAATAGCGTTAACTGCG 
Lmf1 forward LmjF32.0120 GATCGGATCCTGCAGAAGTTTGGACCACTG 
Lmf1 reverse LmjF32.0120 CGATAAGCTTGCTGCATGGCTGACTTACAA 
Lmf2 forward LmjF12.0530 CATGGGATCCTGGAGAGCACCGAAGTCAAT 
Lmf2 reverse LmjF12.0530 TAGGAAGCTTGCTGGTAGAATGCGTGTTGA 
 
Table 10.2.1. Primer sequences of centromere mapping probes.  
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Primer Sequence 
TbTopo-IIß RNAi 
forward 
CATCTCGAGGGTACCGAAAGCAGATCGTAGT
TTAGCACTT 
TbTopo-IIß RNAi 
reverse 
TAGTCTAGAGGATCCATTGATCTGAGTCATA
TTCCACGTC 
TbTopoII Intergenic 
forward 
ACTGGTTCGTTACAGAAG 
TbTopoII Intergenic 
reverse 
TTGTACGGGAATACCCTC 
TbTopo-IIα 12-Myc tag 
forward 
ATAGGGCCCCCGTGAGCACAATACAGATG 
TbTopo-IIα 12-Myc tag 
reverse 
ATATCTAGAGTCACTGAAGTCAAGAGAGGA 
TbTopo-IIα 5‟ Disruption 
forward 
ATAGCGGCCGCGTCGCACCGTTGAGGAAATA 
TbTopo-IIα 5‟ Disruption 
reverse 
CATGGATCCGTACGGGAATACCCTCACCA 
TbTopo-IIα 3‟ Disruption 
forward 
TATGGGCCCCGTCTGTGGAATCTGACTGC 
TbTopo-IIα 3‟ Disruption 
reverse 
AAAGGTACCCATCGGAAACTGAGTCGTCA 
LmfTopo-II Complement 
forward 
ATACCTGCAGGATGGGCAAAACCGTCGAACA 
LmfTopo-II Complement  
reverse 
CATGGCGCGCCCTAGTCACTGAAGCTGTAGT
CGGAGT 
TbTopo-IIα PTP tag 
forward 
ATAGGGCCCCCGTGAGCACAATACAGATG 
TbTopo-IIα PTP tag 
reverse 
ATAGCGGCCGCCCGTCACTGAAGTCAAGAGA
GGA 
TcTopo-II PTP tag 
forward 
ATAGGGCCCGCAAAGGAGATTGCATCCAT 
TcTopo-II PTP tag 
reverse 
ATAGCGGCCGCCCATCACTGAAGTCATATGA
CGATG 
 
Table 10.2.2. Primer sequences for topoisomerase -II characterization.  
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Primer Sequence 
Luciferase 
forward 
AAACCCGGGATCGAAGACGCCAAAAACATA 
Luciferase 
reverse 
GGGGGATCCTTACAATTTGGACTTTCCG 
GAPDH 3‟ UTR 
forward 
GGGCCGCGGGAACAACCTGCCGAAGGAGC 
GAPDH 3‟ UTR 
reverse 
GGGGAGCTCCACACGGCTAGCATACTCTA 
3‟ rRNA Spacer 
forward 
GGGGGTACCTATTATTACTACCACTACTGC 
3‟ rRNA Spacer 
reverse 
GGGGGACCGGCGCGCCTTGATGATCCTTTGAAATGTT 
 
Table 10.2.3. Primer sequences for luciferase expression plasmids.  
 
 
Primer Sequence 
TbSQE-Full 
forward 
TATAAGCTTATGGAGGCGGCCATTATT 
TbSQE-Full 
reverse 
ATATCTAGACAAACCAATTGGCTTCCTTT 
TbSQE-Seq1 ATTATGTGTGACGGCGGTTC 
TbSQE-Seq2 TTCTGCCACACGTACTTTCG 
TbSQE-Seq3 CCCACGTAACCCCTGATAGA 
TbSQE-Seq4 TTATCGTGGGCACTGTATGC 
 
Table 10.2.4. Primer sequences for T. brucei squalene epoxidase.  
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